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Mycobacterium tuberculosis presents a substantial health risk to humans, particularly in Africa. Prevention of 
infectious diseases via vaccination is the most effective strategy in decreasing prevalence; however the 
current BCG vaccine against tuberculosis has shown varying levels of efficacy. M. tuberculosis infection 
represents an on-going interaction between the host and the bacteria, of which we do not yet fully 
understand all the mechanisms contributing to the pathogenesis at a molecular level. A deeper 
understanding of host-pathogen interactions is an important step towards developing new and more 
effective vaccines and therefore combating the disease. Protective immunity against M. tuberculosis is 
induced by stimulating antigen specific T-cells, which recognise peptide antigens presented by HLA 
molecules on infected cells. Identifying epitopes that are capable of binding to HLA molecules and eliciting T-
cell responses form part of the development of subunit vaccines.  
 
An area of mycobacterial biology that is poorly understood is the function of the PE/PPE proteins. These 
proteins are a large, genetically diverse family of immunogenic proteins that are predicted to play a role in 
modulating host immune responses. In particular, the PPE major polymorphic tandem repeat (PPE_MPTR) 
proteins are a subgroup of the PE/PPE proteins which are restricted to pathogenic mycobacterial species and 
represent one of the most genetically diverse set of proteins within the M. tuberculosis proteome. While 
many studies have investigated the presence of T-cell epitopes within the PE/PPE family of proteins, no 
studies have focused specifically on the PPE_MPTR subfamily. Based on the extreme variation in both the 
length and genetic diversity of the PPE_MPTR proteins, it has been speculated that they may represent a 
source of antigenic variation which allows the organism to escape antigen-specific host responses. Given the 
hyper-variable nature of the PPE_MPTR proteins and their possible role in host-pathogen interactions, 
genetic diversity within the PPE_MPTR proteins may differentially modulate human immune response. 
Furthermore, epitopes within the PPE_MPTR proteins may be possible subunit vaccine candidates for M. 
tuberculosis.  
 
Conventional experimental techniques used to identify potential epitopes can often be time consuming and 
expensive. Various computational tools exist to predict binding of peptide sequences to various HLA alleles. 
Using a collection of known M. tuberculosis epitopes from the Immune Epitope Database (IEDB), an 
evaluation of the current open source HLA class II prediction tools has been performed, with the results used 
to inform an in silico identification of human CD4+ T-cell epitopes within the PPE_MPTR proteins. 
Characterisation of the genetic diversity of these proteins is also an essential step in improving our 
understanding of this protein family. Publically available whole genome sequence data from strains 
belonging to various lineages has been used to investigate the level of sequence diversity within these 
ppe_mptr genes, and the impact of genetic variants on epitope density has been investigated. To date, this 
study is the most comprehensive analysis of the genetic variation of the ppe_mptr genes. Predicted epitopes 
have been filtered using a reverse vaccinology approach in order to identify possible subunit vaccine 
candidates for M. tuberculosis.  
 
Findings from epitope prediction analysis support the hypothesis of host-pathogen interactions for the 
PPE_MPTR proteins. Genetic variation results indicate that certain PPE_MPTR proteins are highly variable 
while others are relatively conserved across strains, and that genetically diverse regions are less likely to 
contain epitopes. Therefore no evidence to support antigenic variation was found. Areas of high and low 
epitope density are correlated to areas of non-repeat and repeat regions within the genome respectively, 
and therefore epitopes within the PPE_MPTR proteins are conserved non-repeating peptides. This is 
consistent with previous literature on the conservation of reported M. tuberculosis epitopes within clinical 
strains. Further studies are therefore needed to determine the role of the variable copy number of repeats 
found within the PPE_MPTR proteins. Possible vaccine candidates with high predicted population coverage 
in African countries within the PPE_MPTR proteins have been identified.  






Mycobacterium tuberculosis bied ‘n aansienlike gesondheidsrisiko vir mense, veral in Afrika. Vroegtydige 
inenting is die mees suksesvolle strategie in die bekamping van aansteeklike siektes. Ongelukkig het BCG 
(Bacillus Calmette–Guérin), die enigste entstof teen tuberkulose, wisselvallige sukses bereik in die taak. M. 
tuberculosis infeksies verteenwoordig ‘n aanhoudende stryd tussen beide gasheer en bakterie, waarvan die 
molekulêre meganismes wat bydrae tot patogenese nog nie volledig beskryf is nie. Dus, 'n meer indiepte 
begrip van die gasheer-patogeen interaksie sal die ontwikkeling van doeltreffende inentingsstowwe 
bevorder. Beskermende immuniteit teen M. tuberculosis word geïnduseer deur die stimulering van antigeen 
spesifieke T-selle wat peptied antigene herken wat deur HLA (human leucocyte antigen) molekules 
blootgestel word. Die identifisering van epitope wat aan HLA molekules bind en T-sel reaksies lok, vorm deel 
van die ontwikkeling van subeenheid entstowwe.  
 
Die bydrae en funksie van PE/PPE proteïene in mikobakteriële biologie word tans nog nie volledig verstaan 
nie. PE/PPE proteïene is afkomstig van ‘n groot, geneties diverse familie van immunogeniese proteïene 
waarvan die rol in modulering van die gasheer immuun respons voorspel word. Die PPE “major polymorphic 
tandem repeat” (PPE_MPTR) proteïene, wat ‘n subgroep van die PE/PPE proteïene vorm, is beperk to die 
patogeniese  mikobakteriële spesies en verteenwoordig die mees genetiese diverse stel van proteïene in die 
M. tuberculosis proteoom. Alhoewel baie navorsing al uitgevoer is oor die teenwoordigheid van T-sel 
epitope binne die konteks van die PE/PPE familie van proteïene, is daar nog geen studie wat spesifiek fokus 
op die PPE_MPTR subfamilie nie. As gevolg van die hoë variasie in beide die lengte en genetiese diversiteit 
van PPE_MPTR proteïene, word daar gespekuleer dat PPE_MPTR ‘n bron van antigeniese variasie is wat die 
organisme in staat stel om die antigeen-spesifieke gasheer respons te vermy. Die hoё variasie van PPE_MPTR 
proteïene en hul moontlike rol in gasheer-patogeen interaksie kan die gasheer immunrespons moduleer. 
Epitope binne die PPE_MPTR proteïene kan dus goeie kandidate vir subeenheid entstowwe teen M. 
tuberculosis wees. 
 
Tradisionele metodes wat gebruik word om potensiële epitope te identifiseer is dikwels tydrowend en duur. 
Dus, rekenaargebaseerde tegnieke was ontwikkel om die binding van peptiede aan verskeie HLA allele te 
voorspel. Verskeie oopbron HLA klass II voorspellings tegnieke was gebruik om CD4+ T-sel epitope in silico te 
identifiseer binne die PPE_MPTR proteïene, deur gebruik te maak van ‘n versameling bekende M. 
tuberculosis epitope wat verkry is vanaf die Immune Epitope Databasis (IEDB). Die karakterisering van 
PPE_MPTR proteïene is ‘n noodsaaklike stap in die ontwikkeling van kennis oor hierdie  proteïen familie. 
Openbare heel genoom data van stamme, wat aan verskeie stamfamilies behoort, was gebruik om variasie 
te bepaal binne die ppe-mtpr gene, asook die impak van genetiese variante op epitoop digtheid was bepaal. 
Die huidige studie, wat die PPE_MPTR genetiese variasie ondersoek, is die mees omvattendste analise tot 
dusver. Voorspelde epitope was geselekteer deur gebruik te maak van ‘n tru-vaksinologie benadering om 
subeenheid entstowwe teen M. tuberculosis te identifiseer.  
 
PPE_MPTR protein epitoop voorspellings staaf die hipotese van gasheer-patogeen interaksie. Analises 
rakende die genetiese variasie dui daarop dat sekere PPE_MPTR proteïene baie veranderlik voorkom, terwyl 
ander relatief behoue bly binne hul verskillende stamme. Dus, geen bewyse wat antigeniese varisasie staaf 
was gevind nie. Areas met hoë en lae epitoop digtheid onderskeidelik, korreleer goed met nie-herhalende en 
herhalende dele binne die genoom. Dus, epitope binne die PPE_MPTR proteïene is konservatiewe, nie-
herhalende peptiede. Hierdie is in lyn met vorige literatuur wat die bewaring van M. tuberculosis epitope 
binne kliniese stamme aandui. Verdere navorsing is nodig om die rol van die variasie in aantal herhalings 
binne die PPE_MPTR proteïene te bepaal. Entstof kandidate wat hoë voorspelde dekking bied onder die 
Afrika lande is geïdentifiseer binne PPE_MPTR proteïene. 
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1.1.1 Tuberculosis and BCG vaccine 
 
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) presents a substantial health risk to 
humans, particularly in Africa. An estimated 9.6 million people developed TB and 1.5 million died from the 
disease in 2014 worldwide according to the World Health Organisation (WHO) (WHO 2015). Despite the fact 
that a vaccine and a drug regime for TB exist, with certain countries obtaining near eradication, TB still 
remains a threat worldwide. South Africa in particular is ranked as one of the 30 high burden countries in the 
world, along with 15 other African countries, including Angola, Congo, Central African Republic, DR Congo, 
Ethiopia, Kenya, Lesotho, Liberia, Mozambique, Namibia, Nigeria, Sierra Leone, the United Republic of 
Tanzania, Zambia and Zimbabwe. 
 
Prevention of infectious diseases via vaccination is still the most effective strategy in decreasing prevalence 
and minimizing the impact of disease on the human population (Delany et al. 2014). The Bacillus Calmette-
Guérin (BCG) vaccine, developed more than 80 years ago is still the only approved vaccine against TB; 
however it does not prevent pulmonary disease in adults in all cases and has shown varying levels of efficacy 
(WHO 2015). In a review and meta-analysis of the efficacy and duration of protection by BCG, it was found 
that protection against pulmonary TB in adults is highly variable with substantial protection reported in 
certain studies but with absence of clinically important benefits in others, and duration of protection 
reported at an average of up to only 10 years (Abubakar et al. 2013). Despite numerous efforts to develop 
additional, more effective vaccines against M. tuberculosis, we have yet to find one. 
1.1.2 Host-pathogen interaction 
 
M. tuberculosis infection represents an on-going interaction between the host and the bacteria, of which we 
do not yet fully comprehend all the mechanisms contributing to the pathogenesis at a molecular level. We 
are yet to gain a full understanding of how M. tuberculosis manages to successfully evade the human 
immune system, and create a niche environment. Investigating the virulence and pathogenesis of M. 
tuberculosis is an important step towards developing new and more effective vaccines and therefore 
combating the disease. The genome of M. tuberculosis contains 4090 genes, of which 3933 encode proteins; 
however approximately a quarter of coding sequences do not have an assigned functional category 
according to TubercuList (a relational database presenting genome-derived information about the reference 
strain M. tuberculosis H37Rv) (Lew et al. 2011). Gaining a more comprehensive knowledge of the function M. 
tuberculosis proteins play during host-pathogen interaction is an important first step towards identifying 
potential vaccine targets. 
1.1.3 Immunity against TB 
 
Innate immune response against M. tuberculosis following inhalation into the lungs primarily includes 
ingestion by alveolar macrophages, which initiates a number of signalling pathways involved in inflammation 
as well as the development and regulation of the adaptive immune response (Philips & Ernst 2012). Past 
literature on the adaptive immune response to M. tuberculosis has focused on the role of T-cells rather than 
the role of B-cells and antibodies (which remain relatively unclear) (Kozakiewicz et al. 2013). The crucial role 
of T-cells in the adaptive immune response to TB has been demonstrated in seminal studies using mouse 
models, where transgenic mice with deficient major histocompatibility complex (MHC) class II molecules or 
CD4+ T-cells showed increased susceptibility to M. tuberculosis when compared with wild-type mice (Caruso 
et al. 1999). The role of CD4+ T-cells is also evident when investigating human immunodeficiency virus (HIV) 
positive patients who show increased susceptibility to TB when CD4+ cell counts are low (Kwan & Ernst 
2011). Mouse models have also highlighted the importance of CD8+ T-cells, where mutant mice which lack 
MHC class I molecules and fail to develop functional CD8+ T-cells show a higher bacterial load and a 
decreased time to death compared to wild-type mice (Flynn et al. 1992).  
 




Protective immunity against M. tuberculosis is induced in humans by stimulating antigen specific T-cells, 
which recognise peptide antigens presented by human leukocyte antigen (HLA) molecules on infected cells. 
CD8+ T-cells recognise antigens presented by HLA class I molecules, while CD4+ T-cells recognise antigens 
presented by HLA class II molecules. Peptides presented by HLA class I molecules are mainly derived from 
the degradation of intracellular proteins whereas peptides presented by HLA class II molecules are derived 
from the degradation of external proteins which have been internalized by antigen presenting cells (such as 
macrophages and dendritic cells) (Murphy 2011). Therefore while CD8+ T-cells play an important role in the 
adaptive immune response against M. tuberculosis, the activation of CD4+ T-helper cells is critical in 
regulating the adaptive immune response. Any potential vaccine candidate must therefore be able to 
stimulate CD4+ T-lymphocytes. 
1.1.4 Current approaches to new TB vaccine development 
 
The current approach to TB vaccination uses BCG, a live attenuated vaccine derived from bovine 
mycobacteria, which has lost the ability to cause disease in humans but is still similar enough to M. 
tuberculosis to induce protective immunity (Luca & Mihaescu 2013). In addition to live attenuated vaccines, 
new vaccine candidates currently under development include subunit vaccines and mycobacterial lysates. 
Post-exposure vaccines which aim to prevent reactivation and relapse, and therapeutic vaccines which can 
be used to supplement drug regimens, are also under extensive research (Loxton et al. 2016). 
 
Subunit or peptide based vaccines consist of selected mycobacterial antigens which are delivered via viral 
vectors or adjuvants (Loxton et al. 2016). Immune memory does not need to be generated for every peptide 
in a pathogen, and T-cell responses to one or a set of peptides can be sufficient to provide protective 
immunity (Keating & Noble 2003; Song et al. 2015). Subunit vaccines offer the advantage of decreased 
possible adverse reactions since a vaccine would only contain essential antigens, as well as the ability to 
produce sufficient quantities of purified antigenic components as opposed to other vaccination approaches 
(Nascimento & Leite 2012). In addition, recent literature has shown the possibility of enhancing the 
immunity induced by live attenuated candidates through the addition or overexpression of promising 
antigens (McShane et al. 2005; Billeskov et al. 2012). Examples of subunit vaccine candidates currently 
undergoing clinical trials are shown in Table 1. 
 
Table 1.1: Subunit vaccine candidates in current clinical trials. There are currently 7 subunit vaccines undergoing clinical trials. The 
specific M. tuberculosis antigens within each is shown (Loxton et al. 2016). 
Name Delivery Method Clinical 
Phase 
M. tuberculosis antigens included 
ID93 Adjuvant  (GLA-SE) I Rv2608 (PPE42), Rv3619 (EsxV), Rv3620 (EsxW), 
Rv1813 (latency-associated protein) 
H1 Adjuvant (CAF01/IC31) I Ag85B (mycolytransferase) and ESAT-6 
H4 Adjuvant (IC31) I TB10.4 (Rv0288, member of ESAT6 family) and Ag85B 
H56 Adjuvant (IC31) I Ag85B, ESAT-6 and Rv2660c 
M72A Adjuvant (AS01) II MTB32A (PPE18), and MTB39A (serine protease) 
MVA85A Viral (Modified Vaccinia 
Ankara vector) 
II Ag85A (mycolytransferase) 
Aeras402/ 
Crucell Ad35 
Viral (adenovirus vector) II TB10.4, Ag85A and Ag85B. 
 
Bacterial peptides that are recognised by the host immune system are called epitopes, and identifying 
epitopes that are capable of binding to HLA molecules and eliciting T-cell responses form part of the 
development of subunit vaccines. Experimental techniques used to identify potential epitopes can often be 
time consuming and expensive. Reverse vaccinology (RV) pipelines which use in silico approaches to identify 
potential subunit vaccine candidates provide an alternative option. RV pipelines make use of genomic data, 
sequence analysis tools and predictive algorithms to search for potential vaccine candidates 
computationally. These approaches may offer the benefit of identifying antigens which may be difficult to 




work with experimentally and therefore missed by traditional approaches. The use of RV approaches in the 
search for new TB vaccines is expanded upon in Chapter 2. 
 
Two of the subunit vaccine candidates in Table 1.1, ID93 and M72A include antigens from the PE/PPE protein 
family of M. tuberculosis. ID93 which includes PPE42/Rv2608 has shown to be well tolerated and protective 
in animal models (Bertholet et al. 2010) and is currently undergoing phase I clinical trials. M72A, which 
includes PPE18/Rv1196, has undergone both phase I and II clinical trials and has demonstrated safety as well 
as both humoral and cell-mediated immune responses (Day et al. 2013). 
1.1.5 PE/PPE proteins 
 
An area of mycobacterial biology that is poorly understood is the function of the PE/PPE proteins. These 
proteins are a large, genetically diverse family of immunogenic proteins that are predicted to play a role in 
modulating host immune responses. While the functions of these proteins are largely unknown (Lew et al. 
2011), there is evidence for certain members of the family to support interaction with toll-like receptors 
(TLR) (Basu et al. 2007), promote macrophage uptake (Brennan et al. 2001), as well as inhibiting antigen 
processing (Cole et al. 1998). Certain members have also been shown to illicit B-cell responses, CD4+ and 
CD8+ T-cell responses (Sampson 2011). 
 
The genes encoding the PE/PPE proteins make up approximately 10% of the M. tuberculosis genome (Cole et 
al. 1998). The PE/PPE proteins are divided into two groups and are named for their proline-glutamate 
residues (PE) or proline-proline-glutamate (PPE) residues at the start of the encoded proteins. These two 
groups are then further subdivided based on their C-terminal domains which are highly variable in their 
length and sequence features (Figure 1.1). 
 
 
Figure 1.1: PE/PPE Genomics. PE/PPE proteins can be divided into subgroups based on their unique C-terminal features. While the 
PE/PPE region of the sequence has been shown to be highly conserved between strains, the variable C-terminal domains are highly 
polymorphic; most notably the polymorphic GC-rich sequence (PGRS) and major polymorphic tandem repeat (MPTR) sub-families 
which represent two of the most variable regions in the M. tuberculosis genome. (Adapted from Sampson (2011)). 
1.1.6 PPE_MPTR proteins and their possible interaction with the immune system 
 
The PPE Major polymorphic tandem repeat (MPTR) proteins are a subgroup of the PE/PPE proteins which 
are restricted to pathogenic mycobacterial species (Gey van Pittius et al. 2006). The protein sequence 
includes the conserved PPE region of roughly 170-180 amino acids, and the MPTR region which ranges from 
between 420 to 3700 amino acids. The genes encoding the PPE_MPTR proteins are associated with 
imperfect repeats (Figure 1.1) and are hotspots for recombination events and mutations (Cole et al. 1998; 
McEvoy et al. 2009). Evidence indicates that certain PPE_MPTR proteins (PPE_MPTR34 (Rv1917c) and 




PPE_MPTR64 (Rv3558)) localise to the cell wall (Sampson et al. 2001; Sani et al. 2010), placing them in an 
ideal position to interact with host components and potentially modulate immune responses. PPE_MPTR42 
(Rv2608), one of the antigens included in vaccine candidate ID93, has shown to elicit B-cell responses 
(Choudhary et al. 2004; Ireton et al. 2010), as well as T-cell responses which confers protective immunity 
(Bertholet et al. 2008). Other studies suggest that PPE_MPTR proteins play multiple roles in infection 
(Sampson 2011), including blocking trafficking of M. tuberculosis to acidified phagosomes (PPE_MPTR10 
(Rv0442c), PPE_MPTR16 (Rv1135c) and PPE_MPTR54 (Rv3343c)) (Stewart et al. 2005; Brodin et al. 2010), 
interacting with TLR-2 and inducing dendritic cell maturation (PPE_MPTR34 (Rv1917c)) (Bansal et al. 2010). 
 
Based on the extreme variation in both the length and genetic diversity of the PPE_MPTR  proteins, it has 
been speculated that they may represent a source of antigenic variation which allows the organism to 
escape antigen-specific host responses (Karboul et al. 2008; Akhter et al. 2012). Antigenic variation, which is 
described as the asynchronous expression of functionally conserved yet antigenetically distinct proteins is a 
mechanism used by many bacterial and non-bacterial pathogens to evade the host immune system (van der 
Woude & Baumler 2004). Typically, a pathogen will possess the genetic information to produce a family of 
antigenic variants but only one variant is expressed at a given time, allowing the pathogen to evade or re-
infect a host as the variable antigens will no longer be recognised by the host immune system. In general, 
antigenic variation is achieved through the assortment and recombination of repeated genes or gene 
segments (Borst 1991). Classic examples of bacterial species in which antigenic variation occur include: 
Borrelia burgdorferi which uses recombination of its vlsE genes to produce variable lipoproteins resulting in 
waves of sickness each time a new variant emerges (Koomey 1997);  Campylobacter fetus which uses 
recombination of its SapA genes to produce variable surface layer proteins (Dworkin & Blaser 1997); and 
Neisseria meningitidis and Neisseria gonorrhoeae which are able to produce millions of different, 
antigenically distinct fimbriae/pili that extend from the cell surface (Nassif et al. 1993; Hagblom et al. 1985). 
Epitopes within these antigens are generally under selective pressure leading to more variation within the 
corresponding gene sequences. To date however, M. tuberculosis epitopes have been found to be highly 
conserved (inconsistent with antigenic variation) (Comas et al. 2010), and instead the bacteria seems to use 
the host immune cells to create a niche growing environment (Ernst 2012).  
 
Previous studies have investigated the possibility of antigenic variation within the highly diverse PE_PGRS 
sub-family (Copin et al. 2014). Along with the PPE_MPTR sub-family, these proteins are some of the most 
variable regions in the M. tuberculosis genome (Cole et al. 1998). Bioinformatics methods were used to test 
whether sequence diversity in the PE_PGRS genes may be selected by human T-cell recognition; however 
results showed that despite being genetically diverse, few predicted epitopes were found within the PGRS 
domain. The authors concluded that human T-cell recognition is not a significant factor driving sequence 
diversity within the PE_PGRS proteins (Copin et al. 2014). Similar analysis has not been performed for the 
PPE_MPTR proteins, and the role of the extensive genetic variation observed within the PPE_MPTR proteins 
is unclear, particularly whether genetic diversity within these genes contributes to the pathogenicity of M. 
tuberculosis. Whether or not the PPE_MPTR proteins are a source of antigenic variation is therefore yet 
unanswered. 
 
To date no studies have systematically addressed the role of the PPE_MPTR proteins in host-pathogen 
interactions, and given the possible role of these proteins in the interaction with the immune system, they 
may be candidates for potential vaccine targets that should be further explored. 
 
1.2 Problem Statement 
 
Members of the PPE_MPTR family are known to be unique to pathogenic mycobacteria and are thought to 
play a role in host-pathogen interactions. Nevertheless this set of proteins is relatively poorly characterized, 
and the exact mechanisms and consequences of the host-pathogen interactions are not well understood. 
The presence and distribution of epitopes within this sub-family of M. tuberculosis proteins have also not 
been fully explored. The PPE_MPTR proteins are known to be highly variable, leading to the possible 
assumption that these proteins may play a role in antigenic variation seen in other pathogens but not (yet) in 
M. tuberculosis. Determining the mechanisms underlying ppe_mptr diversification will also aid in the 




understanding of the role of these genes in the evolution of mycobacterial pathogenicity. A better 
understanding of the role of the PPE_MPTR proteins in modulating or evading host immune responses will 
aid in the development of novel interventions such as vaccines in order to favourably influence the outcome 
of infections with M. tuberculosis.  
 
Conventional wet lab approaches used to ascertain host-pathogen interactions are often time-consuming 
and costly due to the large number of possible experiments needed. Computational methods offer the 
opportunity to use the large amount of existing data together with mathematical and statistical techniques 
to make accurate predictions about the interactions between M. tuberculosis and host components. This will 
allow researchers to gain a better understanding of host-pathogen interactions and will also inform the type 




Given the hyper-variable nature of the PPE_MPTR proteins and their possible role in modulating host-
pathogen interactions, genetic diversity within PPE_MPTR proteins may differentially modulate human 
immune response.  
 
Epitopes within the PPE_MPTR proteins may be possible subunit vaccine candidates for M. tuberculosis.  
 
1.4 Aims and Objectives 
1.4.1 Aim 1: In silico identification of human CD4+ T-cell epitopes in PPE_MPTR proteins 
 
CD4+ T-cell epitopes induce an immune response when bound by HLA/MHC class II molecules presented on 
the cell surface for recognition by T-cells. The conventional approach to identifying T-cell epitopes involves 
synthesizing overlapping peptide fragments and assaying for binding to HLA class II molecules (Figure 1.2). 
However this method can become time consuming and costly, especially for large proteins such as certain 
members of the PPE_MPTR family. Computational methods have been developed which predict binding of 
peptides to HLA molecules using a variety of statistical algorithms based on known epitope data. 
 
 
Figure 1.2: Methodology for identifying potential epitopes. Binding of overlapping peptides along the length of each PPE_MPTR 
protein with various HLA class II alleles is predicted using in silico approaches.  
1.4.1.1 Objective 1: Determination of the optimal epitope prediction pipeline  
 
There are currently more than 20 predictive tools used to predict binding of peptides to HLA class II 
molecules. Using a collection of known M. tuberculosis epitopes from the Immune Epitope Database (IEDB), 
an evaluation of the current open source HLA class II prediction tools will be performed.  As a result, the 
optimal epitope prediction pipeline for M. tuberculosis proteins will be determined. 
  




1.4.1.2 Objective 2: Prediction of PPE_MPTR epitopes 
 
Prediction of binding of overlapping peptides within each of the PPE_MPTR to various HLA alleles will be 
performed using the pipeline determined in objective 1. Resulting predicted epitopes may be potential 
candidates for subunit vaccines, and provide a more targeted starting point for further analysis. 
1.4.2 Aim 2: Characterisation of the level of genetic diversity within the PPE_MPTR family members  
 
The number and type of mutational events such as single nucleotide polymorphisms (SNPs), insertions 
and/or deletions (indels) or large macro-mutations will be determined and compared for each PPE_MPTR 
protein. Publically available whole genome sequences (WGS) from strains belonging to various lineages will 
be used. Results from this analysis will provide insight into the mechanisms underlying PPE_MPTR 
diversification and may shed light on the role that these proteins play in mycobacterial pathogenicity.  
1.4.3 Aim 3: Determine the impact of genetic variants on epitope prediction 
 
Investigating the presence or lack of genetic variants in areas of predicted epitopes will help determine 
whether genetic diversity within PPE_MPTR T-cell epitopes differentially modulates human immune 
response as hypothesized, and therefore whether these proteins may represent a source of antigenic 
variation. These results will also be an important consideration in determining whether epitopes from the 
PPE_MPTR proteins are potential sub-unit vaccine candidates. 
1.4.4 Aim 4: Identification of potential vaccine candidates 
 
Predicted epitopes will be filtered using a reverse vaccinology (RV) approach in order to identify possible 
vaccine candidates. 
 
1.5 Significance of Research 
 
This research may provide novel insights into the function of the PPE_MPTR proteins, and whether they may 
play a role in host-pathogen interaction. 
 
Possible vaccine candidates may be identified that may prompt further research and experimentation. 
 
1.6 Scope and Limitations 
 
This project is limited to the PPE_MPTR proteins of M. tuberculosis and to the prediction of MHC/HLA class II 
responses. 
 
Results are based on purely computational approaches which provide the most likely answer given a set of 
input data. Experimental validation of predictions has not been performed. The results in this project 
therefore provide a starting point for further analysis and validation. 
 
The pe/ppe genes are notoriously difficult to sequence as well as to align/map to a reference genome due to 
the high sequence variation and repeat regions found within these genes. The short reads of the current 
sequencing technology used can result in low confidence mapping over these regions and therefore in the 
resulting variants called. Assembled WGS data used within this project has been gathered from public 
databases and has not been checked for quality. It has been assumed that the assembly of each WGS is 
acceptable, and the resulting gene sequences within the PE/PPE regions are correct. Where possible, 
additional steps have been taken to ensure data is accurate, however no additional targeted sequencing has 
been performed to validate the genetic variation identified. 
 
 




1.7 Chapter Overview 
 
Chapter 2:  Literature review 
The use of immunoinformatics in the identification of vaccine candidates for M. tuberculosis 
 
Chapter 3: Evaluation of MHC class II epitope prediction tools 
Eight prediction tools have been evaluated using experimentally validated M. tuberculosis 
CD4+ T-cell epitopes. 
 
Chapter 4: MHC II epitope prediction 
This chapter presents the results from an in silico identification of MHC class II epitopes 
within the PPE_MPTR proteins.  Various HLA class II alleles have been included. 
 
Chapter 5: Genetic diversity of PPE_MPTR proteins 
This chapter presents genetic diversity results from the analysis of 33 M. tuberculosis strains 
and 5 other mycobacterial strains. The correlation between areas of diversity with areas of 
predicted epitopes has been evaluated. 
 
Chapter 6: Identification of potential vaccine candidates and conclusion 
Using the results from Chapter 4 and Chapter 5 potential vaccine candidates have been 
identified using a Reverse Vaccinology approach. This includes the in silico prediction of the 
potential population coverage of each possible vaccine candidate within South Africa. 
Concluding remarks are given. 
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Chapter 2: Literature Review: 
 










2.1.1 The search for a new vaccine against tuberculosis 
 
The need for a new vaccine against Tuberculosis (TB) has been well documented, with the current Bacillus 
Calmette-Guérin (BCG) vaccine, developed more than 80 years ago, showing varying levels of efficacy (WHO 
2015). Several promising vaccines are currently in various phases of clinical trials (Chapter 1, Table 1.1), 
which include subunit or peptide based vaccines which consist of selected mycobacterial antigens (Loxton et 
al. 2016). Identifying the optimal composition of protective antigens is an essential step towards developing 
new peptide based vaccines (Vivona et al. 2008). Protective immunity against Mycobacterium tuberculosis is 
induced by stimulating antigen specific T-cells which recognise peptide antigens presented on human 
leukocyte antigen (HLA) molecules (Figure 2.1). Bacterial peptides that are recognised by the host immune 
system in this way are called T-cell epitopes, and identifying epitopes that are capable of binding to HLA 




Figure 2.1: Antigen Presentation Pathways. a) Intracellular antigens are degraded by the immunoproteasome and transported to 
the endoplasmic reticulum where they are loaded into HLA class I molecules and presented to CD8+ T-cells. b) Antigens from 
extracellular sources, which include bacterial pathogens are degraded by endolysosomal  enzymes, and loaded into HLA class II 
molecules and presented to CD4+ T-cells (Kobayashi & van den Elsen 2012). 




Experimental techniques used to identify potential epitopes can often be time consuming and expensive; 
however in silico approaches such as those used in immunoinformatics provide an alternative option. 
2.1.2 Immunoinformatics 
 
A large amount of immunological data has accumulated due to clinical research, epidemiological 
investigations and developments in sequencing of both human and pathogen genomes. This has led to new 
discoveries in immune function and disease pathogenesis (Tomar & De 2014). This growing amount of 
immunological data as well as the in silico techniques used to analyse this data has led to the emergence of a 
specific branch of bioinformatics known as immunoinformatics. Immunoinformatics can be described as the 
interface between computer science and experimental immunology (Tomar & De 2014). Having access to 
this wealth of data along with the tools available to analyse it has made searching for vaccine targets a much 
more efficient process. The use of immunoinformatic techniques in the search for potential vaccine 
candidates is termed reverse vaccinology (RV). RV workflows aim to narrow down the potential list of 
antigens to be included in a vaccine which can then be further tested and validated in an experimental 
setting, thereby lowering the time and cost associated with laboratory analysis. The applicability and 
usefulness of RV techniques was first demonstrated by Pizza et al. (2000) in the identification of vaccine 
candidates against Serogroup B Meningococcus (MenB). In this seminal study, whole genome sequence 
(WGS) data was used to predict novel surface exposed or exported proteins, followed by comparative 
genomics in order to test the suitability of the candidate antigens to induce protection against various 
clinical MenB strains. Since then RV techniques have been applied to various other pathogens including M. 
tuberculosis. 
 
The accumulation of the large amount of genomic and experimentally generated immunological data has 
necessitated the need for immunological databases. These databases are needed to not only store and 
categorise data but also enable sharing of the data between researchers. Prediction methods used in RV 
workflows also require large amounts of training data in order to make the algorithms as accurate as 
possible. Immunoinformatics therefore acts as an intersection between immunological data and the 
computational techniques and algorithms used to make predictions (Vivona et al. 2008).  
 
A traditional RV approach includes the use of comparative genomics; epitope prediction; analysis of protein 
properties; and the prediction of protective coverage to identify immunogenic antigens (Figure 2.2). Certain 
workflows within a traditional RV approach may be more or less applicable depending on the pathogen 
being studied, and actual pipelines used should be individually tailored. In certain cases, selection criteria 
(i.e. by type or function of protein) may be used in order to first narrow down the list of possible antigenic 
targets being fed into a RV workflow. The selection criteria should reflect the different mechanisms 
contributing to the pathogenesis of the pathogen. However, in certain cases, a bias may be introduced 
where the actual selection criteria is a reflection of the current knowledge (or lack thereof) of the biology of 
the pathogen in question. In other cases, experimental limitations may result in selection bias focusing on 
proteins that can be studied in a wet lab setting. In these cases, a whole genome approach may overcome 
any selection bias introduced. 
  






Figure 2.2: Traditional Reverse Vaccinology (RV) Workflow. A traditional RV workflow used to identify possible vaccine targets 
generally includes comparative genomics, epitope prediction, analysis of protein properties and prediction of protective coverage 
(Brusic & Petrovsky 2005; Vivona et al. 2008; Movahedi & Hampson 2008; Mora et al. 2006; Serruto et al. 2009; Davies & Flower 
2007; Bambini & Rappuoli 2009; Rapin et al. 2010; Tomar & De 2010). 
•Comparison of multiple strains of the same pathogen allows detection of conserved 
regions within the genome.  
 
•Identification of homologs within other (similar) pathogens will determine whether any 
cross-reactivity with other pathogenic antigens may exist.  
 
•Vaccine candidates should not present homology with human proteins to avoid the 
generation of potential autoimmune responses. 
Comparative genomics 
•In silico tools used to predict both T-cell and B-cell epitopes have been developed. 
 
•B-cell epitope prediction focuses on structural regions of a protein likely to be recognised 
as an epitope. 
 
•T-cell epitope prediction makes use of in silico methods to predict the binding affinity of 
short peptide sequences to various HLA class I and class II molecules. In the case of CD8+ T-
cells, epitope prediction methods may also include other parts of the HLA class I 
presentation pathway including TAP transport. 
Epitope Prediction 
•Prediction of subcellular location. Extra-cellular, intra-cellular, cell-surface or trans-
membrane regions may be more or less accessible to the immune system, or have 
different antigenic properties. The location of a protein may also give an indication of the 
possible role of the protein in host-pathogen interactions. 
 
•Prediction of antigenic and adhesive properties are important when identifying possible 
vaccine candidates. 
Analysis of protein properties 
•A high binding specificity exists between T-cell epitopes and HLA molecules. A given 
epitope will elicit an immune response only in individuals expressing HLA molecules 
capable of binding to that particular epitope. 
 
•Prediction of protective coverage of a peptide based vaccine involves calculating the 
percentage of individuals within a population expected to respond to an epitope or set of 
epitopes given the frequency of HLA alleles within that population. 
Prediction of protective coverage 




2.1.3 Adaption of RV workflows to M. tuberculosis 
 
M. tuberculosis has various unique characteristics, not only in structure but in the interaction of the bacteria 
with the human host. For example, given the importance of T-cells in initiating and regulating the adaptive 
immune response against M. tuberculosis, and the relatively unclear role of B-cells and antibodies, TB 
researchers have primarily focused on the prediction of T-cell rather than B-cell epitopes. In addition, when 
choosing selection criteria, many RV workflows limit searching for possible vaccine candidates to surface 
exposed/secreted proteins which may be involved in adhesion, invasion, secretion and signalling host 
responses (Vivona et al. 2008). While these may be important candidates, limiting the search to these 
proteins may not be appropriate for M. tuberculosis. Immunity against M. tuberculosis is primarily induced 
via stimulation of CD4+ T-cells, which recognise peptides derived from the degradation of bacterial proteins 
which have been internalized by macrophages and presented by HLA class II molecules. In addition, 
apoptosis of the infected cells can result in bacterial fragments taken up by various antigen presenting cells 
which initiates the HLA class I presentation pathway and CD8+ T-cell stimulation (Figure 2.1). Literature has 
shown that BCG vaccination (which primarily induces CD4+ immunity) can be enhanced by promoting 
antigen translocation into the cytoplasm and stimulating CD8+ T-cells, therefore enhancing overall T-cell 
mediated immunity and superior protection against M. tuberculosis (Grode et al. 2005). Subunit vaccines 
combining peptides capable of inducing both CD4+ as well as CD8+ immunity may therefore be most 
effective against M. tuberculosis. For this reason, limiting RV searches to surface exposed/secreted proteins 
may underestimate the range of possible targets. 
 
RV workflows used in the analysis of protein properties may also not be as applicable when considering M. 
tuberculosis. For example, bacterial lipoproteins, may represent a class of possible vaccine candidates for 
many pathogens given their role in cell signalling and substrate binding, for which in silico tools such as 
LipPred have been developed to identify (Taylor et al. 2006). These tools are usually developed specifically 
for either Gram-positive or Gram-negative bacteria. However, while M. tuberculosis belongs to the group of 
Gram-positive bacteria, the lipid-rich outer layer of M. tuberculosis is comparable to the outer membrane of 
Gram-negative bacteria (Rezwan et al. 2007). These in silico tools may therefore be less accurate when used 
to identify lipoproteins for M. tuberculosis. 
 
The level of genetic diversity for different pathogens will determine the importance of comparative 
genomics within the RV workflow. In 1998, the complete genome sequence of a well characterised strain of 
M. tuberculosis, H37Rv, was first completed (Cole et al. 1998). Since then, a large number of strains from 
different lineages have been sequenced allowing for comparative genomic analysis between strains. These 
investigations have helped explain the evolution of M. tuberculosis and identification of essential genes and 
others contributing to pathogenicity. Conserved versus genetically diverse regions within the genome have 
also been identified, making comparative genomics an essential step within the RV workflow as potential 
vaccine candidates should be effective against various clinical strains of M. tuberculosis. This is particularly 
relevant when considering the ppe_mptr genes as each protein contains both a conserved region (PPE) and a 
highly variable region (MPTR). Genetic variation of the ppe_mptr genes across various strains is investigated 
in Chapter 5 and the results used to filter for possible vaccine candidates in Chapter 6. 
 
In addition to WGS data, large amounts of transcriptomic and proteomic data has been generated. 
Combining this omics information with data generated through experimental laboratory analysis has given 
new insights into the function of M. tuberculosis proteins, and their role within host-pathogen interactions. 
However, many encoded proteins within the M. tuberculosis genome still have an unknown or hypothetical 
function, some of which may play a possible role in human immune response. Immunoinformatic techniques 
offer researchers the opportunity to use known data to model various immunological processes, leading to a 
better understanding of the systems and pathways that may be involved in host-pathogen interactions and 
therefore aiding in the search for new vaccine candidates, even within proteins with an unknown or 
hypothetical function. In this way, selection bias imposed by a limited knowledge of the mechanisms of 
pathogenesis for M. tuberculosis may be avoided through RV. 
 




RV workflows that include comparative genomics, epitope prediction and analysis of protein properties have 
been applied to M. tuberculosis. For example, the MycobacRVWebserver is a database containing the results 
of a RV workflow applied to 23 mycobacterial strains (including 13 M. tuberculosis strains, and 10 other 
pathogenic mycobacterial proteomes) (Chaudhuri et al. 2014). These results are available to TB researchers. 
In an alternative study, a RV workflow was applied to the M. tuberculosis H37Rv strain using the New 
Enhanced Reverse Vaccinology Environment (NERVE) software (Monterrubio-López et al. 2015), which has 
been developed to provide researchers with multiple well-known algorithms for protein analysis and 
comparison (Vivona et al. 2006).  
 
In addition to the above, there are a substantial number of other immunological databases and prediction 
methods available to TB researchers which can be used in the search for possible vaccine targets. Databases 
containing T-cell epitope information and tools related to predicting T-cell epitopes and their expected 
protective coverage have been focused on here. This chapter provides a review of these resources including 
examples where in silico immunological techniques have already assisted in identifying vaccine candidates 
for M. tuberculosis.  
 
2.2 Immunological Databases 
2.2.1 T-Cell epitope databases 
 
Immunological databases contain a wide variety of data sources including data from laboratory experiments 
performed to elucidate mechanistic aspects of an immune system and/or response to various infections 
(Vita et al. 2014). A large proportion of these experiments include identifying T cell epitopes. This typically 
involves synthesizing overlapping peptides from a pathogen protein and performing assays to test for 
binding to HLA alleles and/or cellular immune responses of the host to exposure of the antigen peptide. 
Table 2.1 shows current immunological databases containing T-cell epitope data, which are actively being 
updated and contain information relating to mycobacteria. Other databases, such as InnateDB which focuses 
on pathways and interactions involved in the innate immune response rather than the adaptive immune 
response are also available (Breuer et al. 2013). 
 
Table 2.1: T-Cell Epitope Databases. Databases that are currently accessible, actively being updated, and contain information 
relating to mycobacteria have been included. 
Database Reference 
IEDB (Immune Epitope Database) 
Contains experimental data characterising epitopes (B-cell and T-cell) 
involved in infectious diseases (in human and other animal species), allergy, 
autoimmunity and transplant. Data is curated from published literature and 
submitted by NIH funded epitope discovery efforts. 
(Vita et al. 2014) 
www.iedb.org 
Syfpeithi 
Contains data relating to peptide anchor motifs and MHC ligands of humans 
and other animal species, including peptide sequences, anchor positions, 
MHC specificity, source organisms and publication references. Data is 
curated from published literature. 
(Rammensee et al. 1999) 
www.syfpeithi.de 
AntiJen (Previously known as JenPep) 
Contains quantitative binding data for peptides binding to MHC Ligand, TCR-
MHC Complexes, B-cell and T-cell epitopes, TAP and immunological protein-
protein interactions. Additionally, AntiJen integrates this cellular data with 
kinetic, thermodynamic and functional information. Data is curated from 
published experimentally determined experiments. 
(Blythe et al. 2002; 
McSparron et al. 2003; 





Contains detailed information about MHC binding and non-binding peptides 
and T-cell epitopes, peptides interacting with TAP and MHC linked 
autoimmune diseases. 
(Lata et al. 2009) 
http://www.imtech.res.in/rag
hava/mhcbn/ 




The collective knowledge of known M. tuberculosis epitopes contained within databases such as the IEDB 
not only aids in vaccine development but can also identify gaps and suggest potential areas for further 
research and discovery. In 2007, a comprehensive analysis of M. tuberculosis data contained within the IEDB 
was performed, with results showing that at the time epitopes were reported in only 7% of all open reading 
frames, with the top 30 studied protein antigens containing approximately 65% of reported epitopes (Blythe 
et al. 2007). It is evident from this study that the majority of the M. tuberculosis proteome has been under 
explored in the context of epitope identification. The majority of epitopes were found in proteins associated 
with virulence, detoxification and adaption; however epitope density of mycobacterial proteins may not be 
indicative of the true distribution of epitopes within the proteome but rather due to experimental bias. RV 
workflows may therefore be helpful in unbiased identification of epitopes across the proteome without the 
limitations imposed by experimental analysis such as difficulty of protein isolation. This study also 
highlighted an important shortfall of immunological databases in that information relating to the specific 
strain from which the epitope was derived is not recorded, which is an important consideration for a 
pathogen such as M. tuberculosis which contains polymorphic areas within its genome.  
2.2.2 Human immune cell databases 
 
Databases containing genomic information of human immune cells, predominantly focused on HLA 
molecules, are also available to immunological researchers (Table 2.2). These databases aim to capture the 
different alleles reported across various populations resulting from the polymorphic nature of the human 
genome. Both the genetic information of the bacteria and the human host are extremely important when 
studying host-pathogen interactions, particularly when trying to determine the protective coverage of a 
vaccine target (Section 2.5). 
 
Table 2.2: Databases containing human immune data. Human immune cell databases available to TB researches with corresponding 
URLs are given. 
Database Reference 
dbMHC 
Contains DNA and clinical data related to HLA molecules. Includes an 
interactive alignment viewer for HLA and related genes, an MHC 
microsatellite database, a sequence interpretation site for sequencing 
based typing and a primer/probe database. 
 
(Helmberg et al. 2004) 
http://www.ncbi.nlm.nih.gov/proj
ects/gv/mhc/ 
IMGT (International ImMunoGeneTics information system) 
Contains data relating to immunoglobulins/antibodies, T-cell receptors, 
MHC and HLA molecules, and related proteins of the immune system. 





AFND (Allele Frequency Net Database) 
Provides allele frequencies in different populations across the world 
from polymorphic areas in the human genome which are involved in 
immune functions including HLA, killer cell immunoglobulin-like 
receptors (KIR), cytokines and major histocompatibility complex class I 
chain-related genes (MIC). 
 
(González-Galarza et al. 2015) 
www.allelefrequencies.net 
2.2.3 Mycobacterium specific databases 
 
Databases collecting and storing mycobacteria specific data include Tuberculist (Lew et al. 2011) and TBDB 
(Galagan et al. 2010). These databases provide a valuable source of WGS data which can be used to perform 
comparative genomic analysis of various M. tuberculosis strains. Expression data which can provide a 
starting point for selection criteria or alternatively be used as a potential source of validation following the 
identification of potential vaccine candidates is also available. TBDB also provides a complete list of epitopes 
for the clinical strain H37Rv stored within the IEDB. 
  




2.2.4 Data repositories for machine learning 
 
Predictive tools used in reverse vaccinology workflows rely on known experimental data to train machine 
learning algorithms (section 2.3.1). The accuracy of prediction tools is therefore dependent on the amount 
and quality of this data. In addition to the databases shown in Table 2.1, data repositories such as the Dana-
Farber Repository for Machine Learning in Immunology (DFRMLI) have been created. DFRMLI aims to bridge 
the gap between immunologists and computer scientists by providing pre-processed and scaled 
immunological datasets which can be used in machine learning applications (Zhang et al. 2011). 
 
2.3 T-Cell Epitope Prediction 
 
Traditional methods of epitope identification involve the synthesis and testing of overlapping peptides that 
span the entire protein or target antigen using experimental assays. However this systematic mapping 
approach can become costly and time consuming, especially for large proteins within the M. tuberculosis 
proteome and the large repertoire of HLA molecules that exists. This has necessitated the need to develop in 
silico epitope prediction methods. 
 
HLA binding is required for T-cell recognition, and therefore in silico T-cell epitope prediction methods rely 
heavily on predicting the binding affinity of short peptide sequences to various HLA class I and class II 
molecules. Various steps are involved during antigen presentation, of which binding to an HLA molecule is 
just one. The majority of epitope prediction tools are therefore indirect epitope prediction methods since it 
is assumed that a peptide able to bind to an HLA molecule will illicit an immune response. In silico methods 
which model and/or predict other parts of the HLA class I antigen presentation pathway such as proteasomal 
cleavage and the transfer-associated protein (TAP) are also available to researchers and are discussed below. 
 
There are currently over 30 different HLA class I and HLA class II prediction tools openly available. These 
tools are based on various prediction algorithms and methods. The majority of these methods involve 
defining peptide-HLA binding specificities based on large datasets of known HLA binding peptides. These 
datasets are used to train predictive algorithms. 
2.3.1 Prediction algorithms 
 
Various prediction algorithms have been used to predict T-cell epitopes (Table 2.3). These methods are 
grouped into either direct prediction methods which are based on the sequence and/or structural analysis of 
T-cell epitopes such as binding motifs; or indirect methods which are based on statistical learning theory. 
 
  




Table 2.3: Prediction Algorithms. Both direct and indirect prediction algorithms are used within various epitope prediction tools. 
Algorithm Description 
Direct Methods:  
Sequence/Motif and 
structural based. 
These algorithms involve searching for known HLA binding amino acid motifs called 
anchor motifs. Direct methods include using position specific scoring matrices 
(PSSM) or quantitative matrices that take into account the position of each amino 
acid along the length of a peptide and assigns a value based on the frequency of 
occurrence in known T-cell epitopes.  
 
Methods using predicted structural information such as presence of hydrophilic 
and hydrophobic regions from sequence information also fall into this category.  
 
Proteochemometrics-based approaches have also been applied to HLA class II 
binding prediction. These approaches use quantitative structure-activity 
relationship (QSAR) and partial least squares regression analysis (PLS) which relates 
quantitative properties of ligands to their activity. These properties can include 
volume, hydrophobicity, and polarizability for each of the amino acid residues. 
 
Specificity-determining residues (SDR) have been used to describe amino acid 
residues that are responsible for specific interactions between a pair of proteins or 
in the case of HLA binding prediction, a protein and a peptide. In this case, 
developers have used crystal structures of peptide and HLA complexes. 
 
Indirect Methods:  
Machine learning 
methods 
Indirect Methods include using Artificial Neural Networks (ANN), Hidden Markov 
Models (HMM), and Support Vector Machines (SVM) (Vivona et al. 2008). 
 
ANN’s are trained to learn features of appropriate patterns from known data of 
peptide and HLA binding, and subsequently recognise similar patterns in new data 
with unknown binding ability.  
 
HMM’s are statistical models which use a finite set of states, each with an 
associated probability distribution to determine the most likely state of the process 
based on the given input data. 
 
SVM’s are  trained to recognise patterns present in known data by mapping the 
data into a high-dimensional feature space where every coordinate corresponds to 
a particular feature within the data.  
 
2.3.2 Data quantity and quality  
 
Given that the majority of these prediction methods make use of known epitope data to train the predictive 
algorithm, the accuracy of each model is dependent on the quantity and quality of training data used, 
further highlighting the need for the storage and access to immunological data.  
 
There exists a high peptide to HLA molecule specificity and therefore a sufficient amount of binding affinity 
data for each HLA allele is needed to accurately make predictions per allele. Based on this, the accuracy, 
sensitivity, and specificity of each prediction method differ per HLA allele and is reflective of the amount of 
HLA data included in the training set used. This has been demonstrated for both HLA class I and class II 
alleles during a comparative evaluation of the publically available prediction servers (Lin, Ray, et al. 2008; 
Lin, Zhang, et al. 2008). HLA molecules are extremely polymorphic, with over 15,635 alleles reported to date 
on the IGMT/HLA database (accessed 1 November 2016). This makes including data for each HLA allele in a 
training set and therefore prediction method almost impossible. Pan-specific methods have been developed 
in response to this need. Pan-specific methods extend prediction to a wider set of HLA molecules (for which 
little binding data is available), by extrapolating from the binding specificities of the molecules for which 




sufficient binding data is available. This is done using similarities in the binding cores of the HLA molecules 
(Karosiene et al. 2013). However the accuracy of these pan-specific methods is generally lower than for 
other prediction methods (Lin, Zhang, et al. 2008). 
 
In addition to using already trained algorithms, researchers are also able to customize their own predictions 
using their own data sources. EPIMHC is a database of T-cell epitopes and HLA binding peptides and allows a 
user to choose which data to use when constructing motif profiles (Reche et al. 2005). In this way, M. 
tuberculosis researchers are able to train a motif based algorithm using only known M. tuberculosis epitopes, 
while excluding other pathogens. This may improve the accuracy when investigating unknown M. 
tuberculosis proteins. 
2.3.3 Epitope prediction tools 
 
Table 2.4 includes a list of the currently available HLA class I and class II prediction tools available. 
 
In general, the accuracy of HLA class I tools is higher than that reported for HLA class II prediction tools 
(Nielsen et al. 2010). While both HLA class I and class II molecules are heterodimers, with binding grooves 
consisting of a B-sheet and two alpha-helices, structural differences between the two types of HLA 
molecules affect the accuracy of the predictions. HLA class I molecules have a closed binding groove that 
binds an entire peptide (between 8-11 amino acids long); while HLA class II molecules bind peptides 
between 14-18 amino acids long, but have an open binding groove that accommodates a 9-mer binding core 
with the rest of the peptide binding on either side of the binding groove (Nielsen et al. 2010). There is a high 
binding specificity between the 9 mer binding core and the binding groove, while binding of the ends of the 
peptide to the edges of the binding groove is less specific. For HLA class I prediction tools, alignment free 
methods can be easily used since HLA class I peptides are generally of equal length and binding motifs have 
been well characterised, whereas HLA class II epitopes van vary greatly in length making alignment a crucial 
part of estimating binding motifs and predicted binding (Nielsen et al. 2010). This additional complexity has 
resulted in lower reported accuracy. As a result it has been suggested that HLA class I predictors should be 
used for prediction of positive binders while HLA class II predictors should be used for the elimination of 
obvious negatives or non-binders (Pappalardo et al. 2009). Given the objective of finding potential epitopes 
which will be validated in an experimental setting, researchers employing RV workflows often need to 
choose between decreasing the number of potential epitopes (i.e. increasing specificity) versus missing true 
epitopes (i.e. increasing sensitivity), particularly for HLA class II tools with a lower reported accuracy. 
Therefore eliminating obvious negatives is appropriate in the context of finding potential vaccine candidates 
(except in the case of extreme resource limitations). This is further discussed in Chapter 3. 
 
Consensus approaches have been developed that use an average or median prediction value from various 
prediction tools. Evaluations have been performed comparing the accuracy of the various tools with one 
another (Lin, Ray, et al. 2008; Lin, Zhang, et al. 2008), as well as comparing the accuracy with consensus 
approaches (Wang et al. 2008; Wang et al. 2010; Moutaftsi et al. 2006). In general, consensus approaches 
have shown to be superior to individual approaches. Evaluation of HLA class II epitope prediction tools is 
further discussed in Chapter 3.  
  




Table 2.4: T-cell Epitope Prediction Tools. A list of various prediction tools for both MHC class I and class II molecules with their 
corresponding URLs have been given. 
Tool Algorithm Reference URL 













IEDB ANN, ARB, 
SMM 
(Nielsen et al. 
2003; Bui et al. 
2005; Peters & 
Sette 2005) 
http://tools.iedb.org/mhci/ 




MHC BPS SVM (Cui et al. 2006)  
MHC-I Structure-
based model 
(Jojic et al. 2006) http://boson.research.microsoft.com/hlabind
ing/hlabinding.aspx 
MHCPred PLS (Guan et al. 2006) http://www.ddg-
pharmfac.net/mhcpred/MHCPred/ 
MULTIPRED ANN, HMM, 
SVM 




NetMHC ANN, Matrix (Lundegaard et al. 
2008) 
http://www.cbs.dtu.dk/services/NetMHC/ 











ProPred1 Matrix (Singh & Raghava 
2003) 
http://www.imtech.res.in/raghava/propred1/ 
Rankpep Matrix (Reche et al. 
2002) 
http://imed.med.ucm.es/Tools/rankpep.html 
SMM Matrix (Peters et al. 
2003) 
https://zlab.bu.edu/SMM/ 




PeptideCheck Matrix (DeLuca et al. 
2007) 
http://www.peptidecheck.org/ 
HLA Class II     












(Lundegaard et al. 
2008; Karosiene 





IEDB_ARB Matrix (Bui et al. 2005) http://tools.iedb.org/mhcii/ 
 
NN-align ANN (Nielsen & Lund 
2009) 
http://tools.iedb.org/mhcii/  
SMM-align Matrix (Nielsen et al. http://tools.iedb.org/mhcii/ 




Tool Algorithm Reference URL 
2007)  














MULTIPRED ANN, HMM, 
SVM 










Matrix (Bian & Hammer 





ProPred Matrix (Singh & Raghava 
2001) 
http://www.imtech.res.in/raghava/propred/ 
2.3.4 HLA class I antigen presentation pathway tools 
 
Direct epitope prediction tools which take into account the full HLA class I antigen presentation pathway (in 
addition to HLA class I binding) have been developed. This includes the prediction of proteasomal cleavage 
and TAP transport which are essential components of HLA class I antigen processing and presentation. TAP is 
responsible for delivering cytosolic peptides into the endoplasmic reticulum before loading them into the 
binding groove of an HLA class I molecule (Figure 2.1), and therefore TAP binding preferences can 
significantly impact T-cell epitope selection.  
 
PREDTAP (Zhang et al. 2006) and SVMTAP (Daniel et al. 1998) have been developed to predict binding of a 
peptide to human TAP. NetCTL (Larsen et al. 2005) ,WAPP (Dönnes & Kohlbacher 2005), EpiJen (Doytchinova 
et al. 2006) and MAPP (Hakenberg et al. 2003) are methods that integrate predictions of HLA class I binding, 
TAP transport and C-terminal proteasomal cleavage for an overall prediction of CTL epitopes. 
 
2.4 Protective Coverage of Vaccine Candidates 
2.4.1 HLA alleles 
 
The genes encoding HLA molecules are extremely polymorphic, with a large number of HLA alleles reported 
to date. Genetic variations within the peptide binding groove of HLA molecules determine the type of 
peptide with which it is able to bind. There is therefore a high peptide to HLA molecule specificity, where a 
specific epitope may only bind to one, or in the case of promiscuous epitopes, a few HLA alleles. Currently 
15,635 HLA and related alleles have been reported and are included in the IMGT/HLA database (Robinson et 
al. 2014) (accessed 1 November 2016). An individual person carries a limited number of alleles in their 
genome out of the thousands that are present in the population. Good subunit vaccine cocktails should 
therefore include a range of peptides that are able to bind to a wide range of HLA molecules in order to 
provide sufficient population coverage. Promiscuous epitopes which are able to bind to more than one HLA 
molecule may therefore be of particular importance in vaccine design, as they improve the potential 
population coverage when included in a vaccine cocktail. Certain HLA molecules show similar binding 
preferences and consequently HLA supertypes have been defined (Greenbaum et al. 2011). Given the 
similarity in the peptide binding groove within a particular supertype family, an epitope able to bind to one 
HLA molecule within a family should be able to bind to all of the HLA molecules within that family. As a 
result, an epitope-based vaccine can be tailored to be representative of HLA supertype families rather than 
the extensive repertoire of HLA molecules in order to increase potential population coverage. 
 




The frequency of HLA alleles have been shown to exhibit an inter-ancestry distribution, with certain alleles 
more prevalent in certain ethnic populations than others. It has been suggested that 90% population 
coverage of several ethnic groups is possible by targeting 11 HLA molecules, however, in order to reach 90% 
coverage for African and Asian populations, an additional 4 or more alleles are required (Longmate et al. 
2001). In South Africa particularly, the frequency of HLA class I and class II alleles differs significantly 
between Caucasian and Black populations (Paximadis et al. 2012). Black populations also show a broader 
spectrum of alleles compared to the single allele dominance seen in Caucasian populations (Paximadis et al. 
2012). In a recent review, Tshabalala et al. (2015), investigated HLA diversity in Southern African populations 
and showed that the frequencies of HLA alleles vary not only between Southern African populations and the 
rest of the world, but that intra-African diversity also exists. The authors show the existence of uniquely 
African specific alleles from various sources in the literature, and demonstrate the need for additional 
genetic data from these areas in order to fully understand HLA diversity. Polymorphisms within HLA 
molecules are thought to have been maintained within populations through selective pressure from 
exposure to pathogens (Cagliani & Sironi 2013), and in particular, co-evolution between host and pathogen 
has resulted in M. tuberculosis lineages adapting to specific human populations within defined geographical 
settings (Brites & Gagneux 2015). Certain HLA class I alleles have been correlated with increased 
susceptibility to TB (Salie et al. 2014), with certain HLA alleles associated with disease caused by certain 
strains from various lineages such as the Euro-American or East Asian lineages. There is therefore the need 
to investigate both host and pathogen genetic diversity when studying disease development and 
pathogenesis. The protective effect of a vaccine may be compromised as a result of both host and pathogen 
genetic variation where clinical trials are conducted on a sample group that does not fully represent the 
global disease burden. Given the high burden of TB in Southern Africa, and the urgent need for additional 
vaccines that cater for this population, incorporating information on the distribution of HLA alleles across 
different populations is crucial for the success of any potential vaccine candidate.  
2.4.2 Prediction of potential population coverage 
 
It is evident that when using in silico epitope prediction methods, the choice of which HLA alleles to be 
included in the prediction is an important consideration. Identification of promiscuous epitopes, as well as 
predicting the potential population coverage is also an important step within a RV workflow. 
 
Various in silico epitope prediction tools included in Table 2.4 focus on locating promiscuous binding regions, 
including ProPred (Singh & Raghava 2001). Given the existence of HLA supertype families, tools such as 
PEPVAC have been developed to identify peptides able to bind to HLA molecules within a particular 
supertype family (Reche & Reinherz 2005), and in this way are able to limit the number of potential epitopes 
without compromising the potential population coverage. 
 
A tool used to predict the potential population coverage of a given set of epitopes is available within the 
IEDB analysis resource  (Kim et al. 2012).  This algorithm calculates the percentage of individuals expected to 
respond to a given epitope set based on HLA genotypic frequencies from the dbMHC database (Bui et al. 
2006). Researchers are also able to create custom populations with associated HLA allele frequencies, which 
may be useful to estimate the potential protective coverage within a vaccine trial setting. Multiple 
population coverage’s can be aggregated to determine the coverage of a particular set of epitopes across 
various populations for which a vaccine may be targeted at. This tool can also be used to determine the 
minimum number of epitope/HLA combinations recognized by 90% of the population. 
 
PREDIVAC is another particularly useful tool which integrates prediction of HLA class II epitopes with 
population coverage to optimise epitope selection within well-defined ethnic populations (Oyarzún et al. 
2013). Allele frequencies from the AFND database are used in order to identify vaccine candidates 
appropriate for a genetically heterogeneous population. 
  




2.5 Identification of Potential TB Vaccine Candidates 
 
Given the vital need for a new vaccine, it is not surprising that RV workflows have been used extensively 
within M. tuberculosis research. Various selection criteria are often applied. These have either focused on a 
particular family of proteins which are believed to be immunogenic, or broader selection criteria have been 
imposed, focusing on a specific biological aspect such as secreted proteins or those involved in dormancy or 
persistence. To address the inherent selection bias of these approaches, whole genome methods also have 
been applied to the M. tuberculosis genome. In either scenario, determining the genetic diversity within 
epitope-rich regions using data from multiple strains is important and has been used in literature. Evaluation 
of the protective population coverage has shown promising results for potential candidates as well as those 
currently in various phases of clinical trials. In addition, various potential candidates predicted via 
computational tools have been experimentally validated for M. tuberculosis. 
2.5.1 Selection criteria: family of proteins 
 
An example of a protein family where the function is largely unknown but which are speculated to play a 
role in host-pathogen interactions is embodied by the PE/PPE family of proteins.  In particular, given the high 
level of sequence variation within the PE_PGRS and PPE_MPTR subfamilies, it has been hypothesized that 
these proteins play a role in antigenic variation. The PE/PPE proteins and specifically the PE_PGRS proteins 
have therefore been the focus of various computational analyses involving epitope prediction. 
 
An in silico analysis of all PE/PPE proteins was used to predict peptides able to bind to HLA class I molecules 
and therefore elicit a CD8+ T-cell response (Chaitra et al. 2005). An immunoinformatics pipeline was 
followed which included MHC class I epitope prediction using the BIMAS prediction tool and identification of 
self-peptides. Molecular modelling and structural analysis was performed using known crystal structures of 5 
MHC class I molecules in order to validate binding predictions. A large number of the predicted epitopes had 
no significant similarities with human peptides, emphasizing the uniqueness of the PE/PPE proteins in 
mycobacteria, and their potential for being vaccine candidates. Results from this study showed a large 
number of epitopes in subgroups of the PE/PPE family other than the highly variable PE_PGRS proteins 
which showed a low level of binding. Peptides bound to alleles from HLA class I B locus had a greater binding 
affinity than HLA class I A or C locus, and therefore the distribution of HLA B alleles in a population may be an 
important factor when determining a vaccine’s potential protective coverage. Seven peptides predicted to 
be the strongest binders were experimentally tested. (Chaitra et al. 2005; Chaitra, Shaila, et al. 2007; Chaitra, 
Nayak, et al. 2007; Chaitra, Shaila, Chandra, et al. 2008; Chaitra, Shaila & Nayak 2008). Both CD4+ and CD8+ 
T-cell epitopes within the PE_PGRS proteins have also been investigated, and particularly whether the 
genetic diversity within these proteins contributes to human T-cell recognition (Copin et al. 2014). Findings 
from this investigation were consistent with Chaitra et al. as the regions containing T-cell epitopes and the 
genetically diverse regions within the PE_PGRS proteins are distinct, indicating that the most immunogenic 
PE/PPE proteins are the most conserved of the family. These findings are also consistent with other 
literature for M. tuberculosis which has indicated that T-cell epitopes reported thus far are highly conserved 
(Comas et al. 2010). However, to date, no studies have focused specifically on the PPE_MPTR subfamily 
which is also highly variable and possibly involved in host-pathogen interactions. 
 
Thus far two PPE proteins, PPE42 and PPE18, have already been included within peptide-based vaccines 
which have undergone clinical trials. Mtb72F consisting of peptides from pepA as well as PPE18 was the first 
subunit vaccine for M. tuberculosis. Genetic diversity within these genes was investigated using  225 clinical 
strains from two different geographical locations, and a combination of SNP’s and indels resulting in amino 
acid alterations were found within regions of the PPE18 protein with predicted T-cell epitopes (Hebert et al. 
2007). The authors concluded that the ability of Mtb72F to induce protective immunity against multiple 
strains of M. tuberculosis may therefore be compromised as a result of the high degree of genetic variation. 
These findings were recently further investigated using a well-characterized reference collection of 71 M. 
tuberculosis strains from 23 phylogenetic lineages and high variability within the PPE18 gene was confirmed 
even within the normally conserved N-terminal domain (Homolka et al. 2016) These studies yet again 
highlight the importance of comparative genomics within the RV pipeline for M. tuberculosis. 





Another example of a protein family that has been the focus of various vaccine investigations using in silico 
techniques is the ESX family, and in particular the ESAT-6 family members, which are often studied in 
conjunction with the PE/PPE family members given the association of the duplication of the esx gene cluster 
regions with the evolution of the PE/PPE gene family. (Gey van Pittius et al. 2006). RV pipelines using 
biological selection criteria such as growth in macrophages, up or down regulation under hypoxic conditions, 
secretion or membrane association have also often included the addition of both PE/PPE and esx family 
members (Bertholet et al. 2008). A detailed investigation into the vaccine potential of five possible ESX 
dimer substrates resulted in the identification of  a vaccine candidate with high predicted population 
coverage, and similar protection to BCG when experimentally validated (Knudsen et al. 2014). ESAT-6 
antigens have also already been included in the M. tuberculosis subunit vaccine Ag85B-ESAT-6, which is 
currently undergoing clinical trials. Given the implications of the genetic variability in PPE18 gene potentially 
affecting the ability of Mtb72F to induce protective immunity against various clinical strains, genetic 
variation within the genes encoding ESAT-6 (esxA and esxH) was also investigated (Davila et al. 2010). Within 
a sample of 88 clinical isolates, no DNA polymorphisms were found in either the esxA or esxH genes, 
suggesting that the efficacy of Ag85B-ESAT-6 was unlikely to be affected by genetic diversity within various 
M. tuberculosis populations. 
2.5.2 Selection criteria: biological function 
 
Rather than focusing on one particular family of proteins, TB researchers have selected proteins which group 
together based on a particular biological function. Promiscuous epitopes within proteins associated with 
dormancy were chosen for HLA class I epitope analysis using ProPred (Sundaramurthi et al. 2012). Seven 
novel promiscuous epitopes, conserved among virulent M. tuberculosis strains and showing high predicted 
population coverage were identified using this approach. In an attempt to study proteins that are highly 
expressed in vivo, Nguyen Thi et al. (2014) analysed gene expression profiles of M. tuberculosis at various 
stages of infection, and focused on 38 highly expressed proteins in the active, latent and reactivation phases 
before predicting both T-cell and B-cell epitopes. A detailed analysis of 742 predicted extracellular or surface 
localized adhesin and adhesin-like proteins was performed for M. tuberculosis and resulted in a set of 233 
most probable vaccine candidates which included PE/PPE proteins, Mpt proteins, Cfp2, PstS2, ESAT-6, HBHA, 
Antigen 85A, Antigen 85B, Antigen 85C as well as many hypothetical proteins (Chaudhuri et al. 2014). 
Analysis of beta-barrel outer-membrane proteins have also identified possible vaccine candidates within the 
PE/PPE and Mce proteins, as well as other transporters and lipoproteins (Pajón et al.). 
 
Secreted proteins have been one of the main focus areas of various M. tuberculosis vaccine researchers 
(Vani et al. 2006; De Groot et al. 2005). De Groot et al. (2005) focused on nine well characterized secreted 
antigens (antigen 85 complex, Mpt 64, Mpb/Mpt 70, Mpt 63, the 38 kDa protein, the 14 kDa, 16 kDa, 19 kDa, 
and 32 kDa) and used EpiMer (Meister et al. 1995) to identify 23 predicted epitopes within these proteins. In 
addition, a whole genome approach was used to select an additional 17 predicted epitopes, by selecting 
open reading frames containing signal sequences using the EpiMatrix tool (Moise et al. 2015). Predicted 
epitopes were experimentally validated by performing gamma-interferon ELISPOT assays using peripheral 
blood mononuclear cells from latent TB infected individuals. T-cell responses were confirmed for 22 out of 
the 23 predicted epitopes from EpiMer (96%), and 15 out of 17 (88%) epitopes predicted using EpiMatrix. 
Epitopes predicted to be promiscuous and shown to induce significant IFN-γ secretion were chosen for 
inclusion in a prototype vaccine candidate. Of these, one of the most immunogenic epitopes was predicted 
using the whole genome approach and originated from a protein which at the time of publication, had 
unknown function and localization. This paper therefore highlights the important role a computational 
analysis can play in determining vaccine candidates, not only within proteins with known biological 
relevance but in the absence of functional knowledge of a protein using a whole genome approach. 
  




2.5.3 Whole genome approaches 
 
A whole genome approach allows for an unbiased view of which M. tuberculosis proteins may contain 
potential epitopes and therefore vaccine candidates.  Results from a whole genome identification of vaccine 
candidates by Zvi et al. (2008) identified 189 genes with potential epitopes and revealed that the relative 
distribution of these antigens within 3 different functional categories differed to the distribution of genes 
within the genome. Prominent representatives within the predicted vaccine candidates again included the 
PE/PPE and ESX proteins, as well as those involved in dormancy, and proteins localised to the cell wall. 
Conserved hypothetical proteins also contained potential epitopes. Once again, this highlights that proteins 
of unknown function may represent an untapped source of vaccine antigens. 
2.5.4 Protective coverage: 
 
Assessing the genetic diversity across various M. tuberculosis strains should be coupled with assessing the 
HLA genetic diversity in various human populations in order to determine a vaccine’s potential efficacy. This 
has been investigated for the Mtb72F subunit vaccine (McNamara et al. 2010). An in silico prediction with 
different DRB1 genotypes showed that the Mtb72F vaccine would be less effective for several DRB1 
genotypes either due to limited epitope binding or to binding to unconserved PPE18 epitopes. Those DRB1 
alleles also have a high frequency in high burden TB populations. This study therefore demonstrates that 
Mtb72F may not be effective for certain host and pathogen genetic circumstances. The predicted population 
coverage for Ag85B-ASAT-6, Ag85B-TB10.4 and Mtb72f using both HLA class I and II alleles has also been 
investigated in high TB burden populations (Davila et al. 2012). In silico methods were used to predict 
binding of peptide sequences from these vaccine candidates to various alleles. Alleles of concern (alleles 
predicted to bind four or fewer vaccine epitopes) and populations of concern (populations where >30% of 
the population were homozygous for an allele of concern) were determined. Results from this study show 
that the Ag85 vaccine candidates have superior potential population coverage than the Mtb72f vaccine 
candidate. Four HLA class I alleles did not bind to any of the Mtb72f epitopes; with these alleles among the 
three most prevalent alleles in 7 out of the 22 high burden TB countries defined by WHO.  
2.5.5 Experimental validation: 
 
Potential vaccine candidates identified from RV pipelines ultimately need to be validated. Various studies 
discussed in this review have used wet lab testing to validate the results from in silico predictions. Panigada 
(2002) selected mycobacterial cell entry genes to investigate for possible CD4+ T-cell epitopes using the 
TEPITOPE tool. Five peptides predicted to be potential HLA-DR ligands were tested for induction of 
proliferation of CD4+ cells experimentally. This led to the identification of a peptide able to induce CD4+ cell 
proliferation in 50% of the tested subjects. After using a transcriptional based selection criteria, Gideon et al. 
(2012) evaluated the prediction results from ProPred using IFN-γ and IL-2 ELISPOT assays. Twenty three of 
twenty six proteins induced an IFN-γ response and five novel immunodominant proteins were identified. A 
whole genome based approach was used to identify  432 potential CD8+ T-cell epitopes able to bind to 3 HLA 
alleles each representing one of the HLA supertype families, and peptide/HLA binding affinity measured in 
vitro, as well as CD8+ T-cell proliferation assays and intracellular cytokine staining for IFN-γ, IL-2 and TNF-α 
used to validate results (Tang et al. 2011). Seventy out of the 432 epitopes were confirmed, 58 of which 
were novel and have not previously been described by other studies. 
  






There is a crucial need for a new vaccine against M. tuberculosis, and subunit vaccines have shown promising 
results thus far. In silico methods are allowing TB researchers to search the M. tuberculosis proteome for 
epitopes at a much faster rate than ever before. Experimental designs can now be guided and informed by 
the results from an in silico analysis, where the starting point is the most likely outcome, instead of being 
guided by an incomplete current biological understanding. Immunoinformatics, and reverse vaccinology are 
continuously improving and the tools becoming more accurate and reliable, especially given the growing 
amount of data being generated daily used to train the predictive algorithms.  
 
Given the high HLA diversity in the human population as well as genetic variation across strains, comparative 
genomics and prediction of protective coverage is extremely important for a pathogen such as M. 
tuberculosis. Immunoinformatics therefore has the potential to play a large role in vaccine trial planning and 
expected success of the project. Host-customised vaccines where the genetic background of the host is 
taken into account before the most appropriate vaccine cocktail is administered may also be a viable option 
in the future. With time and costs associated with genome sequencing decreasing, not only is host directed 
drug prescription as in the case of pharmacogenetics becoming a reality, but the same could be applied for 
the administration of vaccines. This may overcome the problem of protective immunity being compromised 
by variation in HLA molecules in specific populations. 
 
Many studies from various groups have focused on the PE/PPE family of proteins in their search for potential 
epitopes. In addition, resulting epitopes from whole genome approaches consistently contain at least a 
subset of the PE/PPE proteins within them. The PPE_MPTR protein family however has thus far been left out 
of most investigations, due to their largely unknown function, high genetic variation and difficulty in working 
with them in an experimental setting. The PPE_MPTR proteins are therefore an ideal target for an 
immunoinformatic based approach. 
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An essential step in CD4+ T-cell activation is the recognition of epitopes presented by HLA class II molecules 
on the surface of antigen presenting cells (such as macrophages and dendritic cells) by T-cell receptors. In 
order for this to occur, an antigen peptide (derived from the degradation of internalized pathogen proteins) 
must first bind to the binding groove of an HLA class II molecule before being transported to the cell surface 
(Chapter 2, Figure 2.1). HLA molecules are highly polymorphic, with the majority of the polymorphisms 
reported within this binding groove. Binding of a peptide to an HLA class II molecule is therefore highly 
specific, where an antigen peptide may only bind to one, or in the case of promiscuous epitopes, a few 
specific HLA alleles. The majority of epitope prediction tools indirectly predict epitopes by predicting the 
binding affinity of antigen peptides to various HLA molecules.  
 
There are currently more than 20 different MHC class II prediction tools publically available. The accuracy of 
these tools varies based on the prediction method used (Chapter 2, section 2.3.1), as well as on the amount 
of experimental data which has been used to train the prediction algorithm. 
 
In order to determine the most appropriate tool to be used for the prediction of Mycobacterium tuberculosis 
epitopes within the PPE_MPTR proteins, we have performed an evaluation of 8 MHC II epitope prediction 
tools using known M. tuberculosis epitopes. Previous evaluations of these tools can be found in literature 
(Lin et al. 2008; Wang et al. 2008), which are based on epitope data from a collection of many source 
antigens. The unique characteristics of the M. tuberculosis genome, including the higher GC content 
compared to other bacteria, IS6110 insertion elements, and repeat regions, may influence peptide 
composition and therefore epitopes from M. tuberculosis may display dissimilar binding patterns to HLA 
alleles compared to epitopes from other pathogens. In particular, the peptide compositions of the gly-ala-
asn rich PPE_MPTR proteins may be considerably different from other source peptides used in previous 
evaluations. Prediction methods are trained using known epitope data from a variety of pathogens, and the 
reported accuracy of the tools is heavily dependent on the amount and type of training data used. More 
specifically, a high degree of sequence similarity in the test and training data sets, may lead to overly 
optimistic estimates of the performance of the tools (El-Manzalawy et al. 2008). Therefore if it is indeed the 
case that the binding specificity of M. tuberculosis epitopes differs considerably from other pathogens and 
an insufficient amount of representative M. tuberculosis epitope data is included in the training data set, the 
accuracy of predictions using these tools may differ for M. tuberculosis antigens compared to other source 
antigens. It is therefore important to distinguish whether the results of such an evaluation would differ when 
using only M. tuberculosis proteins rather than a collection of proteins from various source pathogens. 
 
3.2 Methods 
3.2.1 Epitope data 
 
A collection of positive and negative M. tuberculosis epitopes was retrieved from the Immune Epitope 
Database (IEDB), accessed 27/05/2015. Search and filtering criteria are shown in Table 3.1. 
 
Table 3.1: IEDB search criteria. Filtering criteria used to search for M. tuberculosis epitopes are shown. 
Data Column Criteria 
Source Organism M. tuberculosis 
Host Human 
Assay Type MHC Ligand Assays 
MHC allele class II 
Method/Technique purified MHC/competitive/radioactivity 
Assay Group dissociation constant KD (~IC50) 
Result Positive and Negative 
 




Resulting data included MHC ligand assay results in the form of binding affinities (IC50 nM) from 123 unique 
peptides (15 mers) from 9 M. tuberculosis antigens (Table 3.2) for 30 different HLA class II alleles (6 
DPA1/DPB1, 6 DQA1/DQB1, 18 DRB) (Table 3.3). Not every unique peptide had a binding result for all 30 HLA 
alleles included in the data. For certain peptides, binding results for only a limited number of HLA alleles 
were available. In total, the data set contained results for 3,343 peptide/HLA combinations. 
 
Table 3.2: M. tuberculosis antigens included in IEDB evaluation data. For each antigen, the number of unique 15 mer peptides and 
the total number of HLA class II ligand assay results is shown. Each unique peptide was tested for binding for up to 30 different HLA 
molecules. 
M. tuberculosis Antigen  Number of Unique Peptides Total number of assay results 
14 kDa antigen 29 787 
6 kDa early secretory antigenic target 22 604 
Antitoxin Rv2654c/MT2731 15 405 
ESAT-6-like protein EsxB 21 573 
ESAT-6-like protein EsxJ 19 515 
ESAT-6-like protein EsxK 3 81 
PPE FAMILY PROTEIN 12 324 
Putative ESAT-6-like protein 10 1 27 
Putative ESAT-6-like protein 7 1 27 
Total 123 3343 
  




Table 3.3: HLA alleles included in evaluation data. For each HLA allele, the number of M. tuberculosis peptides (15 mers) that were 
tested for binding is shown. 


































Total Peptide:HLA Allele Combinations 3343 
3.2.2 Tools evaluated 
 
Eight prediction tools (Table 3.4) were used to predict the binding affinity of each of the peptide/HLA 
combinations contained in the data described above. The tools chosen included those endorsed by the IEDB 
analysis resource (Kim et al. 2012), as well as those with the best results from previous evaluations found in 
literature (Lin et al. 2008; Wang et al. 2008). ProPred and TEPITOPE tools both make use of the Sturniolo 
database and prediction algorithm, and therefore results for these tools were identical. The IEDB consensus 
tool uses the prediction results from four tools (NN-align, SMM-align, Comblib and Sturniolo) and outputs a 
median value. Certain tools contain only a limited number of HLA alleles for which prediction is possible and 
therefore it was not possible to test all peptide/HLA allele combinations for certain tools. 
  




Table 3.4: Prediction tools included in the valuation. The prediction method used within each tool is shown. For each tool, the 
number of HLA alleles for which prediction is possible out of the alleles included in the IEDB data is shown. 
3.2.3 Interpretation of prediction results 
 
Prediction results from different tools are given in various formats, including predicted IC50 values, raw 
relative scores or median percentile ranks. In order to compare results between the various tools, it is 
necessary to be able to determine comparable cut-off criteria to distinguish between binders and non-
binders. 
 
The predicted results for NetMHCII, NetMHCIIpan, ARB, NN-align, SMM-align and Comblib are given in units 
of IC50 nM, with a lower value indicating a higher binding affinity and therefore a more likely T-cell epitope. 
These values can be directly compared to the actual IC50 nM values in the IEDB data for each peptide/HLA 
allele combination. IEDB guidelines recommend using IC50 nM < 50 as high affinity binding; 50 ≤ IC50 nM < 
500 as intermediate affinity binding, 500 ≤  IC50 nM < 5000 as low affinity binding; and IC50 NM > 5000 as a 
non-binder and therefore not a predicted epitope (Kim et al. 2012). For the purpose of the evaluation study, 
a strict and intermediate cut-off value of <100 and <1000 respectively was used to determine positive 
binders and therefore predicted epitopes. Given the limited size of the data set used in this evaluation, 
choosing a very low IC50 value as a cut-off would substantially decrease the number of positive binders 
making any statistical interpretation of the accuracy of the prediction results unreliable. Therefore a strict 
cut-off value of 100 nM rather than 50 nM was used for the purpose of the valuation. However when using 
the tools to determine epitopes, a lower cut-off value should be used.  
 
The predicted results for Sturniolo (ProPred/TEPITOPE) are given as a raw score, with higher scores 
indicating higher affinity binding. Scores from this analysis ranged between -12.5 to 9. A strict and 
intermediate cut-off value of >1 and >0 respectively was used to determine positive binders and therefore 
predicted epitopes.  
 
For the IEDB consensus tool, prediction results are in the form of a percentile rank which is generated for 
each of the four methods used within the consensus method (NN-align, SMM-align, Comblib and Sturniolo), 
and a median percentile rank is given. The percentile rank is found by comparing a peptide’s binding score 
against the scores of five million random 15 mers selected from the SWISSPROT database. A small percentile 
rank indicates high binding affinity. The IEDB recommends using a score of <10 for binders and therefore 
predicted epitopes. A strict and intermediate cut-off value of <10 and <50 respectively was used to 
determine positive binders and therefore predicted epitopes.  
 
Tool Method HLA alleles Reference DPA1/DPB1 DQA1/DQB1 DRB 
NetMHCII 
ANN 5/6 6/6 14/18 
(Lundegaard et al. 
2008) 
NetMHCIIpan ANN & 
SMM 
6/6 6/6 18/18 
(Karosiene et al. 
2013) 
ARB ANN & 
SMM 
4/6 5/6 14/18 
(Bui et al. 2005) 
IEDB Consensus Consensus 4/6 6/6 15/18 (Wang et al. 2008) 
NN-align 
ANN 5/6 6/6 14/18 
(Nielsen & Lund 
2009) 
SMM-align SMM 4/6 6/6 15/18 (Nielsen et al. 2007) 
Comblib Matrix 4/6 6/6 5/18 (Wang et al. 2010) 
Sturniolo 
(Propred/Tepitope) 
Matrix 0/6 0/6 11/18 
(Sturniolo et al. 1999; 
Zhang et al. 2012; 
Singh & Raghava 
2001) 




The cut-off values for Sturniolo and IEDB consensus were chosen by comparing the distribution of predicted 
results to that of the predicted IC50 nM values. Based on this, a value of 100 nM was comparable to a 
Sturniolo score of 1 and an IEDB consensus percentile rank of 10, and a value of 1000 nM was comparable to 
a Sturniolo score of 0 and an IEDB consensus percentile rank of 50. 
 
The above mentioned cut-off values were used to count the number of predicted binders and non-binders 
from each tool. These were compared to the actual number of binders and non-binders in the data. 
Accuracy, sensitivity and specificity were calculated for each tool.  
3.2.4 Accuracy by HLA allele 
 
Previous studies have shown that the accuracy of specific tools varies by HLA allele (Lin et al. 2008). Accuracy 
statistics for each tool were therefore compared individually for each HLA allele. This was only done for HLA 
alleles for which at least 20 positive data points was available in the data, when using the medium cut-off 
values. For each allele, the tool with the highest accuracy, sensitivity, and specificity using the medium cut-
off value was determined. The IEDB have undergone a similar investigation, where the best tool for each 
allele has been determined (Kim et al. 2012). Results from this evaluation were compared to the IEDB 
recommended tool for each HLA allele. 
 
The accuracy of the tools is expected to differ since different tools are based on different prediction 
algorithms and the amount of data that has been used to train the prediction methods may vary. If a specific 
HLA allele is not found within the training data, predicted binding to that HLA allele will not be available for 
that tool. However pan methods such as NetMHCIIpan have been created to make predictions for those HLA 
alleles for which no training data is available. These predictions are based on the similarity of the binding 
groove to those alleles for which training data is available. The accuracy of the results for these alleles is 
therefore expected to be lower than for alleles for which actual training data is available. Results for 
NetMHCIIpan is therefore split between alleles that are included in NetMHCII and training data is available 
(known) and others which are based on similarity of the binding grooves (unknown).   
 
3.3 Results 
3.3.1 Overall accuracy, sensitivity and specificity  
 
The overall accuracy, sensitivity and specificity (averaged across all HLA alleles included in the evaluation 
study) are shown in Figure 3.1 for both the strict and medium cut-off values.  
 
Strict cut-off values resulted in a lower number of positive data points. Therefore a lower sensitivity and 
higher specificity for the strict cut-off may be indicative of the smaller amount of positive data rather than a 
higher number of false predictions at stricter cut-offs.  Based on the medium cut-off values, the tools with 
the highest accuracy are NN-align and NetMHCII with 79.99%.The IEDB consensus tool has the highest 
sensitivity at 92.49%, but the lowest specificity at 43.19%. Similarly, the SMM-align tool has the highest 
specificity at 88.37%, but the second lowest sensitivity at 55.30%.  
 







Figure 3.1: Comparison of Accuracy, Sensitivity and Specificity across epitope prediction tools. Results using strict and medium cut-
off values are shown in red and blue respectively. 
3.3.2 Results per HLA allele 
 
Similarly to previous evaluation studies in literature, the accuracy of each tool differed by HLA allele. This is 
demonstrated in Figure 3.6 which shows the accuracy from each tool for 3 different HLA DRB1 alleles. Similar 
results were seen for all other HLA alleles. 
 








































Figure 3.2: Accuracy of prediction tools by HLA allele. The prediction tool with the highest accuracy is shown in green, indicating 
there is no one overall most accurate tool to use but rather a most appropriate tool depending on which HLA allele is used in the 
prediction. 
For each HLA allele, the tool with the highest accuracy, sensitivity, and specificity was determined. For those 
alleles that had at least 20 positive data points in the data when using the medium cut-off, the results were 
compared to the IEDB recommended tool (Table 3.5). The preferred tool to use was different depending on 
whether a high overall accuracy, sensitivity or specificity was preferred; highlighting the importance of 
determining which statistic is most preferable given the aim of the study. When considering accuracy and 
specificity, the best tool to use varies greatly by HLA allele; however when considering only the sensitivity of 
each allele, the IEDB consensus tool was the preferred tool for 16/19 alleles. For the majority of the alleles 
(18/19) the IEDB recommended tool is the IEDB consensus tool, possibly indicating a preference for higher 





















































































Table 3.5: Comparison of evaluation results with IEDB recommended tool by HLA allele. For each allele with at least 20 positive data points, the tool with the highest accuracy, sensitivity and specificity is 





Accuracy Sensitivity Specificity IEDB 
Recommended 
HLA-DQA1*01:02/DQB1*06:02 59 64 NetMHCIIpan IEDB Consensus ARB Consensus 
HLA-DQA1*03:01/DQB1*03:02 38 85 NetMHCII IEDB Consensus SMM-Align Consensus 
HLA-DQA1*04:01/DQB1*04:02 52 71 NetMHCII IEDB Consensus ARB Consensus 
HLA-DQA1*05:01/DQB1*02:01 53 70 IEDB Consensus IEDB Consensus ARB Consensus 
HLA-DQA1*05:01/DQB1*03:01 56 67 SMM-Align NetMHCII SMM-Align Consensus 
HLA-DRB1*01:01 75 48 NetMHCIIpan ARB Sturniolo Consensus 
HLA-DRB1*04:01 47 76 SMM-Align IEDB Consensus Sturniolo Consensus 
HLA-DRB1*04:04 39 84 NetMHCIIpan IEDB Consensus ARB Consensus 
HLA-DRB1*04:05 41 82 Sturniolo IEDB Consensus SMM-Align Consensus 
HLA-DRB1*07:01 39 84 NetMHCII IEDB Consensus SMM-Align Consensus 
HLA-DRB1*08:02 56 67 NetMHCII IEDB Consensus SMM-Align Consensus 
HLA-DRB1*09:01 58 65 NetMHCII IEDB Consensus SMM-Align Consensus 
HLA-DRB1*11:01 32 91 Sturniolo IEDB Consensus Sturniolo Consensus 
HLA-DRB1*12:01 24 99 SMM-Align ARB SMM-Align SMM-align 
HLA-DRB1*13:02 31 92 SMM-Align IEDB Consensus SMM-Align Consensus 
HLA-DRB1*15:01 25 98 NetMHCII IEDB Consensus SMM-Align Consensus 
HLA-DRB3*01:01 25 98 SMM-Align IEDB Consensus NetMHCIIpan Consensus 
HLA-DRB4*01:01 46 77 NetMHCII IEDB Consensus SMM-Align Consensus 
HLA-DRB5*01:01 33 90 NetMHCIIpan IEDB Consensus NetMHCII Consensus 
 
Stellenbosch University  https://scholar.sun.ac.za






Given the wide range of options available to researchers when choosing an epitope prediction tool, it is 
important to evaluate the accuracy of these tools in the context of the purpose for which the investigation is 
carried out. In the current project, M. tuberculosis proteins are being investigated in order to identify 
epitopes that may be possible vaccine candidates.  
 
Epitope prediction tools are most commonly used when searching for possible vaccine targets within reverse 
vaccinology pipelines. Resulting epitopes would be fed into wet lab experiments for validation. Therefore 
researchers need to weigh up the advantage of decreasing the number of epitopes to be fed into validation 
from a time and cost perspective (i.e. increasing specificity), but at the same time limiting the number of 
true positive epitopes missed (i.e. increasing sensitivity). A perfect tool would have high values for both 
sensitivity and specificity but this was not the case with the eight epitope prediction tools tested above. 
Tools with a high sensitivity had a low specificity and vice versa, therefore necessitating the need to choose a 
preference for one over the other. When comparing the most appropriate tool for each HLA allele to the 
IEDB recommended tool, in most cases the tool with the highest sensitivity matched the IEDB recommended 
tool, indicating a possible preference for higher sensitivity by the IEDB. This is reasonable given the aim of 
identifying vaccine candidates and therefore limiting the number of true positive results that may be missed.  
 
Experimental data used within this evaluation were derived from M. tuberculosis antigens only, compared to 
previously reported valuations which used antigens from many source pathogens. This was done in order to 
determine whether a specific tool may perform better for M. tuberculosis proteins. Based on a preference 
for sensitivity, the IEDB consensus tool was the preferred tool for the majority of the alleles included in the 
evaluation study. This corresponded to results obtained by the IEDB when using a large number (>10,000) of 
assay results from a variety of pathogens (peptides for 114 proteins from 30 organisms) (Wang et al. 2008). 
Therefore no difference in the preferred tool was found specifically for M. tuberculosis proteins. Even 
though the M. tuberculosis proteome may have unique characteristics from other bacteria and pathogens, 
the short length of the majority of MHC class II epitopes (15 mers) may result in no significant differences in 
the structure of T-cell epitopes between pathogens. 
 
There was a high concordance between the tool with the best sensitivity for each allele according to the 
analysis within this chapter and the IEDB recommended tool for each allele (16/19 alleles). For 3/19 alleles, 
the recommended tool from this study based on sensitivity of the tools did not match the IEDB 
recommended tool. However, given that no significant difference was found when using M. tuberculosis 
proteins only, and that the evaluation by the IEDB was performed using a significantly larger amount of data 
leading to more reliable results, the IEDB recommended tool will also be used for these three alleles. A larger 
number of alleles than what was used within this evaluation will be used in the prediction of epitopes within 
the PPE_MPTR proteins (Chapter 4). The IEDB recommended tool for all alleles will be used for the 
remainder of this project.  
 
The results of this analysis show that no tool is 100% accurate, and therefore the limitations of these tools 
should be kept in mind when analysing the results from epitope predictions, and viewed in the context of 
the study goal. For this study, an overall sensitivity of 92.49% for the IEDB consensus tool is considered to be 
suitably high for the aim of identifying novel vaccine candidates when used within a reverse vaccinology 
workflow. 
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Given previous evidence of the interaction between the PE/PPE proteins with the host immune system, 
including eliciting CD4+ and CD8+ T-cell responses (Sampson 2011) (Chapter 1, section 1.1.6), it is 
hypothesized that multiple epitopes, defined as short peptides capable of producing an immune response, 
exist within the Mycobacterium tuberculosis PPE_MPTR proteins. The PPE_MPTR proteins consist of a 
conserved PPE region at the start of the encoded protein and a variable MPTR region which may contain 
differential epitope density. 
 
Given the large number of PPE_MPTR proteins, with certain members greater than 3000 amino acids, and 
the large number of possible HLA alleles in the human population, the number of experiments that would be 
needed in conventional wet lab approaches used to ascertain host-pathogen interactions would be 
restrictively high. Epitope prediction which makes use of various in silico methods can offer a solution. Using 
the results from an in silico approach the number of experiments needed in subsequent validation steps can 
be reduced, resulting in both cost and time savings.  
 
Based on the evaluation of 8 well known epitope prediction tools using known M. tuberculosis epitopes 
(Chapter 3), the IEDB recommended tool for each HLA allele has been used to predict epitopes within the M. 
tuberculosis PPE_MPTR proteins. 
 
4.2 Methods 
4.2.1 PPE_MPTR protein sequence data 
 
The protein sequence for each of the 23  M. tuberculosis PPE_MPTR proteins for the reference strain H37Rv 
was downloaded from TubercuList (Lew et al. 2011). A multiple sequence alignment of all 23 PPE_MPTR 
protein sequences was performed using Clustal Omega (Sievers et al. 2011), using default parameter values. 
Based on this alignment, three PPE_MPTR proteins were not included in the analysis since the PPE region in 
these proteins was either not similar in size or sequence to the other PPE_MPTR proteins (Rv0304c and 
Rv0354c), or completely missing (Rv2353). Therefore a total of 20 PPE_MPTR proteins were included in the 
analysis (Table 4.1). 
  




Table 4.1: PPE_MPTR proteins. The size of the DNA (bp) and protein (aa) sequence for the 20 PPE_MPTR proteins included in the 
analysis is shown. (Sampson 2011). 
PE/PPE Number Rv number bp size aa size 
PPE_MPTR6 Rv0305c 2892 964 
PPE_MPTR8 Rv0355c 9903 3301 
PPE_MPTR10 Rv0442c 1464 488 
PPE_MPTR12 Rv0755c 1938 646 
PPE_MPTR13 Rv0878c 1332 444 
PPE_MPTR16 Rv1135c 1857 619 
PPE_MPTR21 Rv1548c 2037 679 
PPE_MPTR24 Rv1753c 3162 1054 
PPE_MPTR28 Rv1800 1968 656 
PPE_MPTR34 Rv1917c 4380 1460 
PPE_MPTR35 Rv1918c 2964 988 
PPE_MPTR40 Rv2356c 1848 616 
PPE_MPTR42 Rv2608 1743 581 
PPE_MPTR52 Rv3144c 1230 410 
PPE_MPTR53 Rv3159c 1773 591 
PPE_MPTR54 Rv3343c 7572 2524 
PPE_MPTR55 Rv3347c 9474 3158 
PPE_MPTR56 Rv3350c 11151 3717 
PPE_MPTR62 Rv3533c 1749 583 
PPE_MPTR64 Rv3558 1659 553 
4.2.2 HLA alleles 
 
The most common HLA class II alleles in the general human population were included in the analysis 
(Greenbaum et al. 2011). This list of 27 alleles represent >99% population coverage, based on data available 
from DbMHC  (Helmberg et al. 2004) and allelefrequencies.net (González-Galarza et al. 2015). This list is 
used within the IEDB analysis resource (Kim et al. 2012). In addition, to ensure relevance to study 
populations most affected by TB, the most frequent DRB1 alleles in the 22 high burden countries specified 
by WHO (pre-2015) (WHO 2014), that were not part of the original list by Greenbaum et al. (2011) were also 
included in the analysis. For each of the 22 high burden countries, DRB1 allele frequencies were obtained 
from allelefrequencies.net (González-Galarza et al. 2015), and those with a greater than 5% frequency were 
included. In total, 47 HLA class II alleles were included in the analysis (Table 4.2). 
4.2.3 Prediction of epitopes 
 
Each of the 20 PPE_MPTR protein sequences was segmented into overlapping peptides of 15 amino acids. 
Epitope prediction for each of the overlapping peptides was performed against each of the 47 selected HLA 
class II alleles. Based on the evaluation of MHC class II prediction tools (Chapter 3), the IEDB recommended 
tool for each of the alleles was used, and is shown in Table 4.2. 




Table 4.2: HLA alleles and the IEDB recommended tool for each allele. Alleles in the original list by Greenbaum et al. 2011 are indicated by (*) 
 Allele IEDB Recommended Tool  Allele IEDB Recommended Tool 
1. HLA-DPA1*01:01-DPB1*04:01(*) IEDB Consensus 25. HLA-DRB1*10:01 NetMHCIIpan 
2. HLA-DPA1*01:03-DPB1*02:01(*) IEDB Consensus 26. HLA-DRB1*11:01(*) IEDB Consensus 
3. HLA-DPA1*02:01-DPB1*01:01(*) IEDB Consensus 27. HLA-DRB1*11:02 Sturniolo 
4. HLA-DPA1*02:01-DPB1*05:01(*) IEDB Consensus 28. HLA-DRB1*11:03 NetMHCIIpan 
5. HLA-DPA1*03:01-DPB1*04:02(*) IEDB Consensus 29. HLA-DRB1*11:04 Sturniolo 
6. HLA-DQA1*01:01-DQB1*05:01(*) IEDB Consensus 30. HLA-DRB1*12:01(*) IEDB Consensus 
7. HLA-DQA1*01:02-DQB1*06:02(*) IEDB Consensus 31. HLA-DRB1*12:02 NetMHCIIpan 
8. HLA-DQA1*03:01-DQB1*03:02(*) IEDB Consensus 32. HLA-DRB1*13:01 Sturniolo 
9. HLA-DQA1*04:01-DQB1*04:02(*) IEDB Consensus 33. HLA-DRB1*13:02(*) IEDB Consensus 
10. HLA-DQA1*05:01-DQB1*02:01(*) IEDB Consensus 34. HLA-DRB1*13:03 IEDB Consensus 
11. HLA-DQA1*05:01-DQB1*03:01(*) IEDB Consensus 35. HLA-DRB1*14:01 IEDB Consensus 
12. HLA-DRB1*01:01(*) IEDB Consensus 36. HLA-DRB1*14:04 IEDB Consensus 
13. HLA-DRB1*01:02 Sturniolo 37. HLA-DRB1*14:05 IEDB Consensus 
14. HLA-DRB1*03:01(*) IEDB Consensus 38. HLA-DRB1*15:01(*) IEDB Consensus 
15. HLA-DRB1*03:02 IEDB Consensus 39. HLA-DRB1*15:02 Sturniolo 
16. HLA-DRB1*04:01(*) IEDB Consensus 40. HLA-DRB1*15:03 NetMHCIIpan 
17. HLA-DRB1*04:03 NetMHCIIpan 41. HLA-DRB1*15:04 IEDB Consensus 
18. HLA-DRB1*04:05(*) IEDB Consensus 42. HLA-DRB1*16:01 IEDB Consensus 
19. HLA-DRB1*04:06 NetMHCIIpan 43. HLA-DRB1*16:02 IEDB Consensus 
20. HLA-DRB1*07:01(*) IEDB Consensus 44. HLA-DRB3*01:01(*) IEDB Consensus 
21. HLA-DRB1*08:02(*) IEDB Consensus 45. HLA-DRB3*02:02(*) NetMHCIIpan 
22. HLA-DRB1*08:03 IEDB Consensus 46. HLA-DRB4*01:01(*) IEDB Consensus 
23. HLA-DRB1*08:04 Sturniolo 47. HLA-DRB5*01:01(*) IEDB Consensus 
24. HLA-DRB1*09:01(*) IEDB Consensus    
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The collection of IEDB recommended tools was downloaded from the IEDB analysis resource in the form of a 
mixture of python scripts and Linux 32-bit environment specific binaries, and run locally through command 
line operations (Kim et al. 2012). When choosing the IEDB recommended option when running the epitope 
prediction, prediction results are in the form of a percentile rank, which is found by comparing a peptide’s 
binding score against the scores of five million random 15 mers selected from the SWISSPROT database (Kim 
et al. 2012). A low percentile rank indicates high binding affinity compared to other possible peptides. 
Peptides with a percentile rank of <1% for at least one HLA allele were classified as binders and therefore as 
predicted epitopes. 
4.2.4 Determination of the PPE boundary 
 
Given the hypothesis that genetic diversity within PPE_MPTR proteins may differentially modulate human 
immune response, and that the PPE region is known to be conserved compared to the variable MPTR region 
within the PPE_MPTR proteins, it was important to determine the boundary between the two regions. The 
PPE region is between 170-180 amino acids long and highly conserved between different strains (Cole et al. 
1998), but also relatively conserved between the PPE_MPTR proteins themselves. The amino acid sequence 
of each of the 20 PPE_MPTR proteins from H37Rv were aligned using Clustal Omega (Sievers et al. 2011), 
using default parameters, and this alignment was visually inspected to determine the end of the conserved 
PPE region and the start of the variable MPTR region. The number of amino acids from the start of the 
protein until this boundary for each of the PPE_MPTR proteins was counted (results were between 172 – 
176 amino acids). This boundary was used to determine and compare the number of predicted epitopes 
within the PPE region versus the MPTR region for each protein.  
 
In an analysis of the epitope density within the PE_PGRS proteins, epitope density fluctuated along the 
length of each protein (Copin et al. 2014). Therefore, in addition to comparing epitope density within the 
PPE versus the MPTR region, each protein was segmented into sections of 60 amino acids along the length of 
the protein and the number of epitopes in each segment counted. 
4.2.5 Identification of promiscuous epitopes 
 
A peptide is classified as a binder and therefore a predicted epitope if it is able to bind to at least one HLA 
allele (percentile rank < 1%). A peptide may be able to bind to more than one HLA allele. For each peptide 
classified as a binder, the number of HLA alleles (out of the 47 alleles included) that the peptide is predicted 
to bind to was counted. Peptides that were predicted to bind to more than one allele were classified as 
promiscuous epitopes. The percentage of promiscuous epitopes was compared within the PPE region versus 
the MPTR region as well as along the length of each protein (in segments of 60 amino acids).  
4.2.6 Binding ability of HLA alleles 
 
Literature has shown that specific alleles may be able to bind more universally than others (i.e. able to bind 
to more peptides than others) (Paul et al. 2013). In order to test whether this is true for the PPE_MPTR 
proteins and the 47 alleles used in the prediction, the number of peptides that each of the 47 HLA alleles 
was able to bind to was counted and compared. This was investigated overall for the PPE_MPTR proteins as 
well as for each of the proteins individually. The frequency of the high binding HLA alleles within different 
populations is an important consideration for the potential population coverage of an epitope when used in 
a vaccine cocktail. This is investigated in Chapter 6. 
  





4.3.1 Number of epitopes in PPE versus MPTR region 
 
A total number of 4,548 epitopes were predicted across the 20 PPE_MPTR proteins. Figure 4.1 shows the 
density of predicted epitopes for each of the 20 proteins, in the PPE region versus the MPTR region. Density 
of epitopes is calculated as the number of epitopes in a section weighted by the length of that section. 
 
 
Figure 4.1: Density of epitopes in PPE vs. MPTR region. The density of epitopes in the PPE and MPTR region of the protein is shown 
in blue and red respectively. Density is calculated as the number of predicted epitopes weighted by the length of each of the 
respective sections. 
 
There is a higher density of predicted epitopes in the 
PPE versus the MPTR region of each protein (Figure 
4.1).  A variable density of epitopes in the MPTR region 
can be seen across the different proteins, with certain 
proteins having almost no epitopes in the MPTR region 
compared to the PPE region (Rv0755c, Rv2356c), while 
others show a high density of epitopes comparable  
with the PPE region (Rv1800, Rv2608).  
 
Mean epitope density in the PPE region is on average 
3-fold higher than the epitope density in the MPTR 
region across all 20 PPE_MPTR proteins. This is 











Figure 4.2: Mean density of epitopes in PPE region versus 
MPTR region. The PPE region had an overall epitope 
density of 0.43 compared to an overall epitope density of 
0.14 in the MPTR region across all PPE_MPTR proteins. 
This difference is statistically significantly different. 




4.3.2 Patterns of fluctuation along the length of the protein 
 
When comparing the number of epitopes in each 60 amino acid segment along the length of each protein, 
three major patterns of epitope distribution can be seen (Table 4.3). 
 
Table 4.3: Observed patterns of fluctuation. Three patterns of fluctuation were identified when investigating epitope density along 
the length of the protein for each of the PPE_MPTR proteins. 
Pattern Observed Description 
Fluctuating Alternating areas of high and low number of epitopes can be seen along the 
entire length of the protein (Rv0305c, Rv3055c, Rv0878c, Rv1753c, Rv1917c, 
Rv1918c, Rv3144c, Rv3343c, Rv3347c, and Rv3350c). 
Decreasing A high number of epitopes in the PPE region is seen which decreases substantially 
in the MPTR region (Rv0442c, Rv0755c, Rv1135c, Rv1548c, Rv2356c, Rv3159c, 
Rv3533c, and Rv3556). 
Increasing/Stable The number of epitopes either increases or is stable in the PPE region versus the 
MPTR region (Rv1800 and Rv2608). 
 
Figure 4.3 below shows an example of each of the patterns observed. 
 
 
Figure 4.3: Patterns of fluctuation observed in the number of predicted epitopes along the length of PPE_MPTR proteins. Three 
patterns of fluctuation were seen along the length of the PPE_MPTR proteins. An example of each has been shown. 
The density of predicted epitopes along the length of the protein for all of the PPE_MPTR proteins can be 








4.3.3 Promiscuous epitopes 
 
A given epitope will elicit an immune response only in individuals expressing HLA molecules capable of 
binding to that particular epitope. The higher the number of HLA alleles an epitope is able to bind to, the 
higher the potential population coverage when the peptide is included in a peptide based vaccine. To 
explore this in the context of the PPE_MPTR proteins, the number of HLA alleles that each predicted epitope 





Figure 4.4: Distribution of promiscuous epitopes. Blue bars indicate the percentage of peptides that are only predicted to bind to 
one unique HLA allele. Green, yellow and red bars represent the number of peptides that are able to bind to more than one HLA 
allele (promiscuous epitopes). This is shown separately for the PPE region and MPTR region in A) and B) respectively. 




Overall, the majority of predicted epitopes (56%) bind to only one unique HLA allele. A further 22% are able 
to bind to only 2 HLA alleles, and 11% to only 3 HLA alleles. There is therefore a high peptide to HLA allele 
binding specificity, with less than 1% of peptides able to bind to 10 or more HLA alleles. The maximum 
number of HLA alleles that any one peptide was predicted to bind to was 27 (representing 0.04% of the total 
number of predicted epitopes). These peptides come from Rv2608, which also has the second highest 
percentage of peptides predicted to bind to 10 or more HLA alleles (after Rv0878c). Rv2608 is part of the 
ID93 subunit vaccine candidate currently undergoing clinical trials.  
The distribution in the number of HLA alleles per peptide varies by protein, with certain proteins having a 
larger percentage of promiscuous epitopes than others. Other PPE_MPTR proteins with a high percentage of 
promiscuous epitopes include Rv3558 (which contains the lowest percentage of unique binders), Rv0305c, 
Rv0355c, Rv0878c, Rv1800, Rv3343c, Rv3347c and Rv3350c which all contain epitopes able to bind to 10 or 
more alleles. 
 
The overall percentage of promiscuous epitopes in the 
PPE region and the MPTR region was compared to 
determine whether characteristics within the respective 
regions may be contributing to promiscuity (Figure 4.5). A 
significant difference in the proportion of promiscuous 
epitopes within the PPE region versus the MPTR region 
across all PPE_MPTR proteins was found (p < 0.01). 
 
The percentage of binders versus non-binders, unique 
binders versus promiscuous binders, and distribution of 
promiscuous epitopes for each PPE_MPTR protein is 











The distribution of promiscuous epitopes along the length of each protein (in segments of 60 amino acids) 
was investigated to determine if promiscuous epitopes localise to certain regions. Results for Rv2608 and 
Rv3558 are shown in Figure 4.6. Results for all PPE_MPTR proteins can be found in Appendix B. No apparent 
correlation between the proportion of promiscuous epitopes and location along the length of the protein 
was seen other than when comparing PPE region versus MPTR region.  
  
Figure 4.5: Percentage of promiscuous epitopes. 
Percentage of promiscuous epitopes in the PPE region 
(blue) compared to the MPTR region (red) is statistically 
significantly different (p < 0.01). 





Figure 4.6: Distribution of promiscuous epitopes along the length of the protein. Colours consistent with Figure 4.4 show where 
promiscuous epitopes are predicted along the length of the protein.  
4.3.4 Binding ability of HLA alleles 
 
Figure 4.5 shows the percentage of peptides each of the 47 HLA alleles are able to bind to, overall for all of 
the PPE_MPTR proteins. 
 
 
Figure 4.7: Binding ability of HLA alleles. Percentage of peptides each HLA class II allele is able to bind to is shown above. 
It is evident that certain HLA class II alleles are more universal binders than others. The percentage of 
peptides each of the HLA alleles are able to bind to was also investigated for each of the PPE_MPTR proteins 
individually. These results are shown in Appendix C. The distribution changes significantly when comparing 
different PPE_MPTR proteins. For example, when all of the PPE_MPTR proteins are considered together, 
HLA-DRB1*01:02 is able to bind to the highest number of peptides, however when looking specifically at 
Rv0442c, HLA-DQA1*04:01-DQB1*04:02 is able to bind to the highest number of peptides. It is also well 
known, that HLA alleles are found in different frequencies in different populations (Chapter 2). Therefore 
depending on which PPE_MPTR protein is used within a vaccine cocktail, the population coverage will 
change depending on the frequency of the highest binding alleles in the population of interest. This is an 
important consideration when choosing vaccine candidates, and could be used to customise vaccine regimes 
for specific populations. This is considered in more detail in Chapter 6. 
  






A large number of epitopes are predicted within the PPE_MPTR proteins, supporting the hypothesis that the 
PPE_MPTR proteins may play a role in host pathogen interactions. A larger density of epitopes is found 
within the conserved PPE region, while the density of epitopes within the MPTR region varies by protein. The 
PPE region is thought to be highly conserved and therefore a higher density of predicted epitopes in this 
region is consistent with literature showing conservation of M. tuberculosis epitopes (Comas et al. 2010). 
Fluctuating patterns of epitopes have been identified along the length of the PPE_MPTR proteins. Possible 
reasons for the observed fluctuating patterns may include: 
 
 Areas of conservation versus diversity. The PPE_MPTR proteins are highly variable, and are 
considered to be hotspots for recombination, while M. tuberculosis epitopes have been shown to be 
conserved across strains. Therefore the fluctuating patterns of epitopes along the length of the 
protein may be due to a large number of epitopes in regions of genetic conservation followed by low 
numbers in regions of diversity. However as hypothesized, genetically variable regions may play a 
role in antigenic variation, and therefore fluctuating patterns of epitopes may be due to a large 
number of epitopes in regions of genetic diversity rather than conservation. The MPTR section of the 
protein is characterised by imperfect repeat regions which also may contribute to the presence or 
lack of epitopes within these regions. Certain members of the PPE_MPTR family are known to 
contain large insertions and deletions adding to the genetic complexity of these proteins which may 
also contribute to the presence or lack of epitopes. The effect of genetic variation on epitope 
density will be further explored in Chapter 5. 
 
 Areas of the protein that are more (or less) accessible to the host immune system due to the 3D 
protein structure may contain more (or less) epitopes. The 3D protein structure of the PPE_MPTR 
proteins is largely unknown (Strong et al. 2006), due to the difficulty in solubly expressing, isolating 
and crystallizing these proteins, and therefore this hypothesis is difficult to confirm. However, CD4+ 
T-cell epitopes are derived from M. tuberculosis proteins that have been phagocytised by human 
immune cells such as macrophages and dendritic cells and degraded within phagosomes before 
being presented by HLA class II molecules on the surface of the cell. The 3D structure of internalised 
proteins should therefore not play an important role in whether or not T-cell epitopes are found 
within these regions.  
 
While most predicted epitopes show a high peptide to HLA allele binding specificity, there are certain 
peptides that are able to bind to 10 or more HLA alleles, therefore increasing the possible population 
coverage of any potential vaccine containing these peptides. Certain alleles that may be more or less 
frequent in different populations are also able to bind to a higher proportion of peptides than others. This 
may impact on protective efficacy of PPE-based subunit vaccines in different populations. Predicted 
population coverage and possible vaccine candidates are further explored in Chapter 6. 
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A: Proportion of epitopes versus non-epitopes, unique binders versus promiscuous epitopes, and 
distribution of promiscuous epitopes. 
 































B: Patterns of predicted epitopes showing distribution of promiscuity along length of each protein.  
 
The number of predicted epitopes along the length of each protein is shown, indicating the pattern of 
fluctuation (fluctuating, decreasing or increasing/stable). Colours in the graph represent the number of HLA 


























C: Binding ability of HLA alleles per PPE_MPTR protein 
 
The percentage of peptides each of the HLA alleles are able to bind to was investigated for all of the 
PPE_MPTR proteins together (shown in green), and for each of the PPE_MPTR proteins individually (show in 
blue). Dotted lines represent the average percentage of peptides HLA alleles were able to bind to. The 
distribution across the HLA alleles differs significantly when comparing the different PPE_MPTR proteins, 
indicating that vaccine candidates derived from different PPE_MPTR proteins will have substantially different 
population coverage (Chapter 6). 
 
 








































































5.1.1 PPE_MPTR genomics 
 
The genes encoding the PE/PPE proteins make up approximately 10% of the Mycobacterium tuberculosis 
genome (Cole et al. 1998), of which the PPE_MPTR family is a subset consisting of 23 proteins (Chapter 1, 
Figure 1.1). The PPE_MPTR protein sequence includes the conserved PPE region of roughly 170-180 amino 
acids, and the MPTR region which ranges from between 420 to 3700 amino acids. The genes encoding the 
PPE_MPTR proteins are associated with imperfect repeats and are hotspots for recombination events and 
mutations (Cole et al. 1998; McEvoy et al. 2009). Given that M. tuberculosis is highly clonal, it has been 
hypothesized that recombination within the PPE proteins has been influential in the evolution of M. 
tuberculosis and a major contributor to genetic diversity (Liu et al. 2006). 
5.1.2 Determining the genetic diversity of the PPE_MPTR proteins 
 
The function of the PPE_MPTR proteins is largely unknown, and characterising the genetic diversity of these 
proteins is an essential step in improving our understanding of the possible role they may play in M. 
tuberculosis pathogenesis. Given the characteristics of the PPE_MPTR gene sequences, most specifically the 
imperfect repeats which characterise this family, as well as the limitations in the current sequencing 
technology, this has proven difficult. Repeated gene sequences cause technical challenges for sequence 
alignment and assembly programs given the short read length of most next generation sequencing 
platforms, as they create ambiguities in the alignment and assemblies (Treangen & Salzberg 2012). As a 
result, many genetic variation and phylogenic studies of the M. tuberculosis genome often exclude all of the 
PE/PPE proteins altogether. Even in an analysis focused specifically on the genetic diversity of the PE_PGRS 
protein family, which along with the PPE_MPTR proteins, are the most genetically diverse regions within the 
M. tuberculosis genome, polymorphic sites which included large indels (>25% of the gene) and frameshift 
indels were excluded from the analysis of nucleotide diversity (Copin et al. 2014). In a comparative analysis 
of all of the M. tuberculosis pe/ppe genes, it was shown that the majority of genetic diversity seen within the 
PPE_MPTR family is due to macro-mutations including homologous recombination, IS6110 integration, 
partial and whole gene deletions rather than micro-mutations such as single nucleotide polymorphisms 
(SNP’s) and small indels (McEvoy et al. 2012). Therefore following a similar approach of ignoring largely 
polymorphic regions within the PPE_MPTR proteins would result in a large portion of certain ppe_mptr 
genes discarded and the potential biological reason and importance for these macro-mutations overlooked.  
 
Different methods for analysing and quantifying the diversity of a gene across multiple strains exist, 
including the approach used by Copin et al. (2014) for the pe_pgrs genes where nucleotide diversity (π) and 
indel diversity was calculated using the Nei method (Nei 1987). These and various other methods have been 
made available using software such as the Molecular Evolutionary Genetics Analysis (MEGA) toolkit (Tamura 
et al. 2011). However, these approaches require a multiple alignment of the various strains used in the 
analysis which can be prone to errors when investigating genes containing highly polymorphic regions such 
as those encoding the PE_PGRS and PPE_MPTR protein families, often necessitating the need to exclude 
these regions. IS6110 insertions, recombination and large gene deletions within the ppe_mptr genes result in 
each genome containing a combination of unique lineage-specific segments, regions shared with a subset of 
other strains and segments conserved among all the genomes included (Darling et al. 2004), further 
complicating a multiple alignment. Certain members of the PPE_MPTR family have varying copy numbers of 
the tandem repeats between different strains (section 5.3.2 below), resulting in varying lengths for the same 
gene across different strains, which can also result in ambiguous multiple alignments. Typical genetic 
diversity scores such as nucleotide diversity (π) annotate the large differences in the size of genes between 
strains as large indels rather than a difference in the copy number of tandem repeats. IS6110 insertion 
elements which have resulted from one insertion event are also counted as many nucleotide differences 
(Nei 1987), all of which overestimate the actual genetic diversity. A clustering approach, where repeats, and 
large indels are collapsed into single nucleotide markers has been applied to the human genome (Teixeira-
Silva et al. 2013), and could similarly be applied to the ppe_mptr genes. Genetic diversity scores are also 
sensitive to the choice of strains to be included in the analysis making it extremely important to ensure that 




a large number of strains from various lineages are included to make any quantitative score a reliable one. 
This also makes comparing the scores between studies which have used different strains unreliable. Given 
these observations, quantitative genetic diversity scoring methods may not be suitable for the ppe_mptr 
genes. 
5.1.3 Current approach used 
 
Given the challenges associated with determining the genetic diversity of the ppe_mptr genes, various 
approaches were used within this chapter to try and overcome these. This has included identifying and 
removing IS6110 insertion elements (Section 5.2.4) and using the tandem repeat finder (TRF) tool which 
masks repeat regions (Section 5.2.5). A multiple alignment of genes where the regions that complicate the 
multiple alignment algorithm are masked has resulted in more accurate alignments. Actual gene sequences 
of the masked regions can subsequently be added back into the alignment. Small regions where alignments 
are ambiguous have been excluded, and small variants such as SNP’s and indels have only been included if 
they are seen in at least 2 strains (Section 5.2.6).  
 
The focus of this chapter is determining whether the hypothesis presented within this thesis of “genetic 
diversity within the PPE_MPTR proteins differentially modulating human immune response” is valid or not. 
Therefore genetic variants have been investigated within the context of epitope density. This chapter does 
not try to quantify the genetic diversity similarly to methods used within the MEGA toolkit, but rather 
whether a genetic variant observed has an impact on epitope density within that region, and whether 
epitope dense versus epitope void regions can be explained by genetic diversity within those regions.   
 
  




 5.2 Methodology 
5.2.1 Methodology summary 
 
Figure 5.1 shows a summary of the methodology used to determine the genetic variation within each of the 
ppe_mptr genes and the effects of the different variants on epitope prediction. 
 
 
Figure 5.1: Genetic variation methodology. Methodology used to determine the genetic variation of the ppe_mptr genes involved 
using public WGS data from NCBI, identifying H37Rv orthologs in each strain and identifying IS6110 insertion elements, tandem 
repeats and micro-mutations. The epitope density in repeat and non-repeat regions has been investigated as well as the effect of 
specific micro-mutations on epitope density. 




5.2.2 Strain data 
 
Publically available M. tuberculosis assembled whole genome sequences (WGS) were obtained from the 
National Center for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/genome/genomes/166, accessed 29 September 2015), and TBDB (Galagan et 
al. 2010). Each sequence was downloaded as a complete FASTA sequence. (Gene annotations provided by 
the NCBI prokaryotic genome annotator were not used. See section 5.2.3.)  
 
A total of 32 different M. tuberculosis WGS from various lineages were downloaded (Table 5.1). Information 
about each strain (such as the sequencing technology used and year submitted) was obtained from the 
metadata linked to each genome within the NCBI website where available. Lineage information for each 
strain was determined using CASTB, a publicly accessible web server which accepts WGS data and reports 
the results of spoligotyping, VNTR, lineage, and Beijing typing (Iwai et al. 2015). 
 
In addition, five other mycobacterial strains (M. canetti, M. suricattae, M. bovis, M. africanum and M. bovis 
BCG) were included in the analysis for comparative purposes. With the exception of M. suricattae, all other 
assembled WGS’s were downloaded from the NCBI website in FASTA format 
(http://www.ncbi.nlm.nih.gov/genome/genomes/166, accessed 29 September 2015). The assembled WGS 
for M. suricattae was obtained from Dr. Anzaan Dippenaar from the SAMRC TB research unit, University of 
Stellenbosch.  
 
The M. tuberculosis H37Rv strain was used as the reference strain. Gene sequences for the H37Rv ppe_mptr 
genes were obtained from TubercuList (Lew et al. 2011) in FASTA format. Similarly to the methodology 
followed during epitope prediction (section 4.2.1), three of the ppe_mptr genes (Rv0304c, Rv0354c and 
Rv2353) were not included in the analysis due to dissimilarity in protein sequence structure to the remaining 
PPE_MPTR proteins. 
 
In total, including H37Rv, the additional 32 M. tuberculosis strains from NCBI, and 5 other mycobacteria, 38 
strains were used to analyse the genetic variation within the ppe_mptr genes. 




Table 5.2: Strain Information. Strain information including NCBI accession number, lineage, sequencing source and technology, and year of submission are given for each strain included in the analysis. Lineage 
was obtained from CasTB, while all other information was taken from supporting literature where available.  For certain WGS, the sequencing technology used was not provided within the metadata linked to 
the genome. * Downloaded from TBDB 
Strain Name NCBI accession number Lineage (CasTB) Sequencing Source Sequencing Technology 
Year 
submitted 
CDC1551 NC_002755.2 4 TIGR Whole genome shotgun sequencing 2002 
F11 NC_009565.1 4 Broad 
 
2007 
Haarlem NC_022350.1 4 Broad 
 
2006 
KZN1435 NC_012943.1 4 Broad 
 
2009 
KZN4207 NC_016768.1 4 Broad 
 
2009 
KZN605 NC_018078.1 4 Broad 
 
2009 
W148 NZ_CP012090.1 2 Broad Sanger, Illumina, PacBio. 2010 
CTRI2 NC_017524.1 4 Research Institute for Physical-
Chemical Medicine, Moscow, Russia  
2013 
CCDC5079 NC_021251.1 2 BGI 
 
2011 
CCDC5180 NC_017522.1 2 BGI 
 
2011 
719999 NC_020089.1 4 Center for Biotechnology, Bielefeld 
University  
2012 
Erdman ATCC 35801 NC_020559.1 4 National Center for Global Health and 
Medicine 
ABI3730xl, Roche 454, Illumina 
GAIIx. 
2012 
NITR203 NC_021054.1 4 National Institute of Tuberculosis 
Research, Chennai, India 
Illumina 2013 
NITR206 NC_021194.1 4 National Institute of Tuberculosis 
Research, Chennai, India 
Illumina 2013 
EAI5 NC_021740.1 4 Department of Life Sciences, Mumbai 
University, Mumbai, India 
Illumina 2013 
HKBS1 NZ_CP002871.1 2 
School of Biomedical Sciences, Faculty 
of Medicine, The Chinese University 
of Hong Kong 
 
2011 
BT2 NZ_CP002882.1 2 
School of Biomedical Sciences, Faculty 
of Medicine, The Chinese University 
of Hong Kong 
 
2011 
Stellenbosch University  https://scholar.sun.ac.za




Strain Name NCBI accession number Lineage (CasTB) Sequencing Source Sequencing Technology 
Year 
submitted 
BT1 NZ_CP002883.1 2 
School of Biomedical Sciences, Faculty 
of Medicine, The Chinese University 
of Hong Kong 
 
2011 
K NZ_CP007803.1 2 Seoul National University Sanger, Illumina MiSeq 2015 
KIT87190 NZ_CP007809.1 2 Korean Institute of Tuberculosis Roche 454,  GapFiller 2014 
ZMC13264 NZ_CP009100.1 
 
Affiliated Hospital of Zunyi Medical 
College 
Ion Torrent 2014 
ZMC1388 NZ_CP009101.1 4 Affiliated Hospital of Zunyi Medical 
College 
Ion Torrent 2014 
96075 NZ_CP009426.1 
 
Northern Arizona University Roche 454 2014 
96121 NZ_CP009427.1 1 Northern Arizona University Sanger dideoxy sequencing, Roche 
454. Illumina 
2014 
4902 NZ_HG813240.1 2 JLU 
 
2013 
Kurono NZ_AP014573.1 4 National Center for Global Health and 
Medicine 
PacBio 2014 
Beijing-like NZ_CP010873.1 2 Universidad Nacional de Colombia - 
Sede Bogota 
PacBio 2015 
NITR204 CP005386.1 4 National Institute of Tuberculosis 
Research, Chennai, India 
Illumina 2013 
SCAID187 NZ_CP012506.2 2 SCAID Illumina Hiseq 2000, Ion Torrent 2015 
RGTB327 * 4 Rajiv Gandhi Centre for Biotechnology Roche 454 2012 
RGTB432 * 4 Rajiv Gandhi Centre for Biotechnology Roche 454 2012 
C * 4 Broad Whole genome shotgun sequencing 2005 
.
Stellenbosch University  https://scholar.sun.ac.za




5.2.3 Ortholog coordinates 
 
The coordinates of the H37Rv ppe_mptr orthologs from each strain were needed in order to determine 
genetic variation between strains within each gene. The prokaryotic genome annotations provided by the 
NCBI are predicted genes regions and have not been curated (Tatusova et al. 2016). Visual inspection of 
pairwise alignments between the H37Rv ppe_mptr genes and the orthologs given by the prokaryotic genome 
annotations showed poor correlations and missing sections at the beginning and/or end of certain gene 
sequences (data not shown). It was therefore decided that these automated annotations would not be used.   
 
Coordinates of the H37Rv ppe_mptr orthologs were obtained using the GLSEARCH command line tool 
(version 36.3.8) to perform a global: local alignment between each complete FASTA sequence for each strain 
and each H37Rv ppe_mptr gene sequence. The output of the GLSEARCH tool is in the format of a list of 
possible alignments with a corresponding similarity score. Similarity scores were used to filter alignments 
based on the following criteria:  
 
 Greater than 90% similarity scores:  Coordinates given by GLSEARCH used as is. 
 
 Between 70% and 90% similarity:  A pairwise alignment between the H37Rv gene (extended by  
500 nucleotides on each side) and the possible ortholog 
(extended by  500 nucleotides on each side) was performed 
using the Needleman and Wunsch algorithm (Needleman & 
Wunsch 1970). Alignments were visually inspected to 
determine correct coordinates or discard the alignment. 
 
 Less than 70% similarity scores:  Not used. 
 
For each strain, the coordinates of each gene were checked for overlap (i.e. no two genes had overlapping 
coordinates within one strain). Where overlapping coordinates were found, Needleman and Wunsch 
pairwise alignments (Needleman & Wunsch 1970) were visually inspected, and orthologs discarded where 
necessary. In many cases an overlap between Rv3343c, Rv3347c and Rv3350c was found. After visual 
inspection of the Needleman and Wunsch pairwise alignments for these genes, the coordinates for Rv3343c 
were not able to be confirmed for many of the strains.  High sequence variation across strains was also 
observed for Rv3347c and Rv3350c. The TB Database (TBDB) (Galagan et al. 2010), which also provides WGS 
data for various M. tuberculosis strains, has provided a list of orthologs of all of the genes within each strain 
available in their database. Similarly, this list does not differentiate between Rv3343c, Rv3350c and Rv3347c, 
but rather lists them as one set for H37Rv corresponding to another set of one or two genes within other 
strains. It could be hypothesized that these genes have resulted from duplication events, with a varying 
number and/or combination present in different strains. Given the high similarity of all three of these genes 
within H37Rv, it is therefore extremely difficult to distinguish whether the correct ortholog for each gene 
was found within each strain, and the high sequence variation observed could be a result of the incorrect 
ortholog being used. Therefore genetic variation analysis for Rv3343c, Rv3350c and Rv3347c between strains 
was not performed. Identification of IS6110 insertion elements (section 5.2.4) and tandem repeats (5.2.5) 
was therefore restricted to the gene sequence for H37Rv for these 3 genes. 
 
For certain strains it was not possible to find the coordinates of all of the remaining 17 ppe_mptr genes. 
Missing coordinates may either be due to poor sequencing or missing reads within these regions, or an 
actual deletion of certain ppe_mptr genes within these strains. The number of strains used to determine 
genetic variation within each of the 17 ppe_mptr genes is shown in Table 5.2. 
  




Table 5.3: Number of strains used to determine genetic variation. For certain genes, the ortholog coordinates within each strain 
were not found and therefore not all 38 strains were included. 
 Gene Number of Strains  Gene Number of Strains 
1. Rv0305c 36 10. Rv1917c 34 
2. Rv0355c 37 11. Rv1918c 37 
3. Rv0442c 36 12. Rv2356c 31 
4. Rv0755c 37 13. Rv2608 37 
5. Rv0878c 37 14. Rv3144c 36 
6. Rv1135c 36 15. Rv3159c 37 
7. Rv1548c 37 16. Rv3533c 38 
8. Rv1753c 37 17. Rv3558 37 
9. Rv1800 35    
5.2.4 IS6110 insertion elements 
 
The GLSEARCH command line tool was used to perform a global: local alignment (using default parameters) 
between each of the ppe_mptr orthologs from each strain and the DNA sequence for an IS6110 insertion 
element (provided by Dr. Anzaan Dippenaar from the SAMRC TB research unit, University of Stellenbosch). 
Similarity scores of at least 99% were used. Once identified, IS6110 insertions were removed from the gene 
sequence for further analysis of genetic variation. 
5.2.5 Tandem repeats 
 
The Tandem Repeat Finder (TRF) tool (Benson 1999) was used to find the presence and number of tandem 
repeats within each of the ppe_mptr genes for all strains. This tool also allows the user to output a masked 
version of the gene sequence where areas containing tandem repeats are masked with an ‘X’. A multiple 
alignment of the masked sequences for each gene was performed using Muscle (Edgar 2004). Subsequently, 
the original gene sequences of the masked regions were reintroduced into the multiple alignments. 
 
When performing the identification of tandem repeats, two broad categories of tandem repeats were 
identified. The typical MPTR tandem repeats as well as longer tandem repeats (Non-MPTR). Repeats were 
separated into each category based on length. MPTR repeats were in multiples of 15 bp, while longer 
repeats where between 70-90 bp. Alignment and clustering of repeated segments was used to confirm the 
category of repeat regions. For each ppe_mptr gene, the number of repeats was compared across strains to 
determine whether the copy number was constant or variable. 
5.2.6 Determination of variants 
 
In addition to the multiple sequence alignment described in section 5.2.5, for each of the 17 ppe_mptr 
genes, a Needleman and Wunsch pairwise alignment (Needleman & Wunsch 1970) between the H37Rv gene 
sequence and its corresponding ortholog from each strain was performed using the needle command line 
tool from EMBOSS. The gap opening penalty was set to 100 and gap extension penalty was set to 1 in order 
to favour alignments with fewer long gaps over alignments with many short gaps given the large indels and 
variable copy number of repeats within the ppe_mptr genes. Pairwise alignments were used to determine 
genetic variants including SNPs, insertions and deletions. Each variant found was compared to variation 
results obtained using the multiple sequence alignment described in section 5.2.5. Differences were visually 
inspected to determine the reason for the difference and which variant (if any) was correct. 
 
Due to the known high sequencing error rate within the pe/ppe genes, only variants found in at least 2 
strains compared to H37Rv were confirmed as variants. Furthermore, areas where the alignment with the 
H37Rv gene was ambiguous (i.e. an insertion or deletion could be placed in more than one area and 
therefore a different set of resulting SNP’s reported) were discarded from further analysis. Insertions and 
deletions in areas with repeating bases were also excluded due to the high probability that these indels may 
be due to sequencing error rather than true genetic variation. 
 




Rv1917c is one of the ppe_mptr genes that is extremely variable, particularly in the length of the gene 
between strains. It contains IS6110 insertion elements and both MPTR repeats as well as the longer repeat 
regions in different copy numbers across strains. Removing IS6110 insertion elements and masking repeat 
regions as described in section 5.2.4 and 5.2.5 above still results in an ambiguous multiple alignment, which 
can result in a different set of SNP’s called depending on which alignment is chosen. This may be due to 
additional partial gene deletions within certain strains. For this reason, micro-mutations were not 
investigated for Rv1917c. 
5.2.7 Effect of micro-mutations on epitope prediction 
 
Micro-mutations are defined as SNP’s and small indels (less than 9 bp in length). The effect of each micro-
mutation on the protein and epitope density within the area of the mutation was investigated. For each SNP 
identified, the effect on epitope density within that region was investigated using the following approach: 
 
 Determining the effect of the SNP on the protein sequence (i.e. distinguishing between a 
synonymous SNP (sSNP) versus non-synonymous SNP (nsSNP). Variant gene sequences (containing 
the specific SNP) were transcribed and translated into a protein sequence using the Biopython 
package (Cock et al. 2009), and aligned to the H37Rv protein sequence to determine the position 
and amino acid change. 
 
 Re-performing epitope prediction with variant protein sequence. When epitope prediction is 
preformed, the protein sequence is segmented into overlapping peptides of 15 amino acids in 
length. A non-synonymous SNP can therefore affect 15 different peptides. For each of these variant 
peptides, epitope prediction was rerun with each of the 47 HLA alleles included in Chapter 4.  
 
 Comparison of results from epitope prediction using H37Rv and the variant protein sequence. 
Prediction results were analysed to determine whether the genetic variant has resulted in epitope 
creation or deletion, effect on average predicted binding score and whether the number of HLA 
alleles the peptide is able to bind to has changed. 
  




5.2.8 Epitope density within repeat versus non-repeat regions 
 
Epitope density along the length of the PPE_MPTR proteins shows patterns of fluctuation (Chapter 4, Section 
4.3.2). Whether these fluctuating patterns correlate with repeat versus non-repeat areas was investigated 
for H37Rv using two approaches: 
 
 The total percentage of repeat regions (i.e. regions masked by the Tandem Repeat Finder) out of the 
length of the gene was compared to overall epitope density for each PPE_MPTR protein. 
 
 Repeat and non-repeat regions alternate along the length of the PPE_MPTR proteins (An example 
graphical representation is shown in Figure 5.2). Epitope density within each repeat and non-repeat 
region was calculated separately, and the distribution of epitope density in repeat versus non-repeat 
regions was compared overall for the PPE_MPTR proteins as well as separately for each protein 
individually. Coordinates of repeat regions within each gene was converted into protein coordinates 
which were used to determine epitope density within each individual region.  
 
 
Figure 5.2: Example graphical representation of alternating repeat and non-repeat regions. MPTR repeats (red) as well as longer 
non-MPTR repeats (green) can be found within the ppe_mptr genes dispersed between non-repeated gene regions (blue). The copy 
number of both types of repeats can vary between strains changing the length of the gene sequence and resulting protein.  
  





5.3.1 Summary of genetic variation 
 
Table 5.3 shows a summary of the type and amount of genetic variation seen within each ppe_mptr gene 
sequence. 
 
Table 5.4: Summary of genetic variation observed. For each gene, the number of sSNP, nsSNP’s and small indels is shown, as well as 
whether IS6110 insertion elements were found within at least one strain. The presence of MPTR and long non-MPTR repeats is 
shown as well as whether the copy number was found to be variable or constant. An acceptable multiple alignment of Rv1917c was 
not found and therefore micro-mutations for Rv1917c are not available (section 5.2.6). Ortholog coordinates for Rv3343c, Rv3347c, 
and Rv3350c could not be confirmed and therefore no micro-mutations between strains could be identified (section 5.2.3). IS6110 
insertions and tandem repeats for these genes were searched for using only H37Rv, and therefore copy number of repeats could not 
be calculated. 

















Rv0305c 2   1*   Yes Variable    
Rv0355c 5 8 1   Yes Variable    
Rv0442c   1     Yes Constant    
Rv0755c   1     Yes Constant    
Rv0878c 1       Yes Constant    
Rv1135c       Yes Yes Constant    
Rv1548c   1     Yes Constant    
Rv1753c 2 2     Yes Variable Yes Variable 
Rv1800   4   Yes ***    
Rv1917c       Yes Yes Variable Yes Variable 
Rv1918c   4 1   Yes Constant Yes  Constant 
Rv2356c   1     Yes Constant    
Rv2608   1     Yes Constant    
Rv3144c 1 2     Yes Constant    
Rv3159c   5 1**   Yes Constant    
Rv3343c         Yes     
Rv3347c         Yes     
Rv3350c         Yes     
Rv3533c   1     Yes Constant    
Rv3558 1 3 1**   Yes Constant    
TOTAL 12 34 5      
*H37Rv not wild type 
** Within repeated area and may therefore be due to sequencing error (low confidence). 
***no MPTR repeats were identified by the TRF tool for Rv1800. 
  




5.3.2 IS6110 insertion elements 
 
IS6110 insertion elements were found within three of the ppe_mptr genes, Rv1153c, Rv1800, and Rv1917c. 
Table 5.4 shows the position of the IS6110 elements and which strains they were found in. 
 
Table 5.5: Genes containing IS6110 insertion elements. Position of the IS6110 insertion element within the gene is shown along with 
the strains containing the insertion.  
Gene Position Strains 
Rv1153c 1150 - 2524 4902. 96075, HKBS1, BT1, CCDC5180, BT2, Beijing_like, 
CCDC5079 
Rv1800 1770 - 3142 CTRI2 
976 – 2350 CCDC5180 
Rv1917c 
1587 - 2964 KIT87190, BT1, HKBS1, K, W148, Beijing_like 
1139 - 2511 96075 
1451 - 2826 4902 
For Rv1800, the IS6110 insertion element was found in two strains but in two distinct places within the 
genome. These regions did not overlap. For Rv1917c, the position of the IS6110 insertion elements between 
different strains all overlapped with each other and the difference in position was due to other variation 
within the genomes of these strains (either variable copy numbers of repeats, or other insertions or 
deletions) before the IS6110 insertion element.  
5.3.3 Effect of micro-mutations on epitope prediction 
 
Table 5.5 shows the small indels identified within each ppe_mptr gene. 




Table 5.6: Small indels identified within the ppe_mptr genes. Information for each indel identified and the consequence of the variant on the protein is given. Indels for Rv1917c could not be identified 
determined given the ambiguity in the multiple alignment across strains for this gene. Ortholog coordinates for Rv3343c, Rv3347c, and Rv3350c could not be confirmed and therefore indels were not identified 
for these genes. No indels were identified for Rv0442, Rv0755c, Rv0878c, Rv1135c, Rv1548c, Rv1753c, Rv1800, Rv2356c, Rv2608, Rv3144c, and Rv3533c. 
Protein Position Size H37Rv Allele 
Alt 
Allele % of strains Strains containing Variant Consequence on Protein 
Rv0305c 2428 1 T - 100% (37/37) All except H37Rv Protein sequence changed after 809 amino acids. 
Rv0355c 9888 2 - AT 24.3% (9/37) 
RGTB432, 96121, M. canetti, M. 
africanum, M. suricattae, M. bovis, 
BCG, NITR206, EAI5 
Protein sequence changed after 3296 amino acids, only affecting 
the Last 4 amino acids. However not a multiple of 3, and stop 
codon at the end of the protein is disrupted. 
Rv1918c 1797 1 - A 5.4% (2/37) M. bovis, BCG Change in protein sequence from amino acid 600 – 625, followed 
by a stop codon and therefore a truncated protein. 
Rv3159c 178 3 GCG - 37.8% (14/37) 
BCG, M. bovis, M. suricattae, BT2, 
M. africanum, CCDC5180, Beijing-
Like, BT1, KIT87190, K, CCDC5079, 
96075, W148, 4902 
Deletion of 1 amino acid. No change to the rest of the protein. This 
deletion is within a section with repeating “GCG”. Therefore 
strains may have a variable number of this codon. It may also 
however be a sequencing error and not a real deletion. 
Rv3558 81 3 GGC - 13.5% (5/37) KZN1435, KZN605, KZN4207, F11, 
CTRI2 
Deletion of 1 amino acid. No change to the rest of the protein. This 
deletion is within a section with repeating “GGC”. Therefore 
strains may have a variable number of this codon. It may also 
however be a sequencing error and not a real deletion. 
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Indels for Rv3159c and Rv3558 may be due to sequencing error as they are found within regions containing a 
repeated codon. Effect on epitope prediction for these variants was therefore not investigated. The indel 
within Rv1918c resulted in a truncated protein, and therefore the effect on epitope prediction was not 
investigated. Given that the indel found within Rv0355c only affected the last 4 amino acids, the effect on 
epitope prediction was also not investigated.   
 
A single nucleotide deletion was found in Rv0305c for all strains when compared to H37Rv. H37Rv protein 
sequence is therefore not the wild type sequence. From position 809 in the protein, the amino acid 
sequence is different for H37Rv compared to all other strains. This could potentially have a large impact on 
the results of epitope prediction for this protein. Epitope prediction was therefore rerun using a 
representative “wild-type” sequence from among the strains against all 47 HLA alleles used in Chapter 4, and 
compared to the results using H37Rv. The protein sequence changes within the MPTR region and there 
results are shown for epitopes found within the MPTR region only (Table 5.6). 
 
Table 5.6: Comparison between epitope prediction results for Rv0305c in H37Rv and “wild-type” sequence. The number of 
epitopes within the MPTR region, average binding score and average number of alleles has been compared. 
 H37Rv “wild-type” 
Number of MPTR Epitopes 230 244 
Average binding score 0.456 0.522 
Average number of HLA alleles 2.14 1.81 
 
The number of epitopes within the MPTR region increased from 230 to 244 epitopes. Protein length 
remained the same and therefore epitope density has increased by 6.1%. The average binding score of 
epitopes also increased, however the average number of alleles each epitope is able to bind to decreased. 
 
Table 5.7 shows the SNP’s identified within each ppe_mptr gene. 




Table 5.7: SNP's identified within the ppe_mptr genes. Information for each SNP including which strains contained the variant and the effect on the protein is shown. Micro-mutations for Rv1917c could not be 
identified given the ambiguity in the multiple alignment across strains for this gene. Ortholog coordinates for Rv3343c, Rv3347c, and Rv3350c could not be confirmed and therefore micro-mutations were not 
identified for these genes. 
Protein Position H37Rv Allele 
Alternate 
Allele % of strains Strains containing Variant Type 
Consequence 
on Protein 
Rv0305c 1359 T C 33.3% (12/36) 
HKBS1, CCDC5180, Beijing-Like, BT1, BT2, ZMC1388, CCDC5079, 96075, 
NITR203, W148, SCAID187, 4902 
sSNP None 
2799* T G 80.6% (29/36) All except RGTB327, Kurono, F11, KZN4207, KZN605, KZN1435, CTRI2 sSNP None 
Rv0355c 
353 T C 5.4% (2/37) RGTB432, 96121 nsSNP V118A 
2144 G A 32.4% (12/37) 
Beijing-Like, ZMC1388, NITR203, SCAID187, CCDC5180, BT2, CCDC5180, BT2, 
CCDC5079, 9605, W148, HKBS1, 4902, BT1 
nsSNP G715D 
3357 C A 5.4% (2/37) 
M. africanum, M. suricattae 
sSNP None 
3578 C G 5.4% (2/37) NITR206, EAI5 nsSNP A1193G 
3924 C T 8.1% (3/37) Erdman, 719999, Haarlem sSNP None 
4348 T C 5.4% (2/37) KIT87190, K nsSNP F1450L 
5840 G A 8.1% (3/37) Erdman, 719999, Haarlem nsSNP G1947D 
5982* G A 67.6% (25/37) 
All except RGTB327, C, Erdman, Kurono, F11, KZN4207, KZN605, KZN1435, 
719999, CDC1551, CTRI2, Haarlem 
sSNP None 
7209 A C 8.1% (3/37) M. canetti, M. bovis, BCG sSNP None 
7912 G A 10.8% (4/37) RGTB432, 96121, NITR206, EAI5 nsSNP G2638S 
8022 G T 8.1% (3/37) NITR204, NITR203, NITR206 nsSNP L2674F 
9699 C T 40.5% (15/37) 
Beijing-Like, ZMC1388, ZMC13264, NITR203, SCAID187, BT2, CCDC5180, 
CCDC5079, 96075, W148, HKBS1, 4902, BT1, KIT87190, K 
sSNP None 
9748 A T 24.3% (9/37) 
RGTB432, 96121, M. canetti, M. africanum, M. suricattae, M. bovis, BCG, 
NITR206, EAI5 
nsSNP I3250F 
Rv0442c 23 G A 5.6% (2/36) BCG, M. bovis nonsense Premature 
stop codon. 
Rv0755c 1634 G A 21.6% (8/37) RGTB432, M. africanum, BCG, M. suricattae, M. bovis, 96121, EAI5, M. canetti nsSNP R545K 
Rv0878c 1008 C T 10.8% (4/37) RGTB432, 96121, NITR206, EAI5 sSNP None 
Rv1135c None 
Rv1548c 773* A G 97.3% (36/37) All except Kurono nsSNP D258G 
Rv1753c 1459 C T 5.4% (2/37) ZMC13264, C sSNP None 
1463* A C 91.9% (34/37) All except Kurono, ZMC13264, C nsSNP N488T 
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Protein Position H37Rv Allele 
Alternate 
Allele % of strains Strains containing Variant Type 
Consequence 
on Protein 
1775 A C 5.4% (2/37) ZMC13264, ZMC1388 nsSNP N592T 
1875 C A 21.6% (8/37) C, Haarlem, M. africanum, M. suricattae, M. bovis, Erdman, 719999, BCG sSNP None 








432 T G 17.1% (6/35) BCG, M. bovis, M. africanum, 96121, RGT432, EAI5 nsSNP C144W 
449 C T 14.3% (5/35) C, Erdman, 719999, CDC1551, Haarlem nsSNP A150V 
757 T G 8.6% (3/35) BCG, M. bovis, M. africanum nsSNP F253V 
1508 T C 5.7% (2/35) BCG, M. bovis nsSNP V503A 
Rv1918c 
1871 G A 5.4% (2/37) C, RGTB432 nsSNP G624D 
2602 A C 5.4% (2/37) BCG, M. bovis nsSNP S868R 
2630 G A 5.4% (2/37) NITR206, EAI5 nsSNP G877D 
2687* T C 67.6% (25/37) 
All except RGTB327, C, Erdman, Kurono, F11, KZN4207, KZN605, KZN1435, 
719999, CDC1551, CTRI2, Haarlem 
nsSNP L896S 
Rv2356c 539 C T 16.1% (5/31) NITR203, NITR204, NITR206, ZMC13264, EAI nsSNP S180L 
Rv2608 841 C T 10.8% (4/37) M. suricattae; M. Bovis; M. africanum; BCG nsSNP P281S 
Rv3144c 
676 G A 8.3% (3/36) NITR204, NITR206, EAI5 nsSNP G226S 
996 G A 5.6% (2/36) ZMC1388, ZMC13264 sSNP None 
1198* A C 69.4% (25/36) 
All except RGTB327, C, Erdman, Kurono, F11, KZN4207, KZN605, KZN1435, 
719999, CDC1551, CTRI2, Haarlem 
nsSNP K400Q 
Rv3159c 
97* C G 59.5% (22/37) 
All except NITR204, BCG, M. bovis, M. suricattae, RGTB327, Kurono, F11, 
KZN4207, KZN605, KZN1435, M. africanum, CTRI2, NITR206, EAI5 
nsSNP R33G 
612 C A 5.4% (2/37) BCG, M. bovis nsSNP D204E 
1013 G T 5.4% (2/37) NITR206, EAI5 nsSNP G338V 
1190 C T 5.4% (2/37) NITR206, EAI5 nsSNP T397I 
1681 A G 5.4% (2/37) NITR206, EAI5 nsSNP T561A 
Rv3533c 1026 C A 8.1% (3/37) Erdman, 719999, Haarlem nsSNP S342R 
Rv3558 634 C T 8.1% (3/37) KZN1453, KZN605, KZN4207 nsSNP L212F 
916 G A 10.8% (4/37) 96121, NITR206, EAI5, RGTB432 nsSNP G306S 
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When epitope prediction is preformed, the protein sequence is segmented into overlapping peptides of 15 
amino acids in length. A non-synonymous SNP can therefore affect 15 different peptides. For each nsSNP, 
epitope prediction was rerun for the 15 individual peptides affected by the amino acid change against all 47 
HLA alleles used in chapter 4. For each peptide, the following was investigated: 
 
 Whether the variant resulted in epitope destruction or creation. 
 Whether the overall binding score changed by more than 10%. 
 Whether the number and type of HLA alleles the peptide is able to bind to changed. 
 
These results can be found in Appendix A which has been attached as an excel spread sheet given the large 
size of the table. 
 
In certain cases, a variant was found in an epitope void area, and the change in amino acid did not result in 
epitope creation. The nsSNP’s in these cases therefore had no effect on epitope density. This was seen for 
certain nsSNP’s within Rv0355c, Rv1800, Rv1918c, Rv3159c, and Rv3558c; and for all SNP’s within Rv0755c, 
Rv1548c, Rv1753, and Rv3533c. Certain variants found in epitope dense areas also did not affect the epitope 
density within those areas, i.e. the variant peptide was still a predicted epitope, with no change to binding 
score and number or type of HLA alleles. Certain other nsSNP’s did result in a change in the overall binding 
score of the peptide. This is true for selected SNP’s within Rv0355c, Rv1800, Rv1918c, Rv2608, Rv3144c, and 
Rv3159c. Particular nsSNP’s also changed the type and number of HLA alleles the peptide was able to bind 
to. This can be seen within Rv0355c, Rv1800, Rv1918c, Rv2356c, Rv2608, Rv3144c, Rv3159c, and Rv3559). 
There were limited instances where epitopes were created within an epitope void area as a result of the 
variant. This was seen within Rv1918c, Rv2356c, Rv3159c, and Rv3558. In certain other cases, the nsSNP 
resulted in epitope deletion. This was seen in Rv0355c, Rv1800, Rv1918c, Rv3144, and Rv3159. 
 
Overall, certain SNP’s affected epitope prediction while others did not. A clear pattern of micro-mutations 
affecting HLA class II binding ability could not be identified. 
5.3.4 Epitope density within repeat versus non-repeat regions 
 
The correlation between regions containing tandem repeats and epitope density was investigated in two 
ways: 
 
 The overall percentage of repeat regions within each gene sequence was compared to the overall 
epitope density within a protein (Figure 5.4) 
 
 Given that repeat and non-repeat regions alternate along the length of the PPE_MPTR proteins 
(Figure 5.2), epitope density within each repeat and non-repeat region was calculated separately, 
and the distribution of epitope density within the different regions was compared overall for the 
PPE_MPTR proteins (Figure 5.5) as well as separately for each protein individually (Figure 5.6) 
 





 Figure 5.4: Comparison between epitope density and overall percentage of repeat regions. A) Epitope density is shown in black and percentage of repeats in shown in green. Proteins along the x-axis have 
been ordered in descending epitope density. B) Epitope density and percentage of repeats show a strong inverse correlation (r = -0.73, p < 0.001).  
A 
B 
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A strong inverse relationship between epitope density and percentage of repeats can be seen, indicating 
that those PPE_MPTR proteins with fewer repeat areas as a percentage of the total protein length have on 
average a higher epitope density.  
 
Figure 5.5 shows the results when calculating the epitope density within each separate alternating repeat 
and non-repeat region along the length of all PPE_MPTR proteins. 
 
Figure 5.5 Comparison of epitope density within repeat and non-repeat regions across all PPE_MPTR proteins. A) Mean epitope 
density within non-repeated regions (blue) is compared to repeat regions (purple). Error bars show standard deviation in epitope 
density. Difference in mean epitope density between repeat and non-repeat areas is statistically significant (p < 0.001). B) Box plot 
showing the distribution of epitope density in non-repeat regions (blue) versus repeat regions (purple), with outliers shown in green. 
Overall epitope density within the PPE_MPTR proteins is significantly higher within non-repeat areas, which 
suggests that the fluctuating patterns of epitope density along the length of the PPE_MPTR proteins is due to 
the alternating repeat and non-repeat regions. However within the repeat regions, outliers can be seen 
(Figure 5.5 B), which indicates that there are certain repeat regions with a higher epitope density 
comparable with the non-repeat regions. To investigate whether this is specific to certain PPE_MPTR 

















Figure 5.6: Comparison of epitope density within repeat and non-repeat regions individually for each PPE_MPTR protein. A) Mean epitope density within non-repeated regions (blue) is compared to repeat 
regions (purple) for each PPE_MPTR protein. Error bars show standard deviation in epitope density. Significant differences are shown where applicable (* p < 0.05, ** p < 0.01). B) Box plot showing the 
distribution of epitope density in non-repeat regions (blue) versus repeat regions (purple), with outliers shown in green. 
A 
B 
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Mean epitope density is higher in non-repeat regions for all PPE_MPTR proteins. Given that certain proteins 
have only one or two repeat regions along the length of the protein, the sample size for a statistical test is 
too small and therefore even though it is evident that epitope density is higher in repeat versus non-repeat 
regions, statistical significance cannot be reported. Rv1800 has no repeat regions and one of the highest 
overall epitope densities across all PPE_MPTR proteins. Certain proteins have a zero epitope density in 
repeat regions (Rv0755c, Rv2356c, Rv2608, and Rv3144c). Two proteins have outliers within the repeat 
regions, Rv0305c and Rv1548c, indicating that there are specific repeat regions within these two proteins 




This chapter has explored the genetic variation of the PPE_MPTR proteins and how this potentially affects 
epitope density and therefore interaction with the host immune system. The types of genetic variation 
identified include IS6110 insertions, a variable copy number of tandem repeats and micro-mutations such as 
SNP’s and small indels. When comparing results for individual PPE_MPTR proteins, it is clear that not all 
ppe_mptr genes are equally variable as previously suggested in literature (Chapter 1), but rather that certain 
members are highly variable (Rv0355c, Rv1753c and Rv1917c), while others are relatively conserved across 
strains with either no or at most one micro-mutation identified, no IS6110 insertions and a constant number 
of MPTR repeats (Rv0442c, Rv0755c, Rv0878c, Rv1548c, Rv2356c, Rv2608c, and Rv3533c). This may indicate 
different functional roles and/or importance for the PPE_MPTR proteins, and a possible further sub division 
of the PPE_MPTR family based on either the type of variation (e.g. those with longer non-MPTR tandem 
repeats) or based on potential functional roles. The reason and potential functional impact of a different 
number of tandem repeats is still currently unknown and should be further explored. 
 
Other genetic variation results from this chapter that should be further explored include: 
 
 The role of IS6110 insertion elements within the ppe_mptr genes and the impact on protein 
structure and function as a result of the insertions. 
 
 The relationship between Rv3343c, Rv3350c and Rv3347c and their presence within different M. 
tuberculosis strains. There is a high sequence similarity between these three genes, making it 
difficult to identify which ortholog(s) are present in specific strains. These genes may represent gene 
duplication events and/or recombination hotspots. 
 
 The importance of the highly variable protein Rv1917c. This is by far the most variable of all the 
PPE_MPTR proteins, containing IS6110 insertions elements, and a variable copy number of both 
MPTR and longer non-MPTR repeats. Possible partial gene deletions which make multiple 
alignments difficult may also be present. It is interesting to compare Rv1917c and Rv1918c, which 
are close in proximity within the genome to each other, and both contain MPTR and longer non-
MPTR repeats. However Rv1917c is highly variable while Rv1918c is conserved across strains. The 
relationship between these proteins and whether one arose as a duplication event of the other and 
therefore whether they serve similar roles within the pathogenesis of the bacteria should be 
investigated. This may provide a reason for a lack of selective pressure on Rv1917c and the resulting 
high variability evident. Rv1917c has been shown to be cell wall associated and surface exposed 
(Sampson et al. 2001), and is involved in inducing host cell signalling and promoting Th2 response 
(Bansal et al. 2010), which may be evidence that Rv1917c may indeed differently modulate host 
immune response. 
 
The effect of micro-mutations such as SNP’s and indels on epitope density has been investigated.  However a 
clear pattern of micro-mutations affecting HLA class II binding ability could not be identified. Investigation of 
repeat and non-repeat regions has shown a correlation with the fluctuating patterns of epitopes along the 
length of the protein, with high epitope density seen in non-repeat regions. Overall these findings suggest 
that epitopes within the PPE_MPTR proteins is (in general) restricted to conserved non-repeating regions. 
No evidence to support antigenic variation or that genetic diversity is modulating host-pathogen interactions 




was found. Previous literature however has shown that the PPE_MPTR proteins are differentially expressed 
in M. tuberculosis in vivo (Soldini et al. 2011), and that the gene expression pattern in different types of 
tissue (lung and spleen) is different for each ppe_mptr gene. The ppe_mptr genes may therefore respond 
differently depending on the complex environmental signals within various host tissues (Soldini et al. 2011). 
 
Understanding the genetic variation of the ppe_mptr genes is an extremely important component of 
deciphering the role of these proteins within M. tuberculosis pathogenesis, which is currently largely 
unknown. Given the technical difficulties in sequencing and aligning these genes, previous studies have often 
excluded them in other genetic variation analyses. Therefore, while the technical complications may still be a 
limitation within this investigation that should be kept in mind, to date it is the most comprehensive analysis 
of PPE_MPTR variation. In addition, the small number of strains within this study may also be a limitation, 
and the genetic variation therefore underestimated. A larger number of strains, and high quality next 
generation sequencing data could provide additional information not reported here. Targeted Sanger 
sequencing of specific variations could also be used to validate the genetic variation identified. Further 
studies could also take into consideration possible differences in the expression profile of PPE_MPTR 
proteins with different copy numbers of tandem repeats in various biological conditions similarly to the 
study performed by Soldini et al. (2011). The novel approaches used within this chapter to overcome the 
technical difficulties associated with mapping and aligning the ppe_mptr genes could also be applied to 
other variable and/or repeat regions of the M. tuberculosis genome such as the pe_pgrs genes. 
 
Comparative genomics is an essential part of the reverse vaccinology pipeline, especially for M. tuberculosis 
(Chapter 2). The results from this chapter will therefore be important in identifying potential vaccine 
candidates. Ideally vaccine candidates should be conserved across strains in order to be affective in diverse 
populations affected with strains from various lineages. The more conserved PPE_MPTR proteins may 
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There is a crucial need for a new vaccine against M. tuberculosis, and reverse vaccinology (RV) approaches 
have been used extensively to search for new sub-unit vaccine candidates within the M. tuberculosis 
proteome (Chapter 2). Different selection criteria (i.e. by type or function of protein) are often used to first 
narrow down the list of possible antigenic targets being fed into a RV workflow. This thesis has focused on a 
particular family of proteins, the PPE_MPTR proteins. PE/PPE proteins have previously been used as a 
starting point within RV workflows, and even when whole genome approaches are used, the PE/PPE proteins 
are often in the list of resulting potential vaccine candidates (Chapter 2). Certain members of the PE/PPE 
protein family have also already been included in current vaccines in clinical trials (Chapter 1, Table 1.1). 
However, to date, no studies have focused specifically on the PPE_MPTR subfamily, even though they have 
been hypothesized to play a role in host-pathogen interactions.  
 
Reverse vaccinology workflows include comparative genomics, epitope prediction, analysis of protein 
properties and the prediction of potential population coverage (Chapter 2, Figure 2.2). CD4+ T-cell epitope 
prediction has been performed for the PPE_MPTR proteins (Chapter 3) and a large number of potential 
epitopes have been identified, supporting the hypothesis of a potential role for the PPE_MPTR proteins 
within host-pathogen interactions. The PPE_MPTR proteins have also been speculated to play a role in 
antigenic variation, allowing the bacteria to evade the host immune system. The hypothesis of whether or 
not genetic variation within the PPE_MPTR proteins differentially modulates host immune response and 
therefore supporting the speculation of antigenic variation has been explored in Chapter 5. The analysis of 
genetic diversity within the PPE_MPTR proteins across various M. tuberculosis strains shows a correlation 
between areas of repeat regions and epitope density but no evidence for the PPE_MPTR proteins playing a 
role in antigenic variation was found. The results however do show that certain members of the PPE_MPTR 
proteins are highly variable while others are more conserved. Comparative genomics is an essential step 
within RV workflows, as a potential vaccine candidate should be conserved across strains in order to be 
affective in diverse populations. This chapter uses the results from epitope prediction (Chapter 4) and 
genetic diversity (Chapter 5) to filter potential vaccine candidates within the PPE_MPTR proteins. In addition, 
the potential population coverage within high TB burden countries in Africa of possible vaccine candidates 
has been investigated in order to further narrow down the list of potential candidates. 






Figure 6.1 shows the filtering methodology used within a customised RV workflow in order to identify 




Figure 6.1: RV workflow used for the PPE_MPTR proteins.  Comparative genomics results from Chapter 5 and epitope prediction 
results from Chapter 4 are used to filter the overlapping 15mer peptides within the PPE_MPTR proteins. Potential population 
coverage is calculated to identify high coverage vaccine candidates within the high TB burden countries in Africa. 
Similarly to Chapter 4 and Chapter 5, three of the PPE_MPTR proteins were not included in the analysis due 
to dissimilarity in protein sequence to the remaining PPE_MPTR proteins. The starting point for the RV 
workflow therefore included 20 PPE_MPTR proteins. Results from Chapter 5 were used to filter these 
proteins for those that are highly conserved across strains. Highly conserved proteins are defined as those 
with either no or at most one micro-mutation identified, no IS6110 insertion elements, a constant number of 
MPTR repeats and no long non-MPTR repeats (Rv0442c, Rv0755c, Rv0878c, Rv1548c, Rv2356c, Rv2608c, and 
Rv3533c). Rv1800 has also been included even though more than 1 micro-mutation was identified due to the 
high epitope density within this protein (Chapter 4), and no repeat regions (Chapter 5). Epitope prediction 
results from Chapter 4 were used to identify peptides within these proteins that are predicted promiscuous 
epitopes (percentile rank < 1%, >= 5 HLA class II alleles). Results from Chapter 5 revealed that epitope dense 
regions correlated with non-repeat areas, however there were certain outliers where epitopes were found 
within repeat regions (Rv1548c). An extra filtering step has been included to remove possible vaccine 
candidates within repeat regions, as well as any epitope affected by a micro-mutation. 
 




An epitope clustering analysis was performed on the filtered epitopes using the epitope cluster analysis tool 
available within the IEDB analysis resource (Kim et al. 2012), which groups epitopes into clusters based on 
their sequence identity. Different identity thresholds were used to determine clusters (70% - 100%). 
 
Potential population coverage for the filtered epitopes was calculated using the IEDB population coverage 
tool (Kim et al. 2012; Bui et al. 2006). Population coverage was calculated for 9 African countries within the 
22 high burden TB countries for which HLA class II frequency information is available. The IEDB population 
coverage tool uses HLA class II frequencies from the allelefrequencies.net database (González-Galarza et al. 
2015). Epitopes that have greater than 50% population coverage in at least one country were identified as 
possible vaccine candidates. 
 
6.3 Results 
6.3.1 Results summary 
 
Table 6.1 shows a summary of the resulting number of potential vaccine candidates after each filtering step. 
 
Table 6.1: Summary results of potential vaccine candidates. The number of potential epitopes after each filtering step is shown for 
the 8 conserved PPE_MPTR proteins used in the RV pipeline. 
Protein Number of peptides 
Predicted epitopes 
(Percentile rank > 1%) 
Promiscuous 
Epitopes 





coverage in at 
least one African 
high burden TB 
country 
   PPE MPTR   
Rv0442c 473 115 5 - 5 - 
Rv0755c 631 69 7 - 7 4 
Rv0878c 429 105 - 7 7 7 
Rv1548c 664 76 3 - 3 - 
Rv1800 641 257 - 43 43 11 
Rv2356c 601 105 8 - 8 2 
Rv2608 566 195 - 25 25 8 
Rv3533c 568 108 12 2** 14 3 
Total 4,573 1030 112 112 35 
*None of the predicted promiscuous epitopes where found in repeat regions or were affected by micro-mutations.  
** Overlapping PPE and MPTR boundary. 
Of the 4,573 overlapping 15mer peptides found within the 8 PPE_MPTR proteins included in the RV 
workflow, 1,030 are predicted epitopes able to bind to at least one of the 47 HLA class II alleles included in 
the epitope prediction (Chapter 4). Of these, 112 are able to bind to at least 5 HLA class II alleles. None of 
these 112 promiscuous epitopes were found within repeated regions, nor had micro-mutations affecting the 
amino acid sequence in these regions, further emphasizing that M. tuberculosis epitopes are conserved. 
After further filtering for population coverage in high burden TB countries in Africa, 35 unique high coverage 
vaccine candidates remain. 
6.3.2 Epitope cluster analysis 
 
An epitope cluster analysis was performed using the 112 promiscuous epitopes identified before filtering for 
population coverage, in order to determine the uniqueness of the collection of epitopes. A high similarity 
between epitopes would collapse the number of potential vaccine candidates. Different sequence similarity 
thresholds were investigated when determining clustering.   
 
 When using a threshold of 90% and 100%, no clusters were found, indicating that no two epitopes 
within the 112 epitopes identified were the exactly the same, or even 90% similar. 




 When using a threshold of 80%, one cluster containing only two sequences was identified, indicating 
that two out of the 112 sequences are 80% similar, and the remaining 110 epitopes are more than 
20% dissimilar to each other. These two epitopes come from Rv0755c and Rv3533c. 
 When using a threshold of 70%, 7 clusters each containing only 2 sequences where identified. These 
are shown in Table 6.2 below. 
 
Table 6.2: Epitope cluster analysis at 70% similarity threshold. Seven clusters each containing two epitopes were identified to have 
70% similarity. 
Cluster Protein Position Epitope 
1 Rv3533c 9 ELNSLRMFTGAGSAP 
Rv0755c 10 ETNSLRMYLGAGSRP 
2 Rv3533c 11 NSLRMFTGAGSAPML 
Rv0755c 12 NSLRMYLGAGSRPLL 
3 
Rv0755c 13 SLRMYLGAGSRPLLA 
Rv3533c 12 SLRMFTGAGSAPMLA 
4 Rv3533c 13 LRMFTGAGSAPMLAA 
Rv0755c 14 LRMYLGAGSRPLLAA 
5 Rv0755c 8 PPETNSLRMYLGAGS 
Rv3533c 7 PPELNSLRMFTGAGS 
6 Rv0755c 9 PETNSLRMYLGAGSR 
Rv3533c 8 PELNSLRMFTGAGSA 
7 Rv3533c 107 PLLVAANRNAFAQLV 
Rv2356c 111 PVVVAANRSAFVQLV 
 
Epitopes from Rv0755c and Rv3533c clustered together in six out of the seven clusters. These epitopes are in 
similar positions within the respective proteins indicating a similarity between Rv0755c and Rv3533c within 
this region. One cluster contained an epitope from Rv3533c and one from Rv2356c, also at similar positions 
within the respective proteins. 
 
Given the small number of clusters identified, these results show the uniqueness of the 112 epitopes 
identified within the PPE_MPTR proteins and that the majority of the epitopes are more than 30% dissimilar 
to one another.  
6.3.3 Potential population coverage 
 
Potential population coverage was calculated for each of the 112 promiscuous epitopes for high TB burden 
countries in Africa. These countries include Zimbabwe, Uganda, Tanzania, South Africa, Nigeria, 
Mozambique, Kenya, Ethiopia and Congo. HLA class II frequencies from the allelefrequencies.net database 
are used to calculate population coverage. The information within the allelefrequencies.net database is 
sourced from various literature and relies on contributions made by researchers. Where studies on the 
frequency of HLA alleles in specific countries have not been previously performed, no information for these 
countries will be available within the database and population coverage cannot be calculated.  Information 
within the database is therefore not fully inclusive of all countries. Where information is available for a 
specific country, it should be kept in mind that this information may not be fully comprehensive for all of the 
possible different ethnic groups living within that country, as data may originate from studies specifically 
focused on one geographical area or specific ethnicity that may not be fully representative of the country as 
a whole. Where more than one study within a country is available, or different ethnic groups have been 
included, these different ethnic populations are indicated within the database and population coverage can 
be calculated separately. The HLA allele frequencies for Tanzania and Mozambique are not available within 
the allelefrequencies.net database and these countries were therefore not included within this analysis. 
 
Potential population coverage for all 112 epitopes was 0% for Uganda, Nigeria, and Kenya. This may be due 
to limited HLA allele frequency data available within the allelefrequencies.net database for these countries. 
Results for Zimbabwe, South Africa, Ethiopia and the Congo are shown in Appendix A. The list of 112 




epitopes was further filtered to include only those epitopes that had greater than 50% coverage in at least 
one of the four African countries for which results are available. This narrowed down the list to 35 high 
coverage potential vaccine candidates (Table 6.3). 
 
Table 6.3: High coverage potential vaccine candidates in high TB burden countries in Africa. The predicted population coverage for 
each epitope within each of the four African countries, Zimbabwe, South Africa, Ethiopia and Congo is shown. Coverage > 50% is 
shown is highlighted in red. 





Rv0755c 11 TNSLRMYLGAGSRPL 48.73% 23.96% 62.88% 47.71% 
Rv0755c 12 NSLRMYLGAGSRPLL 48.73% 23.96% 62.88% 47.71% 
Rv0755c 13 SLRMYLGAGSRPLLA 53.90% 24.66% 66.19% 51.61% 
Rv0755c 14 LRMYLGAGSRPLLAA 53.90% 24.66% 66.19% 51.61% 
Rv0878c 415 TARECSIRVIISRVS 62.67% 23.96% 36.48% 53.31% 
Rv0878c 416 ARECSIRVIISRVSS 63.52% 23.96% 36.48% 53.31% 
Rv0878c 417 RECSIRVIISRVSST 72.44% 45.98% 53.90% 64.41% 
Rv0878c 418 ECSIRVIISRVSSTG 71.48% 45.98% 50.11% 60.84% 
Rv0878c 419 CSIRVIISRVSSTGA 72.44% 45.98% 53.90% 64.41% 
Rv0878c 420 SIRVIISRVSSTGAP 70.73% 45.98% 50.11% 60.84% 
Rv0878c 421 IRVIISRVSSTGAPP 70.73% 45.98% 50.11% 60.84% 
Rv1800 425 TMTQYYIIRTENLPL 29.10% 5.91% 77.58% 44.29% 
Rv1800 426 MTQYYIIRTENLPLL 35.20% 6.68% 80.14% 48.32% 
Rv1800 427 TQYYIIRTENLPLLE 35.20% 6.68% 80.14% 48.32% 
Rv1800 428 QYYIIRTENLPLLEP 29.10% 5.91% 76.00% 42.63% 
Rv1800 491 PEVSPVVIADALVAG 53.08% 45.98% 46.91% 49.76% 
Rv1800 492 EVSPVVIADALVAGT 53.08% 45.98% 46.91% 49.76% 
Rv1800 493 VSPVVIADALVAGTQ 53.08% 45.98% 46.91% 49.76% 
Rv1800 494 SPVVIADALVAGTQQ 53.08% 45.98% 46.91% 49.76% 
Rv1800 632 GGLQLLIIISAGRTI 53.62% 0.00% 36.50% 42.16% 
Rv1800 633 GLQLLIIISAGRTIA 72.12% 0.00% 50.18% 42.16% 
Rv1800 634 LQLLIIISAGRTIAN 72.12% 0.00% 50.18% 42.16% 
Rv2356c 118 RSAFVQLVLSNVFGQ 57.75% 23.96% 29.94% 50.04% 
Rv2356c 119 SAFVQLVLSNVFGQN 57.75% 23.96% 29.94% 50.04% 
Rv2608 346 GNEVVVFGTSQSATI 40.71% 23.96% 50.76% 45.89% 
Rv2608 359 TIATFEMRYLQSLPA 62.67% 23.96% 42.85% 53.31% 
Rv2608 360 IATFEMRYLQSLPAH 67.05% 24.66% 46.97% 56.99% 
Rv2608 361 ATFEMRYLQSLPAHL 91.99% 26.21% 90.95% 77.47% 
Rv2608 362 TFEMRYLQSLPAHLR 95.29% 40.86% 90.95% 80.62% 
Rv2608 363 FEMRYLQSLPAHLRP 95.29% 40.86% 90.95% 80.62% 
Rv2608 364 EMRYLQSLPAHLRPG 94.29% 40.86% 86.33% 78.64% 
Rv2608 365 MRYLQSLPAHLRPGL 78.47% 40.86% 46.97% 67.48% 
Rv3533c 106 HPLLVAANRNAFAQL 40.71% 58.40% 26.01% 32.83% 
Rv3533c 7 PPELNSLRMFTGAGS 64.48% 25.52% 36.48% 56.40% 
Rv3533c 8 PELNSLRMFTGAGSA 64.48% 25.52% 36.48% 56.40% 
  




The population coverage of the 35 vaccine candidates within these four African countries varies substantially 
when comparing one country to another, indicating that the best combination of epitopes to be included in 
a vaccine cocktail could be different for different countries. Alternatively a vaccine cocktail should include a 
range of epitopes that provide high coverage within different populations. This would be further exemplified 
if all 22 high burden TB countries were included within a population coverage analysis. No potential epitope 
had population coverage of at least 50% in all four of the African countries investigated, with only one 
candidate (within Rv3533c) with population coverage of more than 50% in South Africa.  
 
6.4 Conclusion  
 
This chapter has used results from epitope prediction (Chapter 4), comparative genomics (Chapter 5), and 
potential population coverage to identify possible vaccine candidates within the PPE_MPTR proteins. Thirty 
five high coverage vaccine candidates within high burden TB countries within Africa have been identified. 
When comparing the population coverage between Zimbabwe, South Africa, Ethiopia and Congo, a 
significant difference can be seen. This is due to the difference in frequencies between HLA alleles in the 
various populations. This result reiterates the vital importance of using various populations to identify 
vaccine targets as well as using various populations within clinical trials, as a vaccine that shows promising 
results in one specific population may not be effective when used in another population in a distinct 
geographical location. Even within one continent such as Africa, HLA allele frequencies can differ 
substantially between countries, which will affect the potential efficacy of a vaccine within those countries. 
This analysis has also shown the importance of having high quality HLA frequency data in all countries, and 
within different ethnic groups within those countries. Currently the allefrequencies.net database is not fully 
comprehensive of all countries and ethnicities. Using HLA allele information, host-customised vaccines may 
offer a solution to increasing a vaccine’s effectiveness. Alternatively, a vaccine cocktail can contain epitopes 
from various proteins that have high coverage within different populations in order to maximise overall 
(global) population coverage.   
 
Only one epitope (out of the 112) had predicted population coverage of greater than 50% in South Africa. 
Vaccine candidates containing epitopes from the PPE_MPTR proteins may therefore not be as effective in 
South Africa compared to other countries, or should be supplemented with epitopes from other proteins in 
order to increase coverage within South Africa. A large proportion of the potential vaccine candidates 
identified had greater than 50% coverage in the other three African countries, with certain epitopes having 
over 90% coverage. The cut-off of 50% used when filtering epitopes can be increased to further narrow 
down the potential list of epitopes to be validated in a wet lab setting. The sensitivity and specificity of the 
population coverage tools has not been extensively investigated within the literature, as validated data 
about an epitope’s population coverage is scarcely available.  The exact cut-off percentage to use therefore 
varies between individual studies. 
 
The results presented within this chapter support the hypothesis presented in Chapter 1 (Section 1.3) that 
epitopes within the PPE_MPTR proteins may be possible subunit vaccine candidates for M. tuberculosis. 
Further studies should also include possible CD8+ T-cell epitopes. These results are based on in silico 
techniques obtained using a reverse vaccinology approach and the thirty five vaccine candidates should be 
fed into an experimental wet lab validation. Experimental validation can include using binding assays to test 
for HLA class II binding, proliferation of CD4+ T-cells, or testing for IFN-γ, IL-2 and TNF-α response. 
 
Results from this thesis reiterate the important role a computational approach can play when trying to 
determine the function of a currently unknown protein or family of proteins. In this case, the possible role of 
the PPE_MPTR proteins within host-pathogen interactions was investigated and whether or not possible 
sub-unit vaccine candidates exist within the PPE_MPTR proteins explored. 
 
  




The main conclusions based on the findings from this thesis include: 
 CD4+ T-cell epitopes exist within the PPE_MPTR proteins, supporting the hypothesis of host-
pathogen interactions for the PPE_MPTR proteins. 
 Certain members of the PPE_MPTR proteins are genetically variable while others are more 
conserved across strains, possibly indicating different functional roles. 
 Genetically diverse regions are less likely to contain epitopes, and no evidence to support antigenic 
variation was found. 
 Areas of high and low epitope density are correlated to areas of non-repeat and repeat regions 
within the genome respectively. Epitopes within the PPE_MPTR proteins are therefore conserved 
non-repeating peptides. 
 There are possible vaccine candidates with high predicted population coverage in African countries 
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A: Population coverage for high burden TB countries in Africa 
 
For each of the 112 promiscuous epitopes identified, the source protein and position within the protein is shown, the HLA alleles the epitope is predicted to bind to, and the 
predicted population coverage within 4 high burden TB countries in Africa is shown. 
 
Table 6.4: Population coverage of potential vaccine candidates in high TB burden countries in Africa. HLA alleles predicted to bind to each epitope (Results from chapter 4), are used to calculate the potential 
population coverage within four African countries with high TB burden. 





Rv0442c 154 MAGYHFDASAAVAQL HLA-DQA1*04:01/DQB1*04:02, HLA-DRB1*09:01, HLA-DRB3*01:01, HLA-
DQA1*03:01/DQB1*03:02, HLA-DRB1*04:01 
2.98% 1.79% 3.25% 6.68% 
Rv0442c 155 AGYHFDASAAVAQLA HLA-DQA1*04:01/DQB1*04:02, HLA-DRB1*09:01, HLA-DRB3*01:01, HLA-
DQA1*03:01/DQB1*03:02, HLA-DQA1*01:02/DQB1*06:02, HLA-DRB1*04:01 
2.98% 1.79% 3.25% 6.68% 
Rv0442c 72 ATQYLAWLSTAAAQA HLA-DQA1*04:01/DQB1*04:02, HLA-DRB1*09:01, HLA-DRB1*08:02, HLA-
DQA1*03:01/DQB1*03:02, HLA-DRB1*10:01 
10.13% 2.58% 5.48% 9.84% 
Rv0442c 73 TQYLAWLSTAAAQAE HLA-DQA1*04:01/DQB1*04:02, HLA-DRB1*09:01, HLA-DRB1*08:02, HLA-
DQA1*03:01/DQB1*03:02, HLA-DRB1*10:01 
10.13% 2.58% 5.48% 9.84% 
Rv0442c 97 ATAFEAALAATVQPA HLA-DQA1*04:01/DQB1*04:02, HLA-DRB1*09:01, HLA-DQA1*05:01/DQB1*03:01, HLA-
DQA1*03:01/DQB1*03:02, HLA-DRB1*01:01 
6.88% 1.79% 0.00% 8.80% 
Rv0755c 10 ETNSLRMYLGAGSRP HLA-DRB1*11:02, HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*13:01, HLA-DRB1*08:04 41.94% 23.96% 32.87% 37.86% 
Rv0755c 11 TNSLRMYLGAGSRPL HLA-DRB1*11:02, HLA-DRB1*07:01, HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*13:01, HLA-
DRB1*08:04 
48.73% 23.96% 62.88% 47.71% 
Rv0755c 12 NSLRMYLGAGSRPLL HLA-DRB1*11:02, HLA-DRB1*07:01, HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*13:01, HLA-
DRB1*08:04 
48.73% 23.96% 62.88% 47.71% 
Rv0755c 13 SLRMYLGAGSRPLLA HLA-DRB1*11:02, HLA-DRB1*07:01, HLA-DRB1*10:01, HLA-DRB5*01:01, HLA-DRB1*01:02, HLA-
DRB1*15:02, HLA-DRB1*13:01, HLA-DRB1*08:04 
53.90% 24.66% 66.19% 51.61% 
Rv0755c 14 LRMYLGAGSRPLLAA HLA-DRB1*11:02, HLA-DRB1*07:01, HLA-DRB1*10:01, HLA-DRB5*01:01, HLA-DRB1*01:02, HLA-
DRB1*15:02, HLA-DRB1*13:01, HLA-DRB1*08:04 
53.90% 24.66% 66.19% 51.61% 
Rv0755c 8 PPETNSLRMYLGAGS HLA-DRB1*11:02, HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*13:01, HLA-DRB1*08:04 41.94% 23.96% 32.87% 37.86% 
Rv0755c 9 PETNSLRMYLGAGSR HLA-DRB1*11:02, HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*13:01, HLA-DRB1*08:04 41.94% 23.96% 32.87% 37.86% 
Rv0878c 415 TARECSIRVIISRVS HLA-DRB5*01:01, HLA-DRB1*01:02, HLA-DRB1*08:04, HLA-DRB1*11:04, HLA-DRB1*11:02, HLA-
DRB1*13:01, HLA-DRB1*11:01 
62.67% 23.96% 36.48% 53.31% 
Stellenbosch University  https://scholar.sun.ac.za









Rv0878c 416 ARECSIRVIISRVSS HLA-DRB5*01:01, HLA-DRB1*01:02, HLA-DRB1*12:02, HLA-DRB1*08:04, HLA-DRB1*11:04, HLA-
DRB1*11:02, HLA-DRB1*13:01, HLA-DRB1*11:01 
63.52% 23.96% 36.48% 53.31% 
Rv0878c 417 RECSIRVIISRVSST 
HLA-DRB5*01:01, HLA-DRB1*01:02, HLA-DRB1*13:03, HLA-DRB1*12:02, HLA-DRB1*08:04, HLA-
DRB1*11:04, HLA-DRB1*11:02, HLA-DRB1*08:03, HLA-DRB1*11:03, HLA-DRB1*13:01, HLA-
DRB1*03:01, HLA-DRB1*11:01 
72.44% 45.98% 53.90% 64.41% 
Rv0878c 418 ECSIRVIISRVSSTG 
HLA-DRB5*01:01, HLA-DRB1*01:02, HLA-DRB1*12:02, HLA-DRB1*08:04, HLA-DRB1*11:04, HLA-
DRB1*11:02, HLA-DRB1*08:03, HLA-DRB1*11:03, HLA-DRB1*13:01, HLA-DRB1*08:02, HLA-
DRB1*03:01, HLA-DRB1*11:01 
71.48% 45.98% 50.11% 60.84% 
Rv0878c 419 CSIRVIISRVSSTGA 
HLA-DRB5*01:01, HLA-DRB1*01:02, HLA-DRB1*13:03, HLA-DRB1*12:02, HLA-DRB1*08:04, HLA-
DRB1*11:04, HLA-DRB1*11:02, HLA-DRB1*08:03, HLA-DRB1*11:03, HLA-DRB1*13:01, HLA-
DRB1*08:02, HLA-DRB1*03:01, HLA-DRB1*14:04, HLA-DRB1*11:01 
72.44% 45.98% 53.90% 64.41% 
Rv0878c 420 SIRVIISRVSSTGAP HLA-DRB1*01:02, HLA-DRB1*08:04, HLA-DRB1*11:04, HLA-DRB1*11:02, HLA-DRB1*08:03, HLA-
DRB1*13:01, HLA-DRB1*08:02, HLA-DRB1*03:01, HLA-DRB1*11:01 
70.73% 45.98% 50.11% 60.84% 
Rv0878c 421 IRVIISRVSSTGAPP HLA-DRB1*01:02, HLA-DRB1*08:04, HLA-DRB1*11:04, HLA-DRB1*11:02, HLA-DRB1*13:01, HLA-
DRB1*08:02, HLA-DRB1*03:01, HLA-DRB1*11:01 
70.73% 45.98% 50.11% 60.84% 
Rv1548c 112 ANRGRLRSLVASNLL HLA-DRB1*04:03, HLA-DRB1*04:06, HLA-DRB1*01:01, HLA-DRB1*10:01, HLA-DRB1*01:02 22.21% 0.80% 29.64% 16.09% 
Rv1548c 113 NRGRLRSLVASNLLG HLA-DRB1*04:03, HLA-DRB1*04:06, HLA-DRB1*01:01, HLA-DRB1*10:01, HLA-DRB1*01:02 22.21% 0.80% 29.64% 16.09% 
Rv1548c 114 RGRLRSLVASNLLGQ HLA-DRB1*04:03, HLA-DRB1*04:06, HLA-DRB1*11:04, HLA-DRB1*01:01, HLA-DRB1*10:01, HLA-
DRB1*01:02 
23.44% 0.80% 29.64% 20.08% 
Rv1800 168 ASWLQRLQSIPGAAS HLA-DRB1*01:02, HLA-DRB1*09:01, HLA-DRB1*10:01, HLA-DRB1*04:03, HLA-DRB1*08:02, HLA-
DRB1*04:06 
21.32% 2.58% 29.64% 16.28% 
Rv1800 169 SWLQRLQSIPGAASL HLA-DRB1*01:02, HLA-DRB1*09:01, HLA-DRB1*10:01, HLA-DRB1*04:03, HLA-DRB1*08:02, HLA-
DRB1*04:06 
21.32% 2.58% 29.64% 16.28% 
Rv1800 192 EAPMGVVRAVNSAIA HLA-DRB1*01:02, HLA-DRB1*09:01, HLA-DRB1*13:02, HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-
DRB1*13:03 
27.92% 7.65% 49.72% 37.62% 
Rv1800 193 APMGVVRAVNSAIAA HLA-DRB1*01:02, HLA-DRB1*09:01, HLA-DRB1*13:02, HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-
DRB1*13:03 
27.92% 7.65% 49.72% 37.62% 
Rv1800 194 PMGVVRAVNSAIAAN HLA-DRB1*01:02, HLA-DRB1*09:01, HLA-DRB1*13:02, HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-
DRB1*13:03, HLA-DQA1*04:01/DQB1*04:02 
27.92% 7.65% 49.72% 37.62% 
Rv1800 195 MGVVRAVNSAIAANA HLA-DRB1*01:02, HLA-DRB1*09:01, HLA-DRB1*13:02, HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-
DRB1*13:03, HLA-DQA1*04:01/DQB1*04:02 
27.92% 7.65% 49.72% 37.62% 
Rv1800 196 GVVRAVNSAIAANAA HLA-DRB1*01:02, HLA-DRB1*09:01, HLA-DQA1*01:02/DQB1*06:02, HLA-DRB1*08:02, HLA-
DQA1*04:01/DQB1*04:02 
14.62% 1.79% 17.63% 11.17% 
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Rv1800 257 GLYPVVVIKNLTFDS HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02 35.84% 23.96% 22.03% 32.38% 
Rv1800 258 LYPVVVIKNLTFDSS HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02 35.84% 23.96% 22.03% 32.38% 
Rv1800 259 YPVVVIKNLTFDSSV HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02 35.84% 23.96% 22.03% 32.38% 
Rv1800 260 PVVVIKNLTFDSSVA HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02 35.84% 23.96% 22.03% 32.38% 
Rv1800 261 VVVIKNLTFDSSVAQ HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02 35.84% 23.96% 22.03% 32.38% 
Rv1800 302 SATISSLVMANLAAS HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*08:02, HLA-DRB1*13:01, HLA-DRB1*11:02 33.41% 23.96% 16.88% 35.87% 
Rv1800 303 ATISSLVMANLAASA HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*08:02, HLA-DRB1*13:01, HLA-DRB1*11:02 33.41% 23.96% 16.88% 35.87% 
Rv1800 304 TISSLVMANLAASAD HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*08:02, HLA-DRB1*13:01, HLA-DRB1*11:02 33.41% 23.96% 16.88% 35.87% 
Rv1800 305 ISSLVMANLAASADP HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*08:02, HLA-DRB1*13:01, HLA-DRB1*11:02 33.41% 23.96% 16.88% 35.87% 
Rv1800 306 SSLVMANLAASADPP HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*08:02, HLA-DRB1*13:01, HLA-DRB1*11:02 33.41% 23.96% 16.88% 35.87% 
Rv1800 307 SLVMANLAASADPPS HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*08:02, HLA-DRB1*13:01, HLA-DRB1*11:02 33.41% 23.96% 16.88% 35.87% 
Rv1800 308 LVMANLAASADPPSP HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*08:02, HLA-DRB1*13:01, HLA-DRB1*11:02 33.41% 23.96% 16.88% 35.87% 
Rv1800 381 PRYPLNFVSTLNAIA HLA-DRB1*11:04, HLA-DRB1*04:03, HLA-DRB1*08:02, HLA-DRB1*04:06, HLA-DRB1*04:05, HLA-
DRB1*11:01, HLA-DRB1*04:01 
31.61% 0.00% 24.67% 23.79% 
Rv1800 382 RYPLNFVSTLNAIAG HLA-DRB1*11:04, HLA-DRB1*14:04, HLA-DRB1*10:01, HLA-DRB1*04:03, HLA-DRB1*08:02, HLA-
DRB1*04:06, HLA-DRB1*04:05, HLA-DRB1*11:01, HLA-DRB1*13:03, HLA-DRB1*04:01 
39.00% 0.80% 33.94% 33.37% 
Rv1800 383 YPLNFVSTLNAIAGT HLA-DRB1*11:04, HLA-DRB1*10:01, HLA-DRB1*04:03, HLA-DRB1*08:02, HLA-DRB1*04:06, HLA-
DRB1*04:05, HLA-DRB1*11:01, HLA-DRB1*13:03, HLA-DRB1*04:01 
39.00% 0.80% 33.94% 33.37% 
Rv1800 384 PLNFVSTLNAIAGTY HLA-DRB1*11:04, HLA-DRB1*10:01, HLA-DRB1*04:03, HLA-DRB1*08:02, HLA-DRB1*04:06, HLA-
DRB1*04:05, HLA-DRB1*11:01, HLA-DRB1*13:03, HLA-DRB3*02:02, HLA-DRB1*04:01 
39.00% 0.80% 33.94% 33.37% 
Rv1800 385 LNFVSTLNAIAGTYY HLA-DRB1*11:04, HLA-DRB1*10:01, HLA-DRB1*04:03, HLA-DRB1*08:02, HLA-DRB1*04:06, HLA-
DRB1*04:05, HLA-DRB1*11:01, HLA-DRB1*04:01 
37.59% 0.80% 29.42% 28.51% 
Rv1800 425 TMTQYYIIRTENLPL HLA-DRB1*13:02, HLA-DRB1*14:01, HLA-DRB1*14:04, HLA-DRB1*04:03, HLA-DRB1*04:06, HLA-
DRB1*04:05, HLA-DRB1*13:03, HLA-DRB1*07:01, HLA-DRB1*04:01 
29.10% 5.91% 77.58% 44.29% 
Rv1800 426 MTQYYIIRTENLPLL 
HLA-DRB1*14:05, HLA-DRB1*08:03, HLA-DRB1*13:02, HLA-DRB1*14:01, HLA-DRB1*14:04, HLA-
DRB1*10:01, HLA-DRB1*04:03, HLA-DRB1*04:06, HLA-DRB1*04:05, HLA-DRB1*11:03, HLA-
DRB1*13:03, HLA-DRB1*07:01, HLA-DRB3*02:02, HLA-DRB1*04:01 
35.20% 6.68% 80.14% 48.32% 
Rv1800 427 TQYYIIRTENLPLLE 
HLA-DRB1*14:05, HLA-DRB1*13:02, HLA-DRB1*14:01, HLA-DRB1*14:04, HLA-DRB1*10:01, HLA-
DRB1*04:03, HLA-DRB1*04:06, HLA-DRB1*04:05, HLA-DRB1*11:03, HLA-DRB1*13:03, HLA-
DRB1*07:01, HLA-DRB3*02:02, HLA-DRB1*04:01 
35.20% 6.68% 80.14% 48.32% 
Rv1800 428 QYYIIRTENLPLLEP 
HLA-DRB1*14:05, HLA-DRB1*13:02, HLA-DRB1*14:01, HLA-DRB1*14:04, HLA-DRB1*04:03, HLA-
DRB1*04:06, HLA-DRB1*04:05, HLA-DRB1*11:03, HLA-DRB1*13:03, HLA-DRB1*07:01, HLA-
DRB3*02:02 
29.10% 5.91% 76.00% 42.63% 
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Rv1800 429 YYIIRTENLPLLEPL HLA-DRB1*13:02, HLA-DRB1*14:01, HLA-DRB1*04:05, HLA-DRB1*11:03, HLA-DRB1*13:03, HLA-
DRB3*02:02 
21.15% 5.91% 45.11% 32.33% 
Rv1800 490 FPEVSPVVIADALVA HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*13:01, HLA-
DRB1*11:02 
43.00% 23.96% 32.87% 41.28% 
Rv1800 491 PEVSPVVIADALVAG HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*03:01 
53.08% 45.98% 46.91% 49.76% 
Rv1800 492 EVSPVVIADALVAGT HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*03:01 
53.08% 45.98% 46.91% 49.76% 
Rv1800 493 VSPVVIADALVAGTQ HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*03:01 
53.08% 45.98% 46.91% 49.76% 
Rv1800 494 SPVVIADALVAGTQQ HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*03:01 
53.08% 45.98% 46.91% 49.76% 
Rv1800 495 PVVIADALVAGTQQG HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*13:01, HLA-
DRB1*11:02 
43.00% 23.96% 32.87% 41.28% 
Rv1800 496 VVIADALVAGTQQGI HLA-DRB1*01:02, HLA-DRB1*15:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*13:01, HLA-
DRB1*11:02 
43.00% 23.96% 32.87% 41.28% 
Rv1800 584 NAALTIVPSYNIHLF HLA-DRB1*01:02, HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-DRB1*15:03, HLA-DRB1*15:01 38.53% 0.00% 36.86% 6.78% 
Rv1800 630 AAGGLQLLIIISAGR HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*11:01, HLA-DRB1*15:01, HLA-DRB5*01:01 35.84% 0.00% 20.42% 29.61% 
Rv1800 631 AGGLQLLIIISAGRT HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*11:01, HLA-DRB1*15:01, HLA-DRB5*01:01 35.84% 0.00% 20.42% 29.61% 
Rv1800 632 GGLQLLIIISAGRTI HLA-DRB1*01:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*12:01, HLA-DRB1*11:01, HLA-
DRB1*15:01, HLA-DRB5*01:01, HLA-DRB1*12:02 
53.62% 0.00% 36.50% 42.16% 
Rv1800 633 GLQLLIIISAGRTIA HLA-DRB1*01:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*12:01, HLA-DRB1*11:01, HLA-
DRB1*11:03, HLA-DRB1*15:03, HLA-DRB1*15:01, HLA-DRB5*01:01, HLA-DRB1*12:02 
72.12% 0.00% 50.18% 42.16% 
Rv1800 634 LQLLIIISAGRTIAN HLA-DRB1*01:02, HLA-DRB1*11:04, HLA-DRB1*08:04, HLA-DRB1*12:01, HLA-DRB1*11:01, HLA-
DRB1*11:03, HLA-DRB1*15:03, HLA-DRB1*15:01, HLA-DRB5*01:01, HLA-DRB1*12:02 
72.12% 0.00% 50.18% 42.16% 
Rv1800 635 QLLIIISAGRTIAND HLA-DRB1*01:02, HLA-DRB1*11:03, HLA-DRB1*15:01, HLA-DRB5*01:01, HLA-DRB1*12:02 13.51% 0.00% 21.55% 6.78% 
Rv2356c 1 VVNFSVLPPEINSGR HLA-DRB1*13:01, HLA-DRB1*15:02, HLA-DRB1*11:01, HLA-DRB1*11:02, HLA-DRB1*11:04 48.45% 23.96% 9.16% 40.12% 
Rv2356c 110 DPVVVAANRSAFVQL HLA-DRB1*11:02, HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-DRB1*09:01, HLA-DRB1*03:01 24.48% 27.07% 17.83% 25.44% 
Rv2356c 111 PVVVAANRSAFVQLV HLA-DRB1*11:02, HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-DRB1*09:01, HLA-DRB1*03:01 24.48% 27.07% 17.83% 25.44% 
Rv2356c 118 RSAFVQLVLSNVFGQ HLA-DRB1*13:01, HLA-DRB1*08:04, HLA-DRB1*11:01, HLA-DRB1*04:05, HLA-DRB1*11:02, HLA-
DRB1*11:04 
57.75% 23.96% 29.94% 50.04% 
Rv2356c 119 SAFVQLVLSNVFGQN HLA-DRB1*13:01, HLA-DRB1*08:04, HLA-DRB1*11:01, HLA-DRB1*04:05, HLA-DRB1*11:02, HLA-
DRB1*11:04 
57.75% 23.96% 29.94% 50.04% 
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Rv2356c 123 QLVLSNVFGQNAPAI HLA-DRB1*13:01, HLA-DRB1*08:04, HLA-DRB1*01:02, HLA-DRB1*11:02, HLA-DRB1*11:04 43.00% 23.96% 32.87% 41.28% 
Rv2356c 124 LVLSNVFGQNAPAIA HLA-DRB1*13:01, HLA-DRB1*08:04, HLA-DRB1*01:02, HLA-DRB1*11:02, HLA-DRB1*11:04 43.00% 23.96% 32.87% 41.28% 
Rv2356c 128 NVFGQNAPAIAAAEA HLA-DQA1*04:01/DQB1*04:02, HLA-DRB1*01:02, HLA-DQA1*01:02/DQB1*06:02, HLA-
DRB1*09:01, HLA-DQA1*03:01/DQB1*03:02 
14.62% 1.79% 17.63% 11.17% 
Rv2608 343 LAAGNEVVVFGTSQS HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*15:02, HLA-DRB1*08:04 33.41% 23.96% 16.88% 35.87% 
Rv2608 344 AAGNEVVVFGTSQSA HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*15:02, HLA-DRB1*08:04 33.41% 23.96% 16.88% 35.87% 
Rv2608 345 AGNEVVVFGTSQSAT HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*15:02, HLA-DRB1*08:04 33.41% 23.96% 16.88% 35.87% 
Rv2608 346 GNEVVVFGTSQSATI HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*15:02, HLA-DRB1*08:04, HLA-
DRB1*07:01 
40.71% 23.96% 50.76% 45.89% 
Rv2608 347 NEVVVFGTSQSATIA HLA-DRB1*11:04, HLA-DRB1*08:02, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*15:02, HLA-
DRB1*04:01, HLA-DRB1*08:04 
33.41% 23.96% 19.84% 37.62% 
Rv2608 348 EVVVFGTSQSATIAT HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*15:02, HLA-DRB1*04:01, HLA-
DRB1*08:04 
33.41% 23.96% 19.84% 37.62% 
Rv2608 349 VVVFGTSQSATIATF HLA-DRB1*11:04, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*09:01, HLA-DRB1*15:02, HLA-
DRB1*04:01, HLA-DRB1*08:04 
35.84% 25.52% 19.84% 41.20% 
Rv2608 359 TIATFEMRYLQSLPA HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*11:01, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-
DRB1*04:06, HLA-DRB1*15:02, HLA-DRB1*04:03, HLA-DRB1*08:04 
62.67% 23.96% 42.85% 53.31% 
Rv2608 360 IATFEMRYLQSLPAH HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*11:01, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-
DRB1*04:06, HLA-DRB1*10:01, HLA-DRB1*15:02, HLA-DRB1*04:03, HLA-DRB1*08:04 
67.05% 24.66% 46.97% 56.99% 
Rv2608 361 ATFEMRYLQSLPAHL 
HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*14:05, HLA-DRB1*11:01, HLA-DRB1*01:01, HLA-
DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*04:06, HLA-DRB1*16:02, HLA-DRB1*13:03, HLA-
DRB1*15:01, HLA-DRB1*09:01, HLA-DRB3*02:02, HLA-DRB1*15:04, HLA-DRB1*14:01, HLA-
DRB1*10:01, HLA-DRB1*15:02, HLA-DRB1*15:03, HLA-DRB1*04:03, HLA-DRB1*04:01, HLA-
DRB1*04:05, HLA-DRB1*08:04, HLA-DRB1*14:04, HLA-DRB1*07:01 
91.99% 26.21% 90.95% 77.47% 
Rv2608 362 TFEMRYLQSLPAHLR 
HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*14:05, HLA-DRB1*11:01, HLA-DRB1*01:01, HLA-
DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*04:06, HLA-DRB1*16:02, HLA-DRB1*13:03, HLA-
DRB1*15:01, HLA-DRB1*09:01, HLA-DRB3*02:02, HLA-DRB1*15:04, HLA-DRB1*14:01, HLA-
DRB1*10:01, HLA-DRB1*03:02, HLA-DRB1*15:02, HLA-DRB1*15:03, HLA-DRB1*04:03, HLA-
DRB1*04:01, HLA-DRB5*01:01, HLA-DRB1*04:05, HLA-DRB1*16:01, HLA-DRB1*08:04, HLA-
DRB1*14:04, HLA-DRB1*07:01 
95.29% 40.86% 90.95% 80.62% 
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Rv2608 363 FEMRYLQSLPAHLRP 
HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*14:05, HLA-DRB1*11:01, HLA-DRB1*01:01, HLA-
DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*04:06, HLA-DRB1*16:02, HLA-DRB1*13:03, HLA-
DRB1*15:01, HLA-DRB1*09:01, HLA-DRB3*02:02, HLA-DRB1*15:04, HLA-DRB1*14:01, HLA-
DRB1*10:01, HLA-DRB1*03:02, HLA-DRB1*15:02, HLA-DRB1*15:03, HLA-DRB1*04:03, HLA-
DRB1*04:01, HLA-DRB5*01:01, HLA-DRB1*04:05, HLA-DRB1*16:01, HLA-DRB1*08:04, HLA-
DRB1*14:04, HLA-DRB1*07:01 
95.29% 40.86% 90.95% 80.62% 
Rv2608 364 EMRYLQSLPAHLRPG 
HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*14:05, HLA-DRB1*11:01, HLA-DRB1*01:01, HLA-
DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*04:06, HLA-DRB1*16:02, HLA-DRB1*13:03, HLA-
DRB1*15:01, HLA-DRB1*09:01, HLA-DRB3*02:02, HLA-DRB1*15:04, HLA-DRB1*14:01, HLA-
DRB1*10:01, HLA-DRB1*03:02, HLA-DRB1*15:02, HLA-DRB1*15:03, HLA-DRB1*04:03, HLA-
DRB5*01:01, HLA-DRB1*16:01, HLA-DRB1*08:04, HLA-DRB1*07:01 
94.29% 40.86% 86.33% 78.64% 
Rv2608 365 MRYLQSLPAHLRPGL 
HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*14:05, HLA-DRB1*11:01, HLA-DRB1*01:01, HLA-
DRB1*13:01, HLA-DRB1*11:02, HLA-DRB1*04:06, HLA-DRB1*16:02, HLA-DRB1*09:01, HLA-
DRB3*02:02, HLA-DRB1*10:01, HLA-DRB1*03:02, HLA-DRB1*15:02, HLA-DRB1*04:03, HLA-
DRB5*01:01, HLA-DRB1*16:01, HLA-DRB1*08:04 
78.47% 40.86% 46.97% 67.48% 
Rv2608 366 RYLQSLPAHLRPGLD HLA-DRB1*09:01, HLA-DRB3*02:02, HLA-DRB1*10:01, HLA-DRB1*03:02, HLA-DRB5*01:01 22.21% 19.54% 5.48% 15.18% 
Rv2608 438 KYPLNVFATANAIAG HLA-DRB1*08:02, HLA-DRB1*11:02, HLA-DRB1*04:06, HLA-DRB1*09:01, HLA-DRB1*04:03 11.83% 1.79% 8.57% 15.18% 
Rv2608 478 PDVLTTYILLPSQDL 
HLA-DRB1*01:02, HLA-DRB1*01:01, HLA-DPA1*02:01/DPB1*01:01, HLA-
DPA1*03:01/DPB1*04:02, HLA-DPA1*01:03/DPB1*02:01, HLA-DRB5*01:01, HLA-DRB1*04:05, 
HLA-DRB1*08:04 
27.58% 0.00% 37.35% 23.17% 
Rv2608 479 DVLTTYILLPSQDLP 
HLA-DRB1*01:02, HLA-DRB1*01:01, HLA-DPA1*02:01/DPB1*01:01, HLA-
DPA1*03:01/DPB1*04:02, HLA-DRB1*10:01, HLA-DRB5*01:01, HLA-DRB1*04:05, HLA-
DRB1*08:04 
33.74% 0.80% 41.68% 27.92% 
Rv2608 480 VLTTYILLPSQDLPL HLA-DRB1*01:02, HLA-DRB1*01:01, HLA-DRB1*04:06, HLA-DRB1*10:01, HLA-DRB1*04:03, HLA-
DRB5*01:01, HLA-DRB1*04:05, HLA-DRB1*08:04 
33.74% 0.80% 47.77% 27.92% 
Rv2608 481 LTTYILLPSQDLPLL HLA-DRB1*01:02, HLA-DRB1*01:01, HLA-DRB1*04:06, HLA-DRB1*10:01, HLA-DRB1*04:03, HLA-
DRB5*01:01, HLA-DRB1*04:05, HLA-DRB1*08:04 
33.74% 0.80% 47.77% 27.92% 
Rv2608 482 TTYILLPSQDLPLLV HLA-DRB1*01:02, HLA-DRB1*01:01, HLA-DRB1*04:06, HLA-DRB1*10:01, HLA-DRB1*04:03, HLA-
DRB5*01:01, HLA-DRB1*04:05 
26.04% 0.80% 38.16% 18.10% 
Rv2608 489 SQDLPLLVPLRAIPL HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*11:01, HLA-DRB1*15:01, HLA-DRB1*15:02 38.22% 0.00% 25.45% 25.95% 
Rv2608 490 QDLPLLVPLRAIPLL HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*11:01, HLA-DRB1*15:01, HLA-DRB1*15:02 38.22% 0.00% 25.45% 25.95% 
Rv2608 491 DLPLLVPLRAIPLLG HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*11:01, HLA-DRB1*15:01, HLA-DRB1*15:02 38.22% 0.00% 25.45% 25.95% 
Rv2608 492 LPLLVPLRAIPLLGN HLA-DRB1*11:04, HLA-DRB1*01:02, HLA-DRB1*11:01, HLA-DRB1*15:01, HLA-DRB1*15:02 38.22% 0.00% 25.45% 25.95% 
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Rv3533c 10 LNSLRMFTGAGSAPM HLA-DRB1*08:04, HLA-DRB1*15:02, HLA-DRB1*09:01, HLA-DRB1*04:01, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*01:02, HLA-DRB1*11:04 
45.24% 25.52% 35.54% 46.37% 
Rv3533c 105 VHPLLVAANRNAFAQ HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-DRB1*03:01, HLA-DRB1*13:01, HLA-DRB1*13:03 30.11% 45.98% 26.01% 28.07% 
Rv3533c 106 HPLLVAANRNAFAQL HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-DRB1*03:01, HLA-DRB1*13:01, HLA-DRB1*03:02, HLA-
DRB1*13:03, HLA-DRB3*02:02 
40.71% 58.40% 26.01% 32.83% 
Rv3533c 107 PLLVAANRNAFAQLV HLA-DRB1*08:02, HLA-DRB1*11:03, HLA-DRB1*03:01, HLA-DRB1*13:01, HLA-DRB1*13:03, HLA-
DRB3*02:02 
30.11% 45.98% 26.01% 28.07% 
Rv3533c 11 NSLRMFTGAGSAPML HLA-DRB1*08:04, HLA-DRB1*15:02, HLA-DRB1*09:01, HLA-DRB1*04:01, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*01:02, HLA-DRB1*11:04 
45.24% 25.52% 35.54% 46.37% 
Rv3533c 12 SLRMFTGAGSAPMLA HLA-DRB1*08:04, HLA-DRB1*15:02, HLA-DRB1*10:01, HLA-DRB1*04:01, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*01:02, HLA-DRB1*11:04 
48.45% 24.66% 39.92% 47.03% 
Rv3533c 13 LRMFTGAGSAPMLAA HLA-DRB1*08:04, HLA-DRB1*15:02, HLA-DRB1*10:01, HLA-DRB1*04:01, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*01:02, HLA-DRB1*11:04 
48.45% 24.66% 39.92% 47.03% 
Rv3533c 151 MVGYHSGASAAAEQL HLA-DRB1*08:04, HLA-DRB1*15:02, HLA-DQA1*04:01/DQB1*04:02, HLA-
DQA1*03:01/DQB1*03:02, HLA-DQA1*05:01/DQB1*03:01 
8.99% 0.00% 12.33% 10.89% 
Rv3533c 168 FQQALQQLPNLGIGN HLA-DRB1*15:02, HLA-DRB1*04:03, HLA-DRB1*10:01, HLA-DRB1*04:06, HLA-DRB1*01:02 18.64% 0.80% 29.64% 12.02% 
Rv3533c 169 QQALQQLPNLGIGNI HLA-DRB1*15:02, HLA-DRB1*04:03, HLA-DRB1*10:01, HLA-DRB1*04:06, HLA-DRB1*01:02 18.64% 0.80% 29.64% 12.02% 
Rv3533c 7 PPELNSLRMFTGAGS HLA-DRB1*08:04, HLA-DRB1*15:02, HLA-DRB1*11:01, HLA-DRB1*09:01, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*01:02, HLA-DRB1*11:04 
64.48% 25.52% 36.48% 56.40% 
Rv3533c 74 GWLSAAAARAAGAAA HLA-DQA1*04:01/DQB1*04:02, HLA-DRB1*09:01, HLA-DQA1*05:01/DQB1*03:01, HLA-
DQA1*01:02/DQB1*06:02, HLA-DRB1*01:01 
6.88% 1.79% 0.00% 8.80% 
Rv3533c 8 PELNSLRMFTGAGSA HLA-DRB1*08:04, HLA-DRB1*15:02, HLA-DRB1*11:01, HLA-DRB1*09:01, HLA-DRB1*13:01, HLA-
DRB1*11:02, HLA-DRB1*01:02, HLA-DRB1*11:04 
64.48% 25.52% 36.48% 56.40% 
Rv3533c 9 ELNSLRMFTGAGSAP HLA-DRB1*08:04, HLA-DRB1*15:02, HLA-DRB1*09:01, HLA-DRB1*13:01, HLA-DRB1*11:02, HLA-
DRB1*01:02, HLA-DRB1*11:04 
45.24% 25.52% 32.87% 44.75% 
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